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General introduction and aims of the thesis  
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Autofluorescence 
Tissue can exhibit fluorescence when excited by a light source of a suitable 
wavelength. This fluorescence emission, arising from endogenous fluorophores, is an 
intrinsic property of the tissue and is called autofluorescence to be distinguished from 
fluorescent signals obtained by adding exogenous markers (like sodium fluorescein). 
The tissue fluorophores absorb certain wavelengths of light (excitation light), transform 
the energy, and release it again in light of longer wavelengths (emission). Several 
tissue fluorophores have been identified, such as collagen, elastin, lipofuscin, NADH, 
porphyrins and tryptophan [1,2]. Each fluorophore has its characteristic excitation and 
emission wavelength, that enables localization and further quantification of a particular 
fluorophore. Autofluorescence can be induced in several tissues and can therefore be 
applied in investigation of several diseases. It is also used to distinguish malignant 
from benign tissue in several tissues, such as the skin and cervix [3-5]. Furthermore, in 
ophthalmology, autofluorescence of the lens has been studied in the past in extension 
[6-8]. It was found that autofluorescence of the lens was increased in ageing and 
diabetes. Autofluorescence of the lens appeared to be caused by glycation and, 
subsequent oxidation of lens crystalline. Products of this non-enzymatic glycation and 
oxidation (Maillard reaction) are also called advanced glycation endproducts (AGEs). 
Accumulation of AGEs in the lens play a major role in cataract formation in ageing and 
diabetes.  
Increased autofluorescence of the skin in patients with diabetes was a finding by 
serendipity in 1996. During measurements on capillary sodium fluorescein leakage in 
patients with diabetes mellitus using a fluorescence microscope setup, unexpectedly 
high levels of skin autofluorescence were found in patients with diabetes mellitus 
compared to healthy volunteers [9,10]. This observation was recognized as a potential 
non-invasive measure for tissue accumulation of advanced glycation endproducts 
(AGEs). Since the publications about lens autofluorescence and the first studies about 
tissue AGEs measurements using ‘Collagen Linked Fluorescence’ (CLF) were 
available [11-13]. AGEs linked to collagen have a characteristic fluorescence spectrum 
at 440 nm upon excitation at 370 nm and is called CLF. Several publications in the Chapter 1 
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1980s and 1990s reported accumulation of AGEs in skin or other tissue and its relation 
to chronic complications of diabetes mellitus [14-17]. In that time, the most frequently 
studied fluorescent AGE was pentosidine (excitation 335 nm, emission 385 nm), which 
consists of a crosslink between lysine and arginine residues. Not all AGEs exhibit 
autofluorescent properties. Examples of non-fluorescent AGEs are N
ε-
carboxymethyllysine (CML), N
ε-carboxyethyllysine (CEL), and pyrraline. The 
different pathways of AGE formation and the relation between AGE-accumulation and 
complications of diabetes and other conditions, like atherosclerosis, renal failure and 
rheumatic diseases are described in extension in Chapter 3.  
Tissue AGE assessments like quantification in extracts from homogenates of skin 
biopsies using high performance liquid chromatography (HPLC) or CLF, require 
invasive sampling. Many biochemical and immunochemical assays for measuring 
fluorescent en non-fluorescent AGEs in serum have been developed over the last 
decades [18-22]. Each technique has however its own limitation, for example poor 
relation with tissue contents of AGEs, low reproducibility, or time-consuming and 
expensive. The advantages and disadvantages of the available AGE-assessment 
methods are described in detail in a single paragraph of Chapter 3.  
The analogy with fluorescence of skin biopsies in previous studies was used to develop 
a tool aiming to non-invasively assess AGE accumulation: the Autofluorescence 
Reader (AFR). Skin autofluorescence, non-invasively assessed using the AFR, can be 
more conveniently applied to large groups of patients and is also more suitable for 
repeated measurement. Because skin autofluorescence is measured in vivo in the tissue 
compartment, it might achieve a better representation of tissue AGE-content compared 
to serum AGE assays.  
The assumption that skin autofluorescence was a measure for tissue AGE-content was 
studied in a validation study previously [23]. Skin autofluorescence was measured in 
46 patients with diabetes and in 46 control subjects. Simultaneously, skin biopsies were 
taken from the lower arm and analysed for collagen-linked fluorescence (CLF) and 
specific AGEs: pentosidine, CML, CEL (JW Baynes, Columbia USA). This validation 
study of the AFR showed good relations between skin autofluorescence and fluorescent Introduction 
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and non-fluorescent AGEs assessed in skin-biopsies, with good reproducibility [23]. A 
later study in the same study group showed that skin AF appeared to be a predictor for 
cardiovascular complications in diabetes patients [24].  
 
 
 
 
 
 
 
 
 
 
Figure 1. Components of the Autofluorescence Reader (AFR), panel A. Schematic drawing of 
the light collection section of the AFR, panel B. 
 
 
The Autofluorescence Reader 
The setup of the AFR consists of a light source, a glass fiber that is connected to a 
spectrometer, and a computer containing the analysing software to which the 
spectrometer is connected, Figure 1A. A schematic drawing of the light collection part 
of the instrument is given in Figure 1B. An 8-Watt blacklight (Philips) was used with 
the excitation range of 350-420 nm (maximum intensity at 370 nm). The AFR 
illuminates a skin surface of ~4cm
2, guarded against surrounding light. Emission light 
and reflected excitation light from the skin are measured with a spectrometer (AVS-
USB2000, Avantes Inc. Eerbeek, The Netherlands) in the 300-600 nm range, using 50-
µm glass fiber (Farnell, Leeds, UK). The fiber is not in contact with the skin, but is 
located at some distance from the skin, leading to an integration area of approximately 
0.4 cm². This is preferred while the area of the tissue that is seen by the detecting 
optical fiber, should be large enough to prevent gross variations of the result by 
particular contributions that occur on small displacements of the probe, such as 
capillaries and other small blood vessels, hair follicles, sebaceous glands, etc. AFR 
8W ‘Black-light’ tube
spectrometer fiber
PC + software
opening
A                                                              BChapter 1 
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measurements were performed at room temperature in a seated position at the volar 
side of the arm approximately 10cm below the elbow fold.  
 
Reproducibility was tested previously by performing repeated AF measurements taken 
over a single day in 25 control subjects and diabetic patients and showed a mean 
relative error in AF of 5.0% [25]. Intra-individual seasonal variance among control 
subjects and diabetic patients also showed a mean relative error of ~5.0%.  
Since skin pigmentation may influence autofluorescence (AF) by light absorption, AF 
was calculated by dividing the average emitted light intensity per nm in the range 420-
600nm (Iem ) by the average excitated light intensity per nm in the range 300-420nm 
(Iexc), and multiplied by hundred. AF was expressed in  arbitrary units (a.u.) [26].  
 
AF  =  Iem  /  Iexc  × 100 
 
Skin reflection was calculated in the range 300-420nm by dividing the mean intensity 
reflected from the skin by the mean intensity reflected from a white Teflon block 
(assuming 100% reflectance). Skin reflection was used in the studies of this thesis to 
exclude patients that were to dark-skinned, leaving too little light to reliably measure 
autofluorescence with the current set-up. Measurements were discarded if skin 
reflection was below <7.5%.  
 
Aims of this thesis 
The first aim of the thesis was to evaluate whether the excitation spectrum of the AFR 
needed to be further optimized to detect possible differences in fluorescence 
characteristics, as the excitation range of the current used AFR is rather broad and 
seems therefore less specific. Therefore, we studied whether specific excitation 
wavelengths could induce different fluorescence peaks corresponding with different 
fluorophores or AGEs (Chapter 2). We hypothesized a possible difference in 
biochemical composition of AGEs between type 1 and type 2 diabetes, as these 
diseases with a different metabolic condition could generate different AGEs. A second Introduction 
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question was whether diabetes patients with complications have different AGEs that 
result to complications, or that it is just the quantity of AGEs that results in 
development of diabetes complications. We therefore selected age-matched type 1 and 
type 2 diabetes patients, both with and without complications, as well as a nondiabetic 
control group. 
 
The second main focus of this thesis is to further clinically validate the AFR. For this 
purpose, skin autofluorescence measurements were performed in a large type 2 
diabetes population (~1000). The relation of skin autofluorescence to clinically used 
variables in diabetes care was evaluated (Chapter 4). Furthermore, it was prospectively 
studied in this cohort, whether skin autofluorescence is a risk indicator for chronic 
diabetes complications and cardiovascular morbidity and mortality (Chapter 5 and 7).  
For this main aim of the thesis, a large population-based cohort of type 2 diabetes 
patients was needed allowing to discriminate possibly confounding factors and to 
extrapolate results to clinical practice. In the Zwolle region there was an ongoing 
epidemiological study in type 2 diabetes patients (ZODIAC-study) [27,28]. 
Fortunately, we had the opportunity to collaborate with this study group. The Zwolle 
Outpatient Diabetes project Integrating Available Care (ZODIAC) study started in 
1999 and was embedded in a shared-care project in a primary care population-based 
cohort of type 2 diabetes patients. These type 2 diabetes mellitus patients are well 
characterised as they participate in the shared-care project with annual regular 
standardised assessment of glycemic and metabolic status and chronic diabetes 
complications. Figure 2 illustrates the origin of the cohort that had an autofluorescence 
measurement in 2001, and was included in the follow-up study.  
Chapter 6 involves a study where skin autofluorescence was not studied, but where 
life-expectancy of the ZODIAC-derived type 2 diabetes cohort was specifically 
studied.  
 
  
 Chapter 1 
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Figure 2. Flowchart of the enrolment of the type 2 diabetes study cohort from 32 general 
practitioners of a district in the ZODIAC study and further derivement of the type 2 diabetes 
cohort entering the skin autofluorescence follow-up study.  
  
 
REFERENCES 
1.  König K, Schneckenburger H. Laser-induced autofluorescence for medical diagnosis. J 
Fluorescence. 1994; 4: 17-40. 
2.  Ramanujam N. "Fluorescence spectroscopy in vivo" in Encyclopedia of analytical 
chemistry, Meyers RA, ed. (John Wiley & Sons Ltd, Chichester, 2000), pp. 20-56. 
3.  Na R, Stender IM, Wulf HC. Can autofluorescence demarcate basal cell carcinoma 
from normal skin? A comparison with protoporphyrin IX fluorescence. Acta Derm 
Venereol. 2001; 81: 246-9. 
Patients with type 2 
diabetes mellitus from 
32 general 
practitioners: 
n= 2094
Treated by an 
internist
n= 441
Treated by a general 
practioner (primary care)
n= 1653
Excluded: terminally 
ill, dementia
n= 67
Participants of ZODIAC 
study in 2000
n= 1441
Invited to participate
n=1586
Included in cohort 
2001 by having 
a proper skin AF 
measurement
n=973
Excluded in 2001: 
- no skin AF measurement
(logistic reasons, refusal), n= 320
-improper skin AF measurement, n= 148
n = 468
Refused 
n= 145Introduction 
16 
4.  Weingandt H, Stepp H, Baumgartner R, Diebold J, Xiang W, Hillemanns P. 
Autofluorescence spectroscopy for the diagnosis of cervical intraepithelial neoplasia. 
BJOG. 2002; 109:947-51. 
5.  Drezek R, Sokolov K, Utzinger U, Boiko I, Malpica A, Follen M, Richards-Kortum R. 
Understanding the contributions of NADH and collagen to cervical tissue fluorescence 
spectra: modeling, measurements, and implications. J Biomed Opt. 2001; 6:385-96. 
6.  Mosier MA, Occhipinti JR, Burstein NL. Autofluorescence of the crystalline lens in 
diabetes. Arch Ophthalmol. 1986; 104:1340-3. 
7.  Koefoed Theil P, Hansen T, Larsen M, Pedersen O, Lund-Andersen H. Lens 
autofluorescence is increased in newly diagnosed patients with NIDDM. Diabetologia. 
1996; 39:1524-7. 
8.  Abiko T, Abiko A, Ishiko S, Takeda M, Horiuchi S, Yoshida A. Relationship between 
autofluorescence and advanced glycation end products in diabetic lenses. Exp Eye Res. 
1999; 68: 361-6. 
9.  Jager J, Oomen PHN, Sluiter WJ, Reitsma WD, Smit AJ. Improved reproducibility of 
the “Large-Window” method of assessing transcapillary and interstitial fluorescein 
diffusion in the skin in healthy subjects and in subjects with insulin-dependent diabetes 
mellitus. Int J Microcirc Clin Exp. 1997; 17:150–158. 
10.  Oomen PH, Jager J, Hoogenberg K, Dullaart RP, Reitsma WD, Smit AJ. Capillary 
permeability is increased in normo- and microalbuminuric type 1 diabetic patients: 
amelioration by ACE-inhibition. Eur J Clin Invest. 1999; 29:1035-40. 
11.  Monnier VM, Vishwanath V, Frank KE, Elmets CA, Dauchot P, Kohn RR. Relation 
between complications of type I diabetes mellitus and collagen-linked fluorescence. N 
Engl J Med. 1986; 314: 403-8. 
12.  Brownlee M: Lilly Lecture 1993. Glycation and diabetic complications. Diabetes. 
1994; 43:836-841. 
13.  Airaksinen KE, Salmela PI, Linnaluoto MK, Ikaheimo MJ, Ahola K, Ryhanen LJ: 
Diminished arterial elasticity in diabetes: association with fluorescent advanced 
glycosylation end products in collagen. Cardiovasc Res. 1993; 27:942-945. 
14.  Monnier VM, Bautista O, Kenny D, Sell DR, Fogarty J, Dahms W, Cleary PA, Lachin 
J, Genuth S: Skin collagen glycation, glycoxidation, and crosslinking are lower in 
subjects with long-term intensive versus conventional therapy of type 1 diabetes: Chapter 1 
17 
relevance of glycated collagen products versus HbA1c as markers of diabetic 
complications. DCCT Skin Collagen Ancillary Study Group. Diabetes Control and 
Complications Trial. Diabetes 1999; 48:870-880. 
15.  Beisswenger PJ, Makita Z, Curphey TJ, Moore LL, Jean S, Brinck-Johnsen T, Bucala 
R, Vlassara H: Formation of immunochemical advanced glycosylation end products 
precedes and correlates with early manifestations of renal and retinal disease in 
diabetes. Diabetes 1995; 44:824-829. 
16.  Baynes JW, Thorpe SR: Role of oxidative stress in diabetic complications: a new 
perspective on an old paradigm. Diabetes 1999; 48:1-9. 
17.  Sell DR, Lapolla A, Odetti P, Fogarty J, Monnier VM: Pentosidine formation in skin 
correlates with severity of complications in individuals with long-standing IDDM. 
Diabetes 1992; 41:1286-1292. 
18.  Thornalley,PJ, Battah,S, Ahmed,N, Karachalias,N, Agalou,S, Babaei-Jadidi,R, 
Dawnay,A: Quantitative screening of advanced glycation endproducts in cellular and 
extracellular proteins by tandem mass spectrometry. Biochem J 2003; 375:581-592. 
19.  Nakayama H, Taneda S, Mitsuhashi T, Kuwajima S, Aoki S, Kuroda Y, Misawa K, 
Yanagisawa K, Nakagawa S. Characterization of antibodies to advanced glycosylation 
end products on protein. J Immunol Methods. 1991; 140:119-25. 
20.  Mitsuhashi T, Vlassara H, Founds HW, Li YM.  Standardizing the immunological 
measurement of advanced glycation endproducts using normal human serum. J 
Immunol Methods. 1997; 207:79-88. 
21.  Münch G, Keis R, Wessels A, Riederer P, Bahner U, Heidland A, Niwa T, Lemke HD, 
Schinzel R. Determination of advanced glycation end products in serum by 
fluorescence spectroscopy and competitive ELISA. Eur J Clin Chem Clin Biochem. 
1997; 35:669-77. 
22.  Wolffenbuttel BH, Giordano D, Founds HW, Bucala R: Long-term assessment of 
glucose control by haemoglobin-AGE measurement. Lancet 1996; 347:513-515. 
23.  Meerwaldt R, Graaff R, Oomen PH, Links TP, Jager JJ, Alderson NL, Thorpe SR, 
Baynes JW, Gans RO, Smit AJ: Simple non-invasive assessment of advanced glycation 
endproduct accumulation. Diabetologia 2004; 47:1324-1330. Introduction 
18 
24.  Meerwaldt R, Lutgers HL, Links TP, Graaff R, Baynes JW, Gans RO, Smit AJ. Skin 
autofluorescence is a strong predictor of cardiac mortality in diabetes. Diabetes Care. 
2007; 30: 107-12. 
25.  Graaff R, Meerwaldt R, Lutgers HL, Baptist R, de Jong ED, Zijp JR, Links TP, Smit 
AJ, Rakhorst G. Instrumentation for the measurement of autofluorescence in the 
human skin. Proc SPIE 2005; 5692: 111-8. 
26.  Na RH, Stender IM, Henriksen M, Wulf HC: Autofluorescence of human skin is age-
related after correction for skin pigmentation and redness. J Invest Dermatol 2001; 
116:536-540 
27.  Ubink-Veltmaat LJ, Bilo HJ, Groenier KH, Houweling ST, Rischen RO, Meyboom-de 
Jong B: Prevalence, incidence and mortality of type 2 diabetes mellitus revisited: A 
prospective population-based study in The Netherlands (ZODIAC-1). Eur J of 
Epidemiol 2003; 18:793-800 
28.  Ubink-Veltmaat LJ, Bilo HJ, Groenier KH, Rischen RO, Meyboom-de Jong B.  Shared 
care with task delegation to nurses for type 2 diabetes: prospective observational study. 
Neth J Med. 2005; 63:103-10.  
 
CHAPTER 2 
 
 
Skin autofluorescence for the risk assessment of chronic 
complications in diabetes: a broad excitation range is 
sufficient 
 
 
M. Koetsier
1, H.L. Lutgers
2, A.J. Smit
2, T.P. Links
3, R. de Vries
3, R.O.B. Gans
2,  
G. Rakhorst
1, R. Graaff 
1 
 
 
 
 
 
1Department of Biomedical Engineering, 
2Department of Medicine, 
3Department of 
Endocrinology, University Medical Center Groningen and University of Groningen, 
Groningen, The Netherlands 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Resubmitted to Optic Express (September 2008) Chapter 2 
20 
 
ABSTRACT 
Introduction Skin autofluorescence (AF) is becoming an accepted clinical method for 
assessing the risk of chronic complications in diabetes mellitus (DM). In this study, the 
role of the excitation wavelength in the recognition of increased risk of diabetes-related 
chronic complications was investigated.  
Methods An Excitation Emission Matrix Scanner (EEMS) was used to perform non-
invasive measurements in four age-matched groups of patients with type 1 and type 2 
DM, with and without chronic complications, as well as in a control group (N=97 in 
total). AF was calculated for excitation wavelengths in the range 355 - 405 nm. Mean 
spectra were assessed per group. 
Results AF values in both type 1 and type 2 DM patients with complications were 
increased compared to the control subjects (p<0.01); this ratio remained practically 
constant, independent of the excitation wavelength. No emission peaks were distinctive 
for specific patient groups. 
Conclusion We conclude that in these groups, no characteristic fluorophores dictate the 
use of a specific wavelength or set of wavelengths. The results show the validity of 
applying a broad excitation wavelength range for risk assessment of chronic 
complications in diabetes. 
 
 
INTRODUCTION 
Autofluorescence of human tissue upon excitation with UV-A light, is caused by 
endogenous fluorophores including collagen, elastin, NADH, tryptophan and 
porphyrins [1,2]. Application of tissue autofluorescence in vivo has been used 
previously to detect local disorders such as cancer [3-8], age-related macular 
degeneration [9], psoriasis [10], and skin burns [11] and the effects of chronic ultra 
violet exposure [12]. 
Moreover, determination of skin autofluorescence from biopsies has been used in 
studies on systemic diseases such as diabetes mellitus (DM) [13]. Advanced glycation 
endproducts (AGEs) that cross-link collagen, are the main source of collagen linked Skin autofluorescence and excitation-emission maps 
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fluorescence (CLF) in skin biopsies and are classically determined by fluorescence at 
440 nm upon excitation at 370 nm [13]. AGEs are products of glycemic and oxidative 
stress, and their formation is increased in pathological conditions like DM, renal 
disease, and also in atherosclerosis. [14-18] Tissue-AGE determination is usually 
performed in skin biopsies. 
Several investigators have studied skin or lens autofluorescence non-invasively [19-
23]. We developed an Autofluorescence Reader (AFR) for non-invasive measurement 
of skin autofluorescence [24-27]. With this AFR, a prototype of the current AGE 
Reader (DiagnOptics, The Netherlands), the skin on the volar side of the forearm is 
illuminated with light in an excitation range of 350 - 420 nm (maximum intensity at 
370 nm), and emission in the range 420 - 600 nm is measured with a spectrometer. A 
strong correlation was not only found with CLF, but also with skin AGEs (pentosidine, 
N
ε-carboxymethyllysine, N
ε-carboxyethyllysine). These skin AGEs were assessed in 
dermal tissue of skin biopsies from DM patients, renal failure patients and healthy 
persons, taken from the same site as where the autofluorescence measurements were 
taken [24,28]. In later studies, AF has been studied in a range of other conditions such 
as atherosclerosis, preeclampsia, systemic lupus erythematosus (SLE), and glycogen 
storage disease (GSD) Ia [29-32]. Moreover, AF has been reported to be an 
independent predictor of macrovascular and microvascular complications [33] and of 
mortality in hemodialysis and DM patients [28,34]. 
The spectrum of the UV-A light source as used in the AFR and in the AGE Reader is 
shown in Figure 1 (continuous line). With the broad and fixed excitation range of this 
setup, we were unable to further identify specific fluorophores or AGEs. Therefore, an 
instrument was developed with a similar setup as in the AFR, but where excitation 
wavelengths could be varied: the Excitation-Emission Matrix Scanner (EEMS), as 
previously described by Graaff et al [25]. With this equipment, matrices of the amount 
of fluorescence as a function of excitation and emission wavelengths can be obtained 
from the skin in vivo to further investigate the skin fluorophores that are involved in 
various clinical conditions. This study will concentrate on EEMS measurements 
obtained from DM patients with and without DM-related chronic complications. Chapter 2 
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The aim of this study is first to determine which excitation and emission wavelengths 
are optimal for differentiation between diabetic and non-diabetic subjects or between 
diabetic subjects with and without DM-related chronic complications. And secondly, to 
evaluate whether the presence of DM-related chronic complications is associated with 
differences in fluorescence spectra. 
 
 
METHODS 
Subjects Excitation-emission spectra were collected in groups of patients with type 1 
and type 2 diabetes, with and without chronic complications, as well as in a control 
group, see Table 1. Diabetes patients were recruited from the University Medical 
Center Groningen. All participants gave informed consent to this study which was 
approved by the local medical ethics committee. 
All participants had an age between 35 and 50 years. This limited range of age was 
chosen, since the amount of accumulated AGEs increases with age [13,27]. Only 
Caucasian patients were included in this study, because dark skin may influence AF 
assessment [26]. We included 17-24 subjects in each group. Patients were classified as 
having chronic complications when retinopathy, neuropathy, microalbuminuria or 
macrovascular disease were present, all defined according to definitions described in 
detail previously [27,33]. Table 1 shows the characteristics of the five subject groups. 
 
Table 1: Characteristics of the five groups. 
  DM type 1 
without compl. 
DM type 1 
with compl. 
DM type 2 
without compl. 
DM type 2 
with compl. 
Control 
N 19 17 21 16 24
Age (yr)  42.3 ± 4.5  43.2 ± 4.6 45.8 ± 4.7 47.5 ± 5.1  46.8 ± 
Gender (M:F) 8:11  6:11 15:6 10:6  7:17
Diabetes 
duration (yr) 
20 ± 11  28 ± 7  5 ± 1  9 ± 6  - 
 Skin autofluorescence and excitation-emission maps 
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Equipment and Measurements For generating excitation dependent emission spectra, 
an instrument had been developed where excitation wavelengths can be varied. This 
instrument was obtained by adaptation of a 0.2 m f/4 monochromator (PTI, New 
Jersey, USA), and was illuminated by a 75 W Xenon lamp. The monochromator has 
been connected to a measuring section, where a glass fiber (with a diameter of  200 
µm) is pointed at the measuring site under an angle of 45 degrees. This glass fiber is 
connected to a spectrometer (USB2000, Avantes, Eerbeek, The Netherlands). The total 
setup, referred to as Excitation Emission Matrix Scanner (EEMS) has a similar setup as 
the previously described tool for measuring skin autofluorescence, the AFR [25]. 
Wavelength scanning of the monochromator was realized with a PC using a LabView 
program (National Instruments, Austin, USA). The spectra were obtained by this 
software as well. Measurements were performed on the volar side of the arm, 
approximately 10 cm below the elbow. A whole series of measurements, including 
measurements at 11 excitation wavelengths (355 - 405 nm, in steps of 5 nm) was 
performed in a few minutes. Optimal integration times were determined by the 
LabView program, therefore, all spectra were measured in the same dynamic range of 
the spectrometer. Dark spectra were also obtained and subtracted for all applied 
integration times. The shape of the peak at each selected excitation wavelength can be 
described by a normal distribution with a standard deviation of 6.5. 
 
Analyses and statistics  Autofluorescence as obtained from the EEMS was defined as a 
function of excitation wavelength for all subjects as  
AFE(λexc) = 100 × <Iem> / <Iexc>     equation (1) 
where <Iem> is the mean measured light intensity in the range 420 - 600 nm and <Iexc> 
is the mean intensity in the range 300 - 420 nm, both for excitation wavelength λexc. 
This same method is used in the AGE Reader to calculate AF from the spectrum. After 
calculating AFE for all subjects, the mean AFE for subjects in the control group per 
excitation wavelength was used as a reference for all four DM subject groups.  Chapter 2 
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For comparison between AF values of DM subject groups and the control group, we 
introduced relative autofluorescence as  
AFE,rel(λexc)=<AFE(λexc)>patient /<AFE(λexc)>control   equation (2) 
where <AFE(λexc)>patient is the mean AFE(λexc) of a DM subject group and 
<AFE(λexc)>control i s  t h e  m e a n  A F E(λexc) of the control group. For each excitation 
wavelength and for all DM groups separately, a Mann-Whitney U-test was performed 
against the control group to evaluate the significance of the difference. These tests were 
performed using SPSS. 
In the AGE Reader, a blacklight is used, emitting a broad band of UV light, as shown 
in  Figure 1. In order to derive an analysis for this light source, a weighted summation 
of measured responses on excitation at given wavelengths was used. The AF resulting 
from the blacklight, AFBL, per subject was calculated using  
AFBL = Σ wi AFi / Σ wi      equation (3) 
where AFi is AFE as calculated from excitation peak i and the weight factor wi was 
determined by multiple regression fitting of the separate peaks to the broad excitation 
peak. The broad excitation peak that can be reconstructed in this way is shown in 
Figure 1 (dotted line). The Mann-Whitney U-test calculations were also performed for 
AFBL. 
 
Figure 1. Spectrum of the UV-A light source as used in the AFR and the AGE Reader 
(continuous line) and a fit using a weighted summation of EEMS responses of separate 
excitation peaks (dotted line). The small peaks at 366 nm and at 405 nm are caused by mercury 
emission within the lamp. Skin autofluorescence and excitation-emission maps 
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To analyze possible differences in the emission spectra between the groups, the spectra 
were all normalized. The mean value of intensity of the emission peak (in the range 
450 - 600 nm) was taken as a reference. Subsequently, mean values were calculated 
(per nanometer) from the normalized spectra of all subjects in each group for each 
excitation wavelength. These mean spectra were used to observe whether emission 
peaks occurred that might be specific for a certain patient group. 
 
 
RESULTS 
Autofluorescence ratio Autofluorescence values (AFE(λex)) were obtained for all 
subjects for excitation wavelengths in the range 355 - 405 nm in steps of 5 nm. Figure 
2A shows the mean relative AFE(λex) values for the four groups. The standard deviation 
of the AF values within each group ranged between 18% and 36% of the mean value. 
Instead of error bars, Figure 2B shows the significance of the differences between 
groups. The figure shows a significantly increased mean AFE for the two groups of DM 
subjects with chronic complications (p < 0.01) for all excitation wavelengths. Also the 
group of type 1 DM subjects without chronic complications tends towards an increased 
AF. It should be noted that the measurements with an excitation wavelength of 360 nm 
were discarded from this part of the study, because of technical problems during the 
measurements. Finally, equation (3) was used to calculate results for the broad 
excitation peak of the AGE Reader. Figure 2 shows similar results for the broad 
excitation peak as compared to the separate narrow excitation peaks. No significant 
differences in mean autofluorescence values between subjects within each group were 
found for smoking, gender and age. The difference between the groups with DM type 1 
and type 2 patients without complications that can be seen in Figure 2B is not 
significant (p > 0.05) and may be caused by the longer diabetes duration of the DM 
type 1 patients. Chapter 2 
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Figure 2. A. Mean relative autofluorescence for the separate excitation peaks (AFE,rel(λex)) and 
the broad excitation peak from the blacklight (BL) as used in the AGE Reader. B. Statistical 
significance (Mann-Whitney U-test) of the differences between AFE values of subjects in the 
respective subject groups and the control group. Squares denote the groups of subjects with type 
1 DM, diamonds denote type 2 DM. Closed figures denote the groups of subjects with chronic 
complications, open figures denote the groups of subjects without complications. 
 
 
Figure 3. Emission peaks from the average spectra of the control group for increasing excitation 
wavelength. The spectra are normalized for emission. 
 
Normalized spectra. The emission peaks of the normalized spectra for the control 
group are displayed in Figure 3. The shape of the spectrum is slightly changing for 
different excitation wavelengths. However, the maximum intensity remains at 
approximately 500 nm, independent of excitation wavelength. The normalized spectra Skin autofluorescence and excitation-emission maps 
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of the four patient groups have a similar shape. The emission spectra of all five groups 
are shown in Figure 4 for excitation wavelengths of 375 nm (a) and 400 nm (b). These 
figures clearly show the similarity of the emission spectra between groups. The 
examples are typical for all other excitation wavelengths as well. 
 
 
 
Figure 4. Emission peaks from the average spectra of the five groups for λexc = 375 nm (a) and 
λexc = 400 nm (b). In (b), the spectrum starts at 443 nm as below that wavelength, the excitation 
peak is still present. 
 
 
 
DISCUSSION 
No specific excitation or emission wavelengths were found that would yield an 
increased distinction between the groups of patients with both types of DM, with or 
without chronic complications, or the control group. In fact, our results show almost 
constant factors and significances for all excitation wavelengths. Consequently, about 
the same factors occur for the broad excitation band from the blacklight as used in the 
AGE Reader. From the observation that the emission spectra of the five groups are 
very similar for each separate excitation wavelength, it can be concluded that no 
fluorophores dictate the use of specific excitation or emission wavelengths in these Chapter 2 
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patient groups. Therefore, the shapes of the spectra do not add more information to 
skin autofluorescence as determined by the AGE Reader for recognizing DM or 
chronic complications in DM. Moreover, from our results, all fluorophores seem to be 
equally increased in the groups of patients with complications. 
The observed broad emission spectrum as seen in the normalized spectra could 
be expected, since many fluorophores exist in the skin [22,35]. It should be noted that 
variation of the excitation wavelength only yields a few changes in the shape of the 
emission spectrum. This implies that the different skin fluorophores have at least 
overlapping excitation spectra. Our results suggest that the role of excitation 
wavelength may not be very important to detect clinical differences, a suggestion that 
also raised in the field of cancer detection [36]. 
It is a remarkable observation that the shapes of the emission spectra for a 
given excitation wavelength are similar for the different groups, even as compared to 
the controls. The high number of different fluorophores in the skin and their 
interwoven emission spectra as well as the turbid nature of tissue, make it very difficult 
to recognize specific fluorophores that might cause differences between the groups. 
Furthermore, the spectra may be influenced by the location of the fluorophores in the 
skin, the biochemical and biophysical environment, and the presence of other (non-
fluorescing) chromophores [22,37,2]. We speculate that the same pool of fluorophores 
causes fluorescence in healthy subjects as in DM patients, since only the amount is 
different, not the composition.  
Our initial expectation was that we might see specific AGE-related emission peaks in 
metabolic diseases like DM as compared to control subjects, since AGEs have an 
essential role in the development of chronic complications in DM [13,38,39]. We 
furthermore expected a possible difference between type 1 and type 2 DM, as these 
diseases with different metabolic conditions could generate different AGEs. Collagen-
linked 370/440 nm fluorescence, as a marker of AGE accumulation, was a proven 
predictor of these complications in earlier studies on skin biopsies, and fluorescent 
AGEs such as pentosidine and argpyrimidine are also related to such conditions. These 
and some other fluorescent compounds (for example NADH) might result in clinically Skin autofluorescence and excitation-emission maps 
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relevant specificities in excitation-emission pairs. However, attempts to derive specific 
emission peaks from our measurements between different groups have not yet been 
successful; the clinical differences manifest themselves proportionally for all 
excitation-emission pairs. 
Even without an exact knowledge of the composition of the fluorophores, a 
correlation exists between the amount of total autofluorescence and presence of DM-
related chronic complications, as has been reported before [27,34]. The study of 
Lutgers et al reported an increased AF for type 2 DM patients without chronic 
complications, while our study showed no increased AF in this group [27]. The type 2 
DM population in that study was however a large unselected cohort. Our rather small 
group of type 2 DM patients without complications was specifically selected for having 
type 2 DM and being in perfect health otherwise. However, our results show a clear 
distinction of the groups of subjects with chronic complications in either DM type, 
with highly significant differences compared to controls and almost constant factors for 
all excitation wavelengths. These significant differences remain present for a broad 
excitation band from a blacklight as used in the AGE Reader. This finding confirms the 
validity of using a broad excitation wavelength for distinguishing complications in 
conditions such as diabetes mellitus. 
 
CONCLUSION 
Our results show that skin autofluorescence at all excitation wavelengths in the range 
355 - 405 nm equally distinguishes increased risk of DM-related chronic complications 
in Caucasian subjects. The fluorophores do not dictate the use of a specific wavelength 
or set of wavelengths in assessing this risk. These results therefore show the validity of 
a broad excitation wavelength range, such as applied in the AGE Reader. 
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ABSTRACT 
Advanced glycation endproducts (AGE) are a class of compounds resulting from 
glycation and oxidation of proteins, lipids or nucleic acids. Glycation is the non-
enzymatic addition or insertion of saccharide derivatives to these molecules. This leads 
to the formation of intermediary Schiff bases and Amadori products and finally to 
irreversible AGE. This classical view has been modified in recent years with 
recognition of the importance of oxidative and carbonyl stress in endogenous AGE 
formation. AGE may also have exogenous sources, in certain foods and tobacco 
smoke. A whole class of specific and non-specific receptors binding AGE has been 
characterized. Apart from cross-linking of proteins by AGE, the effects of receptor 
stimulation contribute to the development of chronic complications of conditions like 
diabetes mellitus, renal failure, and atherosclerosis. Possible interventions to reduce the 
effects of AGE accumulation include AGE formation inhibitors or breakers, or receptor 
blockers, but possibly also dietary interventions. 
Some of the problems with current assay or diagnostic techniques, and several 
unresolved issues on the role of AGE in disease will be discussed. Our review will 
focus on the clinical and pharmaceutical implications of these developments. 
 
INTRODUCTION 
Advanced glycation endproducts (AGE) are a diverse class of compounds resulting 
from a glycation process under the strong influence of oxidative or carbonyl stress. 
Although AGE were initially considered as a noxious byproduct with an adverse effect 
on the function of proteins due to increased cross-linking, it has become evident that 
AGE also bind and interact with several receptors, such as the receptor for advanced 
glycation endproducts (RAGE) and also scavenger receptors like galectin-3 and CD36. 
Binding of AGE to such receptors mediates intracellular signalling and induces 
changes in cellular function, resulting in release of cytokines and growth factors. The 
AGE-receptor interactions are now considered pivotal in the AGE-induced 
pathogenetic changes.  Clinical relevance of AGEs 
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AGE accumulate with age on long-lived proteins, but at a more rapid rate in conditions 
like diabetes mellitus and renal failure. Diabetes and renal failure may serve as 
examples of increased AGE formation and breakdown, respectively, but in both 
conditions the additional role of increased oxidative stress is evident. This review will 
address in more detail the relation between AGE accumulation and chronic 
complications of these and related conditions. We also review the developments of the 
different strategies in reducing AGE accumulation. AGE formation inhibitors 
(aminoguanidine, pyridoxamine and others), AGE breakers (ALT-711) and other 
approaches to reduce AGE accumulation will be discussed. 
 
SOURCES OF AGE FORMATION IN THE BODY 
Endogenous AGE Formation  
It was long believed that glucose, the type of sugar most abundantly contained in an 
organism, was biologically inert. However, proteins, lipids and nucleic acids can be 
modified non-enzymatically by glucose and other reducing sugars [1]. In the early 
stages of AGE formation, the so-called Maillard reaction, the aldehyde groups of 
reducing sugars react with amino groups of N-terminal amino acids or epsilon lysine to 
form Schiff bases, which are then converted by the Amadori process into a more stable 
ketoamine (Amadori product). In most proteins the source of the amino group is the 
epsilonamino group of the amino acid lysine. Reducing sugars in solution exist in both 
open-chain and ring (pyranose or furanose) forms. Only the open-chain structures react 
with proteins. The proportion of the open-chain forms thus  determines the reactivity of 
the sugars in the Maillard reaction with a rank order of glucose < fructose < ribose, 
with phosphorylated sugars such as intracellular glucose-6-phosphate, being more 
potent than their unphosphorylated counterparts [2,3] as well. The reactivity of 
intracellular, phosphorylated sugars is illustrated by a 13.8 fold increase in intracellular 
AGE content after 1 week of incubation of endothelial cells in the presence of high 
glucose [4]. Because the glycation process is concentration-dependent in the early 
rather than later stages of the Maillard reaction, it is enhanced in hyperglycaemia [5,6]. 
During AGE formation, reactive intermediate products are formed [7,8]. These reactive Chapter 3 
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intermediate products are also termed in the literature as: dicarbonyls, oxoaldehydes, 
reactive carbonyl compound (RCO) or ,carbonyl stress, [9]. Well-known examples are 
methylglyoxal (MGO) and 3-deoxyglucosone (3-DG) [10]. MGO can be formed from 
oxidative decomposition of fatty acids, but non-oxidative mechanisms (anaerobic 
glycolysis) predominate in its formation. Mitochondrial overproduction of reactive 
oxygen species, with consequent inhibition of the glycolytic enzyme GAPDH and 
increased triose phosphate levels have a central role in the formation of intracellular 
MGO-derived AGE [11,12]. Overproduction of superoxide by the electrontransport 
chain in mitochondria seems not only to be responsible for increased intracellular AGE 
formation, but also acts as a common pathogenetic pathway for other mechanisms of 
hyperglycaemia-induced damage like PKC activation, and polyol and hexosamine 
pathway induction.  
    The enzyme glycoxalase may have an impairing role in AGE formation by 
promoting the detoxification of dicarbonyls, as was recently described by Miyata [13]. 
AGE formation can also be influenced by reducing compounds such as ascorbate. In 
vitro studies show that anti-oxidants reduce CML (Nε-carboxymethyllysine) formation. 
Oxidation of polyunsaturated fatty acids in the presence of proteins can lead to CML 
formation suggesting that lipid oxidation has a role in AGE formation [14]. In 
inflammatory conditions like rheumatoid arthritis, increased AGE formation arises 
without hyperglycaemia. An in vitro study showed that myeloperoxidase produced by 
activated phagocytes, is able to form reactive carbonyls and CML [15]. Thus, besides 
reducing sugars and peroxidation of lipids, myeloperoxidase seems to play an 
additional role in the formation of AGE precursors and AGE. This could contribute to 
the insights of the pathogenesis of various inflammatory diseases.  
    As a final point in this paragraph of endogenous AGE formation, genetic 
factors might also contribute to the course of glycation. In a classical twin study, it was 
found that the interclass correlations in the clinically well-known Amadori product 
glycated haemoglobin (HbA1c) were considerably higher in monozygotic twins 
compared with dizygotic twins, independent of an also demonstrable genetic effect on 
fasting glucose levels [16]. Another mono- and dizygotic non-diabetic twin study Clinical relevance of AGEs 
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found that, after adjusting for age, current glucose homeostasis and smoking, 28% of 
the interindividual variation in lens protein autofluorescence was attributable to 
hereditary factors (and shared environment for 58%, and non-shared environment for 
14% [17]. Thus, there are indications that glycation levels are partly genetically 
determined, but this area has not been extensively studied so far. 
 
Exogenous Sources of AGE: Food and Smoking 
The Maillard reaction leading to AGE formation was originally described for heating 
food. AGE ingested with food are absorbed to a small extent, although the diversity of 
AGE and assay problems quantification of AGE absorption from food is difficult. Oral 
bioavailability is estimated to be in the order of 10%, the AGE-induced cross-link 
formation is resistant to enzymatic or chemical hydrolysis [18]. The accumulation of 
food derived AGE and alpha-oxoaldehyde AGE precursors has been assumed to 
contribute to AGE derived deleterious effects. When AGE-modified albumin was 
administered to healthy nondiabetic rats and rabbits [19], after 2-4 weeks animals 
displayed diabetes-like vascular complications: a significant increase in vascular 
permeability, significant mononuclear cell migration in subendothelial and 
periarteriolar spaces and a defective endothelium-dependent and -independent 
vasodilatation. Furthermore, glomerulosclerosis and albuminuria, comparable to 
diabetic nephropathy are seen in control rats receiving daily injection with AGE [20]. 
Both animal studies showed the deleterious effect of exogenous AGE. An additional 
human study showed that the daily influx of dietary AGE includes glycotoxins that 
may constitute an added chronic risk for renal-vascular injury in DM [18]. Dietary 
restriction of AGE food is discussed below under the Interventions paragraph. 
    Apart from the direct intake of AGE with food, meals can also influence AGE 
accumulation and production by excursions in glucose levels. After a meal, diabetic 
patients can exhibit a hyperglycaemic state, a so-called post prandial glucose excursion 
(PPGE). These PPGE can even occur when blood glucose is tightly regulated. A study 
showed that the so-called PPGE correlated well with MGO and 3-DG, two highly 
reactive precursors of AGE formation [21].  Chapter 3 
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Tobacco smoke contains products that produced AGE-like fluorescence, protein 
crosslinks, mutagenicity and increased AGE on plasma proteins [22]. Cigarette smoke 
contains high concentrations of GO and MGO from the thermal decomposition of 
saccharides. These are the likely important mediators of smoking associated AGE 
formation. Increased serum AGE levels were found in diabetic smokers compared to 
diabetic non-smokers [23].  
 
REMOVAL OF AGE 
The removal of proteins cross-linked with AGE depends on both the degradation of 
AGE linked proteins to AGE-peptides by macrophages, and on the clearance of AGE 
and AGE-peptides by the kidney [24-27]. Macrophages with special AGE receptors 
engulf and subsequently transport AGE. Miyata et al. provides evidence for filtration 
of the AGE-compound pentosidine through the glomeruli and the active reabsorption 
of pentosidine in the proximal tubules [26]. After modification or degradation in the 
proximal tubules pentosidine was finally cleared in the urine. These findings were 
confirmed for AGE-peptides by Gugliucci et al. [27]. A fall in renal glomerular or 
tubular function thus affects the capacity for AGE removal and result in higher blood 
level of AGE and eventually tissue AGE accumulation.  
    Scavenger receptors in the liver Kupffer and endothelial cells may also result 
in endocytic uptake of AGE proteins from the blood [28,29]. High serum AGE levels 
have been reported in patients with liver failure [30]. The expression of the 
macrophage scavenger receptor (MSR) which is involved in the endocytic AGE uptake 
in liver endothelial cells, but perhaps also subsequent steps like lysosomal degradation, 
may be increased by insulin [29]. It was recently reported that plasma AGE levels are 
markedly elevated in liver cirrhosis and correlated with the severity of disease, while 
serum CML levels correlated inversely with residual liver function [30]. Elevated 
plasma CML levels markedly fell within 3 months after liver transplantation. This 
suggests that the liver also has a function in removal of plasma AGE [31]. Perhaps this 
occurs with the OST-48 or galectin-3 receptor, or the scavenger receptor (SR)-A or -B 
for all of which expression in the liver has been reported [32-34].  Clinical relevance of AGEs 
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As for the rate of AGE removal after restoring normoglycaemia (by islet 
transplantation) in previously diabetic animals, the results of Sensi et al. suggest that 
reversal of accumulated tissue AGE takes many months to occur [35]. This may 
explain discrepancies between circulating and tissue AGE levels which have been 
reported, for example after kidney transplantation [36]. 
 
RATE OF AGE ACCUMULATION 
Equilibrium levels of the reversible Schiff base and Amadori products are reached 
within hours and days, respectively. AGE form over longer period of weeks but remain 
irreversibly bound to amino groups. Using both immunohistochemical methods and 
four monoclonal antibodies for specific AGE molecular structures (including CML and 
carboxyethyllysine (CEL), but also as yet unknown epitopes), Ling et al. identified in 
various organs in fetal rats already at 10 fetal days with increasing accumulation during 
ontogeny [37]. The results suggest that CML as non-fluorescent, non-cross-linked 
AGE starts earlier to accumulate than fluorolink, a fluorescent, cross-linked AGE. 
Thus AGE accumulation starts very early, already in the fetal period. The Maillard or 
browning reactions that eventually lead to cross-linking and denaturation of proteins 
may occur with all proteins in the body, but long-lived proteins such as collagen, which 
represents over 30 percent of body protein, accumulate chemical damage with age. 
Other long-lived proteins include lens-proteins and nerve myelin, which together with 
collagen are the most important targets for AGE formation. Next to these substrates 
other forms of macromolecules containing a free amino group are susceptible to AGE 
formation, like lipids and nucleic acids [38]. Especially in uraemia, associated with 
very high AGE levels, such shorter lived compounds as lipid constituents are affected. 
It must be pointed out that the dynamics of circulating AGE may be quite different: in 
rats with acute renal failure CML levels (measured fluorometrically) increased 
threefold within 48 hours [39]. The various pathways in the formation and removal of 
AGE are summarized in Figure 1. 
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EXAMPLES OF AGE 
As mentioned before, the information on the chemical structure of AGE is limited. Of 
the several dozens of AGE moieties only a minority has been characterized, even less 
have been related to clinical human disease. In 1984 Pongor et al. first proposed a 
structure for AGE. They suggested the fluorescent aromatic heterocyclic compound 2-
(2-furoyl)-4-(5)-(2-furanyl)-1-H-imidazole (FFI) generated through a condensation of 
two Amadori products [40]. They also emphasized that FFI is likely to constitute less  
than 1% of total AGE present in vivo. Sell and Monnier [41] identified a fluorophore 
present on human dura mater collagen. This fluorophore was identified as an imidazo- 
(4,5-b)-pyridinium ring with lysine and arginine side chains, named pentosidine. Two 
other pyrrole-related compounds have now been identified. These are 1-alkyl-2-formyl- 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Steps and pathways in the formation and excretion of glyc(oxid)ation and lipoxidation 
products (normal lines). Products of the diverse steps in AGE formation are able to stimulate 
AGE formation themselves (broken lines). 
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3,4-diglycosylpyrrole (AGFP) and pyrraline (5-hydroxymethyl-1-neopentylpyrole-2-
carbaldehyde). CML, pentosidine and hydroimidazolone are known to be glycoxidation 
products which means that they require oxidation reactions for their formation from 
glucose. As these last three compounds are well characterized they are frequently used 
as marker for AGE levels in plasma and in histological studies. The structure of 
pentosidine and CML, but also of some other AGE like pyrraline, CEL and 
imidazolone has been elucidated. A characteristic property of several AGE is their 
fluorescence. CML is, however, non-fluorescent. CML may be a dominant AGE 
antigen in tissue proteins [42,43]. The known AGE are immunologically distinct and 
coexist on different carrier proteins such as collagen, albumin, haemoglobin, lens 
crystalline, but also LDL cholesterol. Pentosidine and CML are well-known examples 
of advanced glycoxidation products, resulting from combined glycation and oxidation. 
In blood 90% of pentosidine and CML are bound to protein with 10% being free. 
Under normal conditions Hb-AGE accounts for 0.42% of circulating haemoglobin but 
this increases to 0.75% in diabetic subjects [44]. Hb-AGE concentration responded 
slowly to intensive glycemic control and may reflect glycemic control over the 
preceding 10-14 weeks rather than the 6-8 weeks indicated by HbA1c [45]. In early 
studies, using ELISA for total AGE, up to 100 fold increases were reported in serum 
AGE in diabetics with end stage renal disease (ESRD), in later studies 23-fold 
increases in serum pentosidine in ESRD [46].  
    Nagai et al. recently described a new precursor of CML, glycolaldehyde (GA)-
pyridine, which was present in the cytoplasm of foam cells and extracellularly in the 
central region of atheroma in human atherosclerotic lesions [47].  
 
BIOLOGICAL EFFECTS OF AGE 
Changed Protein Function by Conformational Changes, the Role of Cross-Linking 
A common consequence of AGE formation is covalent cross-linking, mostly to 
proteins. These cross-links may result in entrapment of proteins, lipoproteins and 
immunoglobulins [2]. Cross-linking of collagen proteins, for example, contributes both 
to the rigidity and the loss of elasticity of tissues, and increases resistance to proteolysis Chapter 3 
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[48-51]. The latter process inhibits tissue remodelling. Among the consequences are 
the thickening of capillary basement membrane observed in diabetes. This protein 
modification is also responsible for crystalline lenses becoming opaque in cataracts, a 
degenerative disease that is frequent in diabetic or aged persons. Glomerular sclerosis 
is another consequence. These processes are discussed in more detail below. 
    Small soluble AGE peptides released into the circulation by macrophages after 
degradation of AGE proteins may react and covalently bind to proteins such as 
collagen and LDL. Such reactive intermediates from degraded AGE can form ,second 
generation, AGE and so actively contribute to the biological AGE effects. 
    AGE-formation on the extracellular matrix results in a decreased elasticity and 
increased thickness and rigidity of the vascular wall and in narrowing of the vessel 
lumen.  
    Diminished arterial elasticity in humans with diabetes was related to enhanced 
AGE-formation before [52]. AGE formed on vascular matrix proteins mediate 
defective endothelium-dependent vasodilatation by quenching nitric oxide [53]. 
Moreover, incubations of rat aorta segments with high-glycosylated human 
haemoglobin inhibited endothelium-dependent relaxation in this vessel [54]. At the 
microvascular level, the toxic effect of AGE on retinal capillary pericytes and 
endothelial cells was shown in vitro [55]. The functional effects of AGE on the 
endothelium include inhibition of prostacyclin production and increased plaminogen 
activator inhibitor 1 (PAI-1) and vascular endothelial growth factor (VEGF) production 
[56,57]. AGE also induce the expression of the potent vasoconstrictor endothelin-1 
[58]. Part of these latter effects may be due to more effects mediated by AGE receptors 
than by conformational changes, as further discussed below. 
    Lipoprotein modification by AGE contributes to the dyslipidaemia frequently 
observed in diabetic patients [1]. Such a modification of LDL in diabetes may render 
the LDL particles more atherogenic, contributing to the atherogenic risk for diabetic 
patients. Another consequence may be that lipoproteins are trapped by AGE formed on 
the matrix components of the vascular wall, resulting in an impaired cholesterol efflux 
and subsequently in vascular lipoprotein accumulation [59]. This has, however, been Clinical relevance of AGEs 
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debated by others [60]. Glycated LDL also triggers endothelial transcription activators 
like STAT-5 [61].  
 
Induction of Oxidative Stress 
AGE binding to cellular binding sites results in depletion of cellular antioxidant 
defense mechanisms such as vitamin C and glutathione and the generation of oxygen 
free radicals [62,63]. These mechanisms may also involve receptor stimulation. For 
example, activation of NADPH oxidase in AGE-RAGE mediated generation of 
reactive oxygen species in human endothelial cells [64]. Semicarbazide-sensitive amine 
oxydase (SSAO) may have a contributory role by production of MGO [65]. Other 
experiments showed a potentially important role for oxygen free radicals and NO in 
mediating permeability and blood flow changes induced by AGE involving increased 
protein kinase C activity and VEGF production [66]. An additional study confirmed 
increased VEGF expression by AGE-albumin through the activation of hypoxia 
inducible factor-1 (HIF-1)[67]. In diabetes, persistent hyperglycaemia causes increased 
production of free radicals via the processes of autoxidation of glucose and non-
enzymatic protein glycation, discussed above, and via an enhanced flux of glucose 
through the polyol pathway [68]. Oxidation of plasma lipids may stimulate 
autoxidative reactions of sugars, enhancing damage to both lipids and proteins in the 
circulation and the vascular wall. In this way, the cycle of oxidative stress and damage 
is continued and reinforced. Bucala et al. first showed the effect of advanced 
glycosylation on lipid oxidation [69]. Its role in accelerating atherosclerosis has been 
discussed by Vlassara and by Bierhaus [2,70].  
 
Receptor Stimulation and Post-Receptor Effects of AGE 
AGE formation not only changes the physiological properties of proteins and other 
molecules, but also induces cellular dysfunction through interaction with more or less 
specific cell surface receptors. An increasing number of AGE-receptors has been 
identified and characterized. These receptors include the receptor for AGE (RAGE), Chapter 3 
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AGE-R1, AGE-R2 and AGE-R3, but also other receptors classified as scavenger 
receptors (SR), SR-A and SR-B.  
    RAGE was identified in 1992 as a 35-kDa protein in bovine lung endothelial 
cells, and is still considered as a representative AGE receptor on endothelial cells. It 
belongs to the immunoglobulin superfamily [71,72]. In contrast to scavenger receptors, 
binding of AGE to RAGE does not result in endocytosis of AGE, but results by 
intracellular signalling in, abnormally sustained, activation of NF-kappa-B, and 
subsequent expression of endothelial adhesion molecules and tissue factor [73,74]. 
Epithelial-myofibroblast transdifferentiation, an important step in the development of 
tubulointerstitial fibrosis which is often observed in diabetic nephropathy, is caused by 
AGE-RAGE interactions [75]. Enhanced RAGE expression also has been correlated 
with nephropathy, retinopathy, neuropathy, autoimmune, and inflammatory disorders. 
In the vasculature RAGE has been associated with the induction of apoptotic death 
[76]. This action may be responsible for several complications related to diabetes, 
including vascular leakiness and nonresponsiveness. Animal studies using soluble 
RAGE to block the RAGE receptor also show a reduction in vascular permeability and 
a suppression of vascular lesion formation. RAGE antibodies were also found by 
Esposito et al. to prevent an increase in adhesion of peripheral blood mononuclear cells 
during hyperglycaemia [77]. Not only AGE but also amphoterin and amyloid beta-
peptide are major ligands for RAGE. Amyloid beta-peptide is thought to be important 
in the pathogenesis of Alzheimer’s disease; the role of AGE in this disease is discussed 
below. At least 9 polymorphisms of the RAGE gene exist. One of these polymorphisms 
(-429 C allele) has an increased prevalence in type 2 diabetes patients with compared to 
those without retinopathy [78]. A low expression of the AGE-R1 gene in macrophages 
from diabetic (type 1 like) mice, but also in fresh peripheral blood mononuclear cells 
and in Epstein-Barr virus (EBV)-transformed cells from type 1 diabetic patients with 
complications, together with elevated serum AGE levels, suggests that the normal 
function of AGE R1 receptor in the turnover of AGE may be ineffective in these 
patients, possibly by genetic influences [79]. Double transgenic mice with both 
overexpression of human RAGE in vascular cells, and development of insulin-Clinical relevance of AGEs 
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dependent diabetes had renal histological changes and increased serum creatinine and 
albuminuria. The development of histological and functional diabetic nephropathy was 
prevented with the AGE-inhibitor OPB-9195 [80]. Thus, the functional consequences 
of RAGE binding depend not only on AGE levels, but also on variations in gene 
polymorphism and expression. Galectin-3 is a lectin-like protein that has been 
identified as a component of p90, a 90 kDa AGE-binding protein, originally identified 
in the rat liver [81]. Galectin-3 modulates cell adhesion, cell cycle control, and mRNA 
splicing. Galectin-3 may have a protective role against diabetic glomerulopathy, as 
suggested by the increased AGE accumulation and accelerated glomerulosclerosis in 
galectin-3 knockout mice made diabetic [82].  
    AGE which are negatively charged have been shown to bind to SR-A type I 
and II. In these experiments AGE-BSA underwent active endocytosis upon binding to 
SR-A [24]. Remarkably, CML does not bind to SR-A while glycolaldehyde-modified 
proteins which generate CML do [47]. CD36, a highly glycosylated protein of 88kDa, 
binds various ligands such as fatty acids, collagen, oxidized LDL and has recently been 
shown to act also as an AGE receptor [83]. CD36 acts in adipocytes as a fatty acid 
transporter and in macrophages as a receptor for oxidized LDL [84]. CD36  is 
markedly expressed in the core of atherosclerotic lesions. CD36 is considered as an 
important oxidized LDL receptor. AGE-binding to this receptor may contribute to the 
acceleration of atherosclerotic lesions. Apart from modification of LDL-cholesterol by 
LDL-AGE-formation which is much slower degraded in macrophages, as discussed 
elsewhere in this paper, and apart from the effects on CD36 as an important receptor 
for oxidized LDL, AGE may also more directly affect cholesterol metabolism by 
binding to another scavenger receptor, the SR-B1. SR-B1 is very similar, if not 
identical, to the one that internalizes acetyl LDL (and oxidized LDL) [34]. SR-B1 also 
recognizes high density lipoprotein (HDL) and mediates its uptake [85]. SR-B1 is 
considered to accelerate reverse cholesterol transport by promoting cholesterol efflux 
from peripheral cells, for example from macrophages in the vascular wall, and 
mediates selective uptake of HDL-cholesterol by hepatocytes. Ohgami et al. showed 
that SR-B1 recognized AGE as a ligand. No cross-competition as ligands seems to Chapter 3 
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exist between HDL and AGE-binding proteins. However, intracellular processing of 
HDL may be affected by an interaction between SR-B1 and AGE [59]. AGE also affect 
SR-B1 mediated cholesterol efflux but not SR-B1 independent cholesterol efflux. Thus 
AGE seem to inhibit reverse cholesterol transport [86].  
    Expression of the different AGE receptors has been found on a wide range of 
cell-types including monocytes, macrophages, endothelial cells, mesangial cells, 
fibroblasts, smooth muscle cells and tubule cells [64,74,79,87].  
 
MARKERS OF AGE AND PROBLEMS WITH CURRENT ASSAYS 
Because the structure of AGE is complex and heterogeneous, measurement of tissue 
and serum AGE has been difficult, and, as there is no recognized standard, different 
groups may not be measuring in exactly the same way. Reproducibility of many assays 
is rather poor. The limited knowledge on the specific structure of different AGE 
moieties also makes it difficult to draw any firm conclusions on the relative toxicity of 
different specific AGE. Table 1 summarizes the different markers of AGE and their 
advantages and disadvantages. Classically fluorescence is the method used in many 
clinical studies as a marker of AGE. AGE has a yellow brownish pigmentation with a 
characteristic fluorescence pattern: excitation in the range 350-390 nm and 
fluorescence emission at 440-470 nm. Applying fluorescence spectroscopy, AGE have 
been measured in serum, urine and also in different kinds of tissues [88-90]. The 
presence of other, non-AGE, fluorescent substances like NADPH and of non-AGE 
protein adducts, such as glucose- or lipid-derived oxidation products, that exhibit 
similar fluorescence spectra, as well as the interference by non-protein tissue 
components, makes the specificity of this method low. Fluorescent  quenching 
associated with biological samples may also impede specificity. Furthermore, many but 
not all AGE have fluorescent properties. Examples of non-fluorescent AGE are CML 
and pyrraline [91,92]. The fact that most clinical data on the relation with AGE 
accumulation have still been based on association with fluorescence makes this method 
still valuable. However, tissue samples are required, which makes this invasive  Clinical relevance of AGEs 
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technique less suitable for repetitive AGE monitoring. Recently, Meerwaldt et al. 
reported on a rapid, non-invasive measurement of skin autofluorescence to asses AGE 
accumulation [93]. Although the above mentioned limitations of fluorescence still are 
valid, this non-invasive technique is much more convenient. If a relation with clinical 
data and its prognostic value are confirmed, this method might offer a feasible method 
in patient care.  
    AGE with known structures, such as pentosidine and CML, can be measured 
with a high degree of specificity using HPLC [94,95]. More sophisticated methods like 
GCMS and LC-MS became recently available for the determination of AGE. These 
methods are, however, quite time-consuming, require considerable training and, are 
thus expensive. Furthermore, the AGE with a known biochemical structure might only 
account for a small portion of the total amount of circulating and tissue AGE. Whether 
the AGE with known structure are clinically relevant is not sure.  
   Less time intensive, cheaper and more feasible for clinical use, are 
immunoassay methods, using antibodies against AGE. Nakayama first produced and 
characterized antibodies raised against keyhole limpet haemocyaninebound AGE [96]. 
The result was a polyclonal anti-AGE antiserum that was used in an ELISA. Also, an 
immunochemical detection of AGE in vivo was developed using antibodies raised 
against bovine serum albumin (BSA)-AGE or RNase-AGE [97,98]. In this way, AGE 
could be detected that were immunochemically different from characterized AGE such 
as CML, pentosidine and pyrraline. Thus far it remains uncertain whether these 
antibodies can identify all AGE produced in vivo. A common structure in AGE 
modified macromolecules that interacts with polyclonal antibodies has been suggested 
[97]. But, polyclonal antibodies against AGE-BSA or AGERNase failed to recognize 
CML which is claimed to be a dominant AGE in human serum albumin and in tissue 
proteins [99]. Another problem may be that factors in human serum interfere with the 
measurement [100]. Roche Diagnostics (Penzberg, Germany) has developed a 
commercially available competitive ELISA, using an anti-CML monoclonal antibody 
4G9 [101,102].  Clinical relevance of AGEs 
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Although many different antibodies have been produced, reproducibility and sensitivity 
remains a substantial problem. This is probably due to a lack of a well-defined set of 
antigens. Before antibody assays can be used as a standard, reproducible synthesis of 
well-defined antigens should be attained. A recent report demonstrated that shortterm 
heating, as used in the heat-induced epitope retrieval technique in formalin-fixed, 
paraffin-embedded tissue sections, results in artificial AGE formation and profoundly 
affects CML formation .  T h i s  m a y  a l s o  h a v e  s e r v e d  a s  a n  a r t e f a c t  i n  
immunohistochemistry studies [103].  
    A competitive radioreceptor assay based on AGE-specific receptors on the 
macrophage-like tumour cell line RAW 264.7 was developed earlier, but is also not 
widely used, possibly due to the strong interference in this assay with polyanions such 
as heparin [104].  
    As an indirect measure of AGE, collagen crosslinking has been proposed. The 
extracellular matrix protein collagen is highly prone to AGE-formation. It has been 
shown that the susceptibility of collagen to digestion by pepsin provide an index of 
protein cross-linking [91,105]. In this method, often tissues are used with high amounts 
of collagen, like rat tail tendon, to increase specificity of the measurement. Thus, this 
method only provides an indication of tissue AGE accumulation. Moreover, some AGE 
such as CML and pyrraline do not occur as crosslinks in proteins. Applying differential 
scanning calorimetry (DSC), crosslinking can also be determined in tissues with less 
collagen. Although this method will provide a quantitative method for determining the 
crosslinking of collagen in vitro, it lacks the specificity to assess crosslinking in vivo. 
Mentink et al. showed that DSC was able to detect a lower rate of crosslinking by 
aminoguanidine in rat tendons (but not in rat skin) [106]. However, no effect of the 
AGE breaker ALT-711 was found in either tissue with DSC. The advantage of DSC is 
that it is quick and can be well quantified in comparison with methods like enzyme 
digestibility.  
    Miyazaki recently attracted attention to the problems associated with preparing 
AGE-BSA (bovine serum albumin) complexes that are used in ligand experiments for 
scavenger receptors. Their preparations belong to the extensively modified preparations Chapter 3 
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in comparison to those from some other laboratories [86]. Marked differences in ligand 
activity to scavenger receptors may exist even when specific AGE like CML are 
present in both of them. They suggested that the presence of glycolaldehyde may be 
important for binding behaviour of AGE preparations to receptors.  
    Subramaniam warned against the widely used dichlorofluorescein assay to 
assess cellular oxidant stress by microtiter plate assay because of MGO effects [107]. 
Hui et al. found that trace amount of redox-active metal ions in biological buffers may 
induce oxidative stress and alterations in cellular functions which would otherwise be 
possibly ascribed to AGE-proteins [108].  
 
AGE IN DISEASE 
A dynamic equilibrium seems to exist between AGE circulating in blood, AGE 
accumulating in tissue and renal (and perhaps hepatic) clearance of AGE. It is no 
surprise that AGE accumulation exceeds normal in patients with diabetes mellitus or 
renal failure [109-112]. The association with various chronic complications of these 
diseases is discussed below in more detail. AGE have also been reported to accumulate 
in amyloid associated diseases such as dialysis related amyloidosis and Alzheimer 
Disease, and in the plaques found in atherosclerosis. In the neurological field increased 
local AGE accumulation has also been reported in amyotrophic lateral sclerosis. 
Accumulation of AGE in cartilage has been linked to synovial inflammatory diseases, 
including rheumatoid arthritis and osteoarthritis.  Table 2 shows an overview of all 
diseases discussed in this paragraph with related references.  
 
AGE Accumulation in Diabetes Mellitus (DM) and Chronic Complications 
Increased concentrations of AGE have been associated with chronic complications in 
cross-sectional studies in DM: AGE (CML, pentosidine, others) content of skin 
collagen has been shown to be a risk marker for microvascular complications of 
diabetes, independent of actual glucose or recent HbA1c values [113]. Serum AGE are 
increased in diabetic patients compared to controls [46,114,115]. AGE concentrations 
in serum, but also in kidneys, skin and vascular tissue may rise within 5 weeks after Clinical relevance of AGEs 
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Table 2. Overview of diseases or complications in which AGE accumulation has been described 
in the literature  to play a pathogenetic role. 
 
Diseases with increased AGE accumulation  References 
Diabetes Mellitus    
  Cardiovascular disease  35, 47,116, 120, 167 
 Retinopathy,  cataract  6,  121-132 
  Nephropathy  46, 80, 90, 121, 133-136 
 Neuropathy    137-142 
 Periodontitis  191,  192 
Renal failure    
  Peritoneal dialysis    3, 147, 151 
 Hemodialysis    3,  150,  152-156 
 Kidney  transplantation    36,  163-165 
 Dialysis  related 
amyloidosis 
76, 157-159 
  Disturbed bone metabolism  160, 161 
Atherosclerosis    109, 114, 166-174 
Alzheimer disease   175-182 
Amyotrophic lateral sclerosis   183,  184 
Arthritis (Osteoarthritis, Reumatoid 
arthritis) 
 185-187 
Amyloidosis   188-190 
    
 
making an animal diabetic, for example with STZ [96]. Serum AGE levels are higher 
in both type 1 and type 2 DM, are already increased early in the disease, as shown in 
prepubertal diabetic children to approximately 1.5-fold, and are associated with the 
severity of retinopathy and nephropathy, but also with coronary heart disease in type 2 
diabetes mellitus patients [116]. Hb-AGE rises from 0.42 to 0.75% in diabetic subjects 
[44]. In patients with DM combined with ESRD serum AGE levels were increased 
100-fold compared to diabetics with normal renal function, in another study serum 
pentosidine was increased 23-fold in DM with ESRD [46,117]. Comparable rank 
orders for subjects with DM and ESRD, DM without renal disease and controls have 
been reported for arterial wall AGE content [46]. Vascular wall AGE content has been 
semi-quantitatively found to be increased in subjects with DM and vascular disease, 
being present in fatty streaks and macrophages [118].  
    When exogenous AGE are administered to rats to attain plasma levels 
equivalent to those in diabetic rats the renal AGE content was 50% greater than in 
control rats after 5 months, accompanied by a glomerular sclerosis with a 50% Chapter 3 
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expansion of the glomerular volume, and with an increase in mesangial matrix and 
capillary basement membrane thickness [119].  
    Sensi et al. investigated the effects of restoring normoglycaemia 4 months 
after homologous islet cell transplantation in different organs of rats previously made 
diabetic shortly or for longer periods before transplantation [35]. Only after a longer (8 
months) preceding period of DM AGE content was elevated in all organs. In the eye 
lens but not in the aorta AGE content was lower than in nontransplanted diabetic 
control rat. This suggests that in DM prolonged time periods are an essential 
prerequisite not only for the accumulation of AGE to develop, but also to be reversed.  
    In addition to the earlier discussed biological effects, AGE accumulation may 
also contribute to dyslipidaemia in diabetes both by affecting the HDL receptor and by 
AGE-modified LDL [1]. The modification of LDL in diabetes may render the LDL 
particle more atherogenic, thereby increasing the atherogenic risk for diabetic patients. 
Park and co-workers showed that administration of the soluble extracellular domain of 
the receptor for AGE (RAGE) completely suppressed diabetic atherosclerosis in STZ-
diabetic apolipoprotein E-deficient mice, in a manner independent of the level of 
glucose and lipids [120].  
 
Diabetic Retinopathy and Cataract 
Background diabetic retinopathy has developed after 25 years in almost all patients 
with DM, a much lower percentage has then developed proliferative retinopathy (8 to 
26%). CML and pentosidine skin collagen accumulation is associated with the severity 
of retinopathy in type 1 diabetes patients, independent of age and diabetes duration [6]. 
In an autopsy study CML was present around retinal blood vessels in diabetics, but not 
in controls. Furthermore it is shown that formation of AGE measured by ELISA in skin 
biopsies are preceded and correlated with early manifestations of retinopathy as well as 
nephropathy [121]. Immunohistochemical studies in rats have revealed that AGE 
(CML) reactivity was increased in diabetic retinas [122-124]. No difference was 
present between subjects with DM with proliferative retinopathy and those with 
background retinopathy [125]. In two diabetic animal studies the AGE formation Clinical relevance of AGEs 
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inhibitor aminoguanidine (see below) prevented microaneurysm formation, pericyte 
loss, and the development of accelerated diabetic retinopathy, respectively [126,127]. 
Also the development of DM-related abnormalities of the retina could be prevented by 
aminoguanidine, indicating a prominent role for AGE in this complication [122].  
    Glycation of lens crystalline, and subsequent oxidation, may play a major part 
in accelerated cataract formation in DM. Alterations in Na+/K+-ATPase activity due to 
glycation may contribute to this. Evidence for AGE formation has also been found in 
the vitreous body using an AGE-specific ELISA, and was found to be related to age 
and the presence of DM [128]. In the vitreous body of patients with diabetic 
retinopathy and in a nondiabetic control group the increased levels of pentosidine in 
diabetics are strongly related to VEGF and other cytokines [129]. AGE accumulation 
has also been observed in the cornea of diabetic patients [130-132]. The formation of 
AGE on fibronectin and laminin in Descemet’s membrane in the cornea of the eye 
inhibited the attachment and spreading of endothelial cells . This may contribute to the 
increased prevalence of corneal endothelial abnormalities in patients with DM [131]. 
Thus, several lines of evidence indicate a role for AGE in the development of several 
forms of diabetes related eye disease, especially retinopathy, with a favourable effect of 
aminoguanidine.  
 
Diabetic Nephropathy 
Diabetic nephropathy develops in approximately 40% of patients with DM. Multiple 
studies have shown that AGE are important factors in the pathogenesis of nephropathy. 
CML, pyrraline and pentosidine have all been found in increased quantities in kidneys 
of patients with DM with or without ESRD [133]. AGE accumulation is related to the 
severity of diabetic nephropathy. Animal studies in rats have immunohistochemically 
shown AGE accumulation in the glomerular extracellular matrix. Expression of 
proteoglycans which form an important constituent of the kidney extracellular matrix is 
decreased in cultured kidney epithelial cells at CML-protein concentrations as found in 
diabetes [134]. In fact, the hyaline depositions in the classical Kimmelstiel-Wilson 
lesions of diabetic kidneys consist for a major part of AGE. Exposition to AGE-Chapter 3 
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crosslinked proteins results in increased oxidative stress in rat mesangial cells and in an 
increase in protein kinase C activity. Makita et al. showed that the increase in 
circulating AGE-peptides of diabetic patients correlates with the severity of renal 
function impairment [46]. Deuther-Conrad highlighted the toxic effect of the AGE-
peptides in cultured kidney epithelial and proximal tubular cells [135]. Overexpression 
of RAGE in transgenic diabetic mice resulted in histological and functional changes of 
diabetic nephropathy [80].  
   Pharmacological  inhibition of AGE-formation by aminoguanidine prevented 
the development of kidney lesions, albuminuria and mesangial expansion in diabetic 
rats [90,136]. In human studies discussed in more detail below, aminoguanidine 150 
mg twice a day reduced proteinuria significantly in a large (690 patients) study in 
patients with type 1 DM and moderate renal impairment. As mentioned before, 
Beisswenger and colleagues showed that formation of AGE measured by ELISA in 
skin biopsies preceded and correlated with early manifestations of retinopathy as well 
as nephropathy [121]. 
 
Diabetic Neuropathy 
Using sensitive methods the large majority of patients (80-90%) with DM will 
eventually develop symptoms or signs of diabetic polyneuropathy, a much smaller 
percentage develops autonomic neuropathy. The important role of glycation in the 
development of diabetic neuropathy has been recently reviewed [137]. In vitro, diverse 
mechanisms involving AGE in neuropathy seem to play a pathogenetic role: 
accumulation of AGE in vasa nervorum results in wall thickening, occlusion and 
ischemia of nerves, and consequent myelin damage with segmental demyelination. 
Glycation of the axonal cytoskeletal proteins such as myelin and neurofilament results 
in slowed axonal transport and axonal degeneration [138]. Nerve fiber regeneration 
may be reduced because the function of nerve growth factor and other growth factors 
like fibrin, but also because laminin in Schwann cell basal laminas is glycated and 
impeded in its function [139]. In animal studies aminoguanidine prevented AGE-
induced reductions in peripheral sensory nerve conduction velocity and action Clinical relevance of AGEs 
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potentials [140,141]. In diabetic humans more CML is found in the perineurium, in 
pericytes of endoneurial microvessels and in both myelinated and unmyelinated fibers, 
with a correlation between CML accumulation and myelinated fiber loss [142].  
   Furthermore,  aminoguanidine treatment reduced experimental diabetic 
neuropathy, as shown by a significant improvement of the reduced motor nerve 
conduction velocity, partially through the correction of the endoneurial 
microcirculation [141].  
    Taking all this together, considerable evidence exists supporting that AGE 
contribute prominently to the development and exacerbation of diabetic neuropathy.  
 
AGE in Renal Insufficiency, Renal Replacement Therapy and Kidney Transplantation 
Accumulation of reactive carbonyl compounds (RCO) and AGE is markedly increased 
in plasma, serum and tissues of diabetic and non-diabetic patients with ESRD [143-
145]. This has also been shown by Meng et al. for CML levels in plasma and skin in 
patients with chronic renal failure (CRF) both with and without diabetes [146]. Thus, 
hyperglycaemia is not a prerequisite for AGE accumulation. High serum AGE levels 
are also found in patients on hemodialysis (HD) or continuous ambulatory peritoneal 
dialysis (CAPD), probably by the introduction of high concentrations of glucose in 
dialysis fluids in CAPD (74-214 mM) [3,147]. Impaired clearance of AGE and AGE 
precursors is responsible for this increased AGE accumulation. Although direct 
evidence is insufficient, increased oxidizing conditions and the development of reactive 
oxygen species might also accelerate the formation of AGE [8,148,149]. 
Polymorphonuclear leukocyte activation by uremic toxins and interaction with the 
dialysis membrane in HD facilitate this. Diminished clearance of low molecular weight 
precursors of AGE and diminished catabolism of AGE precursors may further 
contribute to tissue AGE accumulation in CRF [3,150]. Lal et al. addressed the 
question of AGE-dependent signaling in the mesangium and found evidence for an 
important role of oxidative stress [149]. HD clears only the free and not the protein 
bound forms of AGE. CAPD is associated with lower plasma pentosidine levels, 
possibly by clearance of albumin-bound pentosidine in the peritoneum [3]. In rats Chapter 3 
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structural and permeability changes of the peritoneum with increased nitric oxide 
synthase expression are found associated with vascular deposits of AGE in chronic 
uraemia [151]. As for the relation with cardiovascular complications in renal failure, 
remarkably Schwedler et al. showed that circulating AGE levels (total fluorescent 
AGE, and CML, both in serum) do not predict mortality in HD patients [152]. Plasma 
pentosidine as an AGE and marker of ,carbonyl stress, was neither found to be related 
to intima media thickness or atherosclerotic plaques in the carotids in HD patients 
[153]. Schwedler et al. proposed that the benefit of high serum AGE levels might 
reflect a better nutritional support, which improves survival. However, an alternative 
explanation is that plasma or serum AGE levels may not adequately reflect tissue AGE 
accumulation. Floridi et al. found that a shift from standard dialysis regimen 3 times a 
week to daily HD resulted after 6 months in substantially lower plasma AGE levels 
(pentosidine and two AGE peptides), but did not measure AGE in other tissues [154]. 
High concentrations of glucose (and alpha-oxoaldehydes) in dialysis fluids also 
increase glycation. Vitamin-E coated dialysis filters prevented the rise in serum AGE 
levels found with conventional polysulfone filters. After six months of HD with these 
vitamin E coated filters, the pre-dialysis levels of AGE and other markers of oxidative 
stress were reduced [155]. Very high flux polysulfone filters reduced pre-dialysis 
serum values of free and protein-bound pentosidine and AGE peptides and beta2-
microglobulin (B2-MG) [156]. Several different AGE have been detected in B2-MG 
amyloid deposits arising after chronic renal HD [157]. Amyloid deposits are found in 
bone, articular cartilage, synovium, muscle and ligaments, giving rise to shoulder 
periarthritis, carpal tunnel syndrome and flexor tendosynovitis. AGE-modified B2-MG 
induces chemotaxis of monocytes and the production of cytokines (interleukin (IL) 1b, 
IL-6 and TNFa ). AGE-modified B2-MG is cleared less than native B2-MG through 
dialysis membranes [157]. Hou et al. showed that the local inflammatory response to 
B2-MG amyloid deposits by monocytes/macrophages which is a characteristic 
histological feature of dialysis-related amyloidosis (DRA), is dependent on delayed 
apoptosis of monocytes by AGE-modified B2-MG [76]. These cytokines may stimulate 
local production of B2-MG and bone destruction. RAGE expressed by synovial Clinical relevance of AGEs 
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fibroblasts may mediate some of these responses involved in DRA [158]. CML-
haemoglobin has been proposed as a possible predictor of progression of bone cysts in 
DRA [159]. Thus, at least a close relation between AGE accumulation in renal failure 
and the development of dialysis related amyloidosis exists. As for the possible osseous 
sequela of AGE accumulation, it should be added that pentosidine is related inversely 
to parathyroid hormone (PTH) and bone alkaline phosphatase in HD patients. The 
authors found this to be in agreement with AGE accumulation as a factor in reduced 
bone turnover in dialysis patients [160]. Yamamoto also found that AGE-BSA in vitro 
inhibits osteoblastic activity and inhibits PTH secretion in response to hypocalcaemia 
[161].  
    Renal transplantation is considered to be the best therapy for lowering AGE in 
patients with renal failure. Although a dramatic reduction in plasma AGE levels 
following transplantation has been found, the levels remain higher compared with the 
general population [162]. Studies to date, investigating the influence of kidney 
transplantation on tissue AGE accumulation show contradictory results [36,163-165]. 
While most studies report a reduction of about 50%, the only prospective study showed 
no significant reduction in tissue AGE. Despite the improvements in 
immunosuppression and an excellent short-term transplant survival in kidney 
transplantation, 10-year graft survival remains relatively poor with 50-60% (chronic 
renal transplant dysfunction, CRTD) while cardiovascular morbidity and mortality also 
remain high, and are associated with an increased prevalence of cardiovascular risk 
factors. Perhaps persistently high levels of AGE in tissues, enhanced by sustained 
oxidative stress, contribute to the development of CRTD. When AGE are administered 
to healthy rats, CRTD-like lesions develop in the kidney [20]. At present, no data is 
available on the long-term course of plasma and tissue AGE in human CRTD.  
 
AGE ACCUMULATION IN OTHER DISEASES 
Atherosclerosis 
The accumulation of AGE in the vessel wall has also been related to lipoprotein 
metabolism, as discussed above, and to the development of atherosclerosis [166]. AGE Chapter 3 
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accumulation has been found by immunohistochemistry on the extracellular matrix 
proteins and within macrophage- and smooth muscle cell-derived foam cells in 
atherosclerotic plaques [114,167]. Normolipidemic and euglycaemic subjects with 
atherosclerosis had increased AGE in the apolipoprotein B100, as did patients with 
uraemia [1,118]. It was claimed that AGE-modified LDL had decreased clearance from 
circulation and metabolism but this was a characteristic of LDL glycated to higher 
extent than found physiologically [168]. The expression of the RAGE and scavenger 
receptors were increased in atherosclerosis [169]. Interaction of AGE-modified 
proteins with AGE receptors may stimulate cytokine and growth factor production that 
sustains the development of the atherosclerotic plaques [109,170-172]. Atherosclerotic 
lesions in apoE knockout mice that were accelerated under STZ-induced diabetic 
conditions were significantly suppressed by intraperitoneal administration of a soluble 
form of RAGE [120]. The process of atherosclerosis may also stimulate local AGE 
formation. Activated macrophages in the intima make the local environment of 
atheroma oxidizing, which may increase AGE formation. If glycation of LDL 
stimulated its oxidation in vivo then glycation would be a critical initiating factor in 
macrovascular disease. Currently, however, there is no agreement on this, although 
glycated collagen stimulated peroxidation of membrane lipids in vitro [173,174]. Other 
factors influence LDL oxidation - antioxidant and triglyceride content, for example - 
and it is not yet clear how important glycation is compared to these. Once 
atherosclerosis is initiated, however, increased formation of AGE within the locus of 
the plaque and induction of AGE receptor expression is expected to sustain plaque 
expansion.  
 
Alzheimer’s Disease (AD)  
AGE accumulation is found in senile plaques and neurofibrillary tangles of persons 
with AD [175-177]. In the cerebrospinal fluid of patients with AD increased levels of 
Amadori products on all the major proteins are found. This may contribute to increased 
AGE deposition in the brain of AD patients [178]. Although Meli et al. reported 
increased serum pentosidine levels, using HPLC, in patients with AD, so far no other Clinical relevance of AGEs 
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evidence exists for systemic increases of AGE levels [179]. In contrast, 
chromatographic analysis of acid hydrolysates of brain frontal cortex for CML and 
pentosidine showed no significant increase in AD subjects, relative to controls. 
Pyrraline and pentosidine were not detected in beta-amyloid or apolipoprotein-E 
extracted from brain tissue of AD subjects, and immunohistochemistry with an anti-
AGE antibody showed no staining of senile plaques [180,181]. Data on RAGE 
expression and binding in AD are also controversial. Thus, the role of AGE in AD is, 
therefore, currently uncertain. It has been proposed that reactive carbonyls are 
implicated as neurotoxic mediators of oxidative damage in the progression of AD and 
so may result in AGE accumulation [182].  
 
Amyotrophic Lateral Sclerosis (ALS) 
In sporadic ALS, CML as a marker of lipid peroxidation or protein glycoxidation and 
pentosidine as a marker of protein glycoxidation are increased along with markers of 
lipid peroxidation immunohistochemically in the spinal cord in almost all motor 
neurons and in reactive astrocytes and microglia/macrophages  [183]. The authors 
implicate the formation of CML, pentosidine or lipid peroxidation products in motor 
neuron degeneration. A special familial form of ALS exists with superoxide dismutase-
1 (SOD-1) gene mutations, characterized by the presence of neuronal Lewy body-like 
hyaline and astrocytic hyaline inclusions. Ultrastructurally these inclusions contain 
granule-coated fibrils positive for a SOD-1 protein but also modified by AGE. The 
formation of AGE-modified mutant SOD-1 is probably one of the mechanisms 
responsible for the fibril formation [184].  
 
Arthritis 
Drinda et al. detected CML in the synovial tissue in patients with osteoarthritis and also 
rheumatoid arthritis [185]. Adverse changes induced by AGE in the collagen network 
in bone are associated with a loss of toughness of  bone in elderly people [186]. De 
Groot et al. found in in vitro experiments with cartilage from osteoarthritis or 
rheumatoid arthritis patients that increased cartilage AGE reduced cartilage Chapter 3 
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degradation by matrix metalloproteinases (MMP) in synovial fluid, suggesting that 
aged cartilage is less sensitive to the MMP-mediated cartilage destruction that occurs 
in osteoarthritis and rheumatoid arthritis. This may have effect on their rate of 
progression [187].  
 
Amyloidosis 
In various types of amyloidosis abnormal amyloid fibril proteins are associated with 
AGE accumulation [188]. Familial amyloidotic polyneuropathy (FAP), Portuguese 
type, is caused by amyloid depositions of a mutated transthyretin, and is associated 
with gastrointestinal symptoms like diarrhea, malabsorption due to severe dysmotility 
of the gastrointestinal tract. RAGE has been implicated in amyloid toxicity, and 
transthyretin amyloid fibrils have been shown to have affinity for RAGE and to induce 
NF-kappaB activation and apoptosis (also see above for RAGE effects ). In autopsy 
samples immunoreactivity for AGE and RAGE was found at the same sites as amyloid 
deposits and transthyretin [189,190].  
 
Periodontitis 
AGE present in diabetic gingiva may be associated with a state of enhanced oxidant 
stress, a potential mechanism for accelerated tissue injury [191]. The degree of 
collagen crosslinking has a marked influence on bone regeneration of calvarial defects 
in rat studies. This may suggest a negative role of AGE-crosslinked collagen on 
recovery from periodontitis [192].  
 
INTERVENTIONS 
Different approaches may be used to counter AGE accumulation and its deleterious 
effects. The first approach is to reduce the formation of AGE at one of the many steps 
involved. This ranges from interventions aimed at reducing glucose levels in diabetes 
to drugs specifically aimed at one of the late steps in the Amadori process. Recent 
studies of the group of Vlassara et al. address the possibility to reduce AGE 
accumulation by limiting the exogenous supply of AGE from food. Since smoking is Clinical relevance of AGEs 
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another source of exogenous AGE and associated with increased AGE accumulation, 
therefore smoking cessation is another candidate in this category. The second approach 
is to increase breakdown of AGE. One drug, ALT-711, is now in advanced phase II 
studies as an AGE-breaker. The third approach aims to prevent the deleterious effects 
of AGE. It includes interventions aimed at reducing protein cross-links, or at blocking 
or competing for one or more of the different AGE receptors (summarized in Table 3).  
 
Table 3. Interventions  to  reduce  AGE  accumulation.      
Inhibition of AGE formation 
Specific: aminoguanidine, OPB-9195, ALT-946, pyridoxamine (or other “Amadorins”) 
Aspecific: metformine, cerivastatine, ACE-inhibitors, ATII-antagonists, other 
pharmaceuticals that reduce oxidative stress 
AGE breaker 
ALT-711 
AGE-RAGE interaction blockers 
Reduction of exogenous AGE 
ceasing tobacco use, low-AGE diet           
 
Inhibitors of AGE Formation  
As discussed above AGE formation is a complex process and under the influence of 
diverse mechanisms like glycation and oxidative stress. This offers many opportunities 
to prevent AGE formation. In fact, any treatment aimed at lowering glycation or 
oxidative stress may be considered. Usually, however, attention is focused more on 
interventions aimed at one of the steps in the Amadori process directly preceding AGE 
formation. The drug attracting most attention has been aminoguanidine.  
   Aminoguanidine. In 1986 Brownlee et al. showed that aminoguanidine 
prevented both the formation of fluorescent AGE and the formation of glucose-derived 
collagen cross-links in vitro [193]. Furthermore, administration of the drug to diabetic 
rats prevented fluorescent AGE-formation and cross-linking of arterial wall connective 
tissue protein in vivo. Aminoguanidine reacts with Amadori-derived reactive 
intermediates such as 3-deoxyglucosone. Incubation of model Amadori products with 
aminoguanidine produces a triazine compound which prevents the further 
rearrangement of intermediates to protein-protein and protein-lipid crosslinks [194]. 
Price et al. addressed the chelating activity of aminoguanidine and other AGE 
inhibitors (carnosine, OPB-9195) and breakers (ALT-711). They conclude that rather Chapter 3 
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than by trapping reactive carbonyl intermediates they act primarily as chelators and 
antioxidants [195]. Aminoguanidine does not interfere with already formed AGE. 
Aminoguanidine also reduces NO formation through inhibition of inducible NO-
synthase. Several studies claim that aminoguanidine selectively inhibits NO-synthase, 
probably both the constitutive and the inducible form [196-200]. Furthermore, 
aminoguanidine may act as a free radical scavenger and so reduce oxidative stress 
[201,202]. Many studies have addressed its use in preventing diabetic micro- and 
macrovascular complications. The beneficial effect of aminoguanidine is considered by 
most authors to be mainly due to its direct effect on AGE formation. However, 
dissociations between reductions in albuminuria and effects on skin AGE formation 
have also been described [203]. Studies in diabetic animal show that aminoguanidine 
treatment prevents or reduces the major long-term complications of diabetes, 
nephropathy, neuropathy and retinopathy. Reduction of AGE accumulation, 
albuminuria and kidney lesions were established [90,136,204,205]. It is remarkable 
that the lesions at the tubulointerstitial level are improved by aminoguanidine 
[206,207]. Increase in motor nerve conduction velocity, partially through correction of 
endoneurial microcirculation, normalization of nerve blood flow and improvement of 
nerve conduction were also found [141,208,209]. Diabetic retinopathy was inhibited by 
aminoguanidine treatment, with prevention of abnormal endothelial cell proliferation 
and microaneurysms, and reduction in pericyte dropout, even when in one of these 
studies no effect of aminoguanidine on AGE (pentosidine in aorta and tail collagen, 
Hb-AGE) [122,209]. Clinical studies with aminoguanidine or its generic form, 
pimagedine, are still in progress.  
    In addition, aminoguanidine interferes with the development of atherosclerotic 
lesions: increasing elasticity and decreasing fluid filtration in large arteries, decreasing 
levels of total cholesterol, triglycerides and LDL-cholesterol in diabetic patients treated 
with aminoguanidine [210].  
    Outside the field of diabetes aminoguanidine reduced aortic pulse wave 
velocity in non-diabetic rats. Aminoguanidine seems to prevent the age-related increase 
in wall stiffness, although no effects on wall stress or composition were found [211]. Clinical relevance of AGEs 
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As for toxicity, a small percentage of patients develops flu-like symptoms. During 
longer use, macrocytic anaemia is found in a considerable percentage of patients and 
antinuclear cytoplasmic antibodies may develop at high doses, which is clinically 
associated with crescentic glomerulonephritis in three cases. Further side effects in 
human trials included nausea and headache. The daily dosage of aminoguanidine is 
usually 300 mg a day, taken with food. Aminoguanidine has a half life of only 4-hours, 
so these dosages would be best administered over the day into split doses. Checks of 
full blood counts and autoimmune antibodies are advised before and during treatment.  
   Other  aminoguanidine-like compounds, without an influence on NO-synthase, 
have recently been described. They exhibit similar effects as aminoguanidine: 2,3 
diaminophenazine (NNC39-0028) attenuated the development of diabetic mesenteric 
hypertrophy [212]; Oturai et al. found in STZ diabetic rats improved collagen 
solubility, in contrast to the lack of effect of the AGE-breaker PTB (see below). 
However, the increased urinary albumin excretion and the increased leakage in the eye 
of labeled albumin were not reduced by either drug [213]. 4-amino-3-hydrazino-5-
isopropyl 4H-1,2,4-triazole and 3,5-diamino-4-hydroxy-benzoic acid dihydrochloride 
increased tail tendon collagen solubility in treated rats [105]. OPB-9195 [(+/-)-2-
isopropylidenehydrazono-4-oxo-thiazolidin-5-yla cetanilide] inhibits both AGE and 
advanced lipoxidation endproducts (ALE) formation probably by its ability to trap 
reactive carbonyl compounds like GO, MGO and 3-DG [214]. It improved the delayed 
motor nerve conduction velocity in diabetic rats, and reduced the expression of 
immunoreactive AGE in the nerves [215]. ALT-946 was more potent than 
aminoguanidine in diabetic rats in suppressing immunohistochemically measured AGE 
production after 32 weeks. Albuminuria was equally reduced in the three groups 
treated from week 0 to 32 with aminoguanidine, or from week—32 or 16-32 with 
ALT-946 [216]. In a transgenic rat model with angiotensin II dependent hypertension, 
along with STZ-induced diabetes and severe diabetic nephropathy ALT-946 and 
aminoguanidine both reduced glomerulosclerosis and glomerular AGE 
immunolabeling. ALT-946 but not AG also reduced cortical tubular degeneration and 
albuminuria. Thus even with a strong hypertensive stimulus for developing Chapter 3 
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nephropathy in diabetic rats AGE formation inhibitors may protect against diabetic 
nephropathy [217].  
    Pyridoxamine inhibits formation of AGE derived from the alpha-dicarbonyl 
compound MGO in vitro [218]. It also reduces formation of lipoxidation end products 
(ALE). It has this capacity at least in part by trapping reactive carbonyl intermediates 
in the formation of AGE and ALE [219]. In diabetic rats pyridoxamine prevented after 
29 weeks the development of structural changes of diabetic retinopathy and CML 
accumulation in the retinal vasculature [220]. Diabetic nephropathy is also inhibited by 
pyridoxamine to a similar extent as aminoguanidine in STZ-diabetic rats, associated 
with a marked reduction of AGE/ALE, CML, CEL, cross-linking and fluorescence in 
skin collagen [221]  
   In 1999, a novel group of inhibitors of the conversion of Amadori 
intermediates to AGE, named "Amadorins" was described [222]. The therapeutic 
potential of these drugs is currently being investigated. Other agents such as Carnosine 
and Acetyl-L-Carnitine also prevent AGE formation. Carnosine (beta-alanyl-lhistidine) 
is physiologically present in muscle and nervous tissues in many animals, especially 
long-lived species [223]. As yet only in vitro studies found that N-acetylcysteine 
suppressed CML production during prolonged incubations [224].  
    In a recent study it was demonstrated that ACE inhibition with ramipril and 
aminoguanidine after 12 weeks equally reduced renal AGE accumulation, assessed by 
immunohistochemistry and serum and renal fluorescence, in STZ-induced diabetic 
animals. Both drugs prevented diabetes-induced increases in expression of RAGE and 
also AGE R2, R3 receptors and NFkappaB. The link between inhibition of the renin-
angiotensin system and of AGE accumulation may reside in the reduction of oxidative 
stress [225]. The inhibition of AGE production by interventions in the renin-
angiotensin system is confirmed by an in vitro study by Miyata et al. for the 
angiotensin II type 1 receptor antagonist olmesartan and the ACE-inhibitor 
temocaprilat. In a comparison with nifedipine, both olmesartan and temocaprilat 
inhibited the formation of pentosidine and CML [226]. An in vitro study with different Clinical relevance of AGEs 
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calcium antagonists showed some antioxidative properties of calcium antagonists but 
no inhibitory effect on the formation of AGE precursors [227].  
    Beraprost sodium, a prostacyclin analogue and cyclic-AMP-elevating agent, 
was found to protect retinal pericytes with prevention of AGE-induced apoptotic cell 
death from AGE-induced cytotoxicity through its antioxidative properties [228].  
 
AGE-Breakers 
In 1996, Vasan and colleagues described a new compound that cleaves glucose-derived 
protein cross-links in vitro and in vivo [229]. Its action is based on the assumption that 
AGE are formed in a pathway involving reactive α-dicarbonyl intermediates. The 
AGE-breakers Nphenacylthiazolium bromide (PTB) or the chloride form developed by 
Alteon ALT-711, 3-phenacyl-4, 5-dimethylthiazolium chloride, is able to break this α- 
dicarbonyl bond, and can thereby remove established AGEcrosslinks (Table 3). 
However, taking into account the high reactivity of these α-dicarbonyl bonds, a 
crosslink containing this bond is not likely to occur. Because in vitro and in vivo 
studies indeed confirm the ability of PTB to actually diminish AGE derived crosslinks, 
therefore, future research should be focused on finding different mechanisms by which 
PTB breaks AGE crosslinks. Wolffenbuttel et al. performed the first in vivo study in 
rats, showing that chronic treatment with an AGE-breaker restored large artery 
properties in experimental diabetes [230]. In a study in aging dogs ALT-711 1mg/kg 
reversed the age-related increased stiffness of the myocardium within four weeks 
[231]. Left ventricular stiffness was reduced by approximately 40%. Studies on the 
effects of ALT-711 on older rhesus monkeys showed that an injection of 10 mg/kg 
ALT-711, every other day for three weeks, improved vascular compliance and 
elasticity [232]. The improved vascular compliance persisted over time, with maximum 
improvement seen six weeks after the end of ALT-711 treatment, and a gradual return 
to baseline 39 weeks after treatment was stopped.  
    After phase I clinical studies with ALT-711, Kass et al. described last year a 
randomized, double blind, placebo controlled trial in 93 individuals over the age of 50, 
with as selection criterion a systolic blood pressure > 140 mmHg and pulse pressure of Chapter 3 
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at least 60 mmHg [233]. Treatment consisted of ALT-711 210 mg daily or placebo for 
eight weeks, in addition to usual antihypertensive treatment. ALT-711 lowered pulse 
pressure with 5.6 mmHg drops in the treated group compared to a -0.5 mmHg drop in 
patients receiving placebo. ALT-711 significantly improved large artery compliance 
and distensibility by 11% to 18%, compared to placebo. The drug is now tested in 
several phase II trials in isolated systolic hypertension, addressing the vascular and left 
ventricular effects (Alteon website: SAPPHIRE and SILVER trials) and in diastolic 
heart failure.  
 
AGE-RAGE Interaction Blockers 
As discussed above, AGE-RAGE interactions may be important in numerous diseases. 
Attempts to block the deleterious effects of AGE at the receptor level are still in an 
experimental phase [74]. 
 
Prevention of other AGE-Induced effects 
A novel approach in preventing deleterious effects of AGE has been proposed by 
Okamoto. He used incadronate to prevent AGE-induced angiogenesis from 
microvascular endothelial cells probably by blocking protein farnesylation [234].  
    Cerivastatin, a lipid lowering drug from the class of statins, prevents the AGE-
induced increase in NF-kappaB and activator protein-1 activity, suppressed VEGF 
mRNA upregulation in cultured endothelial cells [235].  
 
Interventions Aimed at Reducing Exogenous AGE, Food and Smoking 
Vlassara addressed the effect of food derived proinflammatory AGE on inflammatory 
mediators in diabetic subjects by comparing otherwise comparable diets with a high 
AGE content or with a 5-fold lower AGE content. Serum AGE, measured as CML-
sensitive ELISA, were approximately 70% higher on the high AGE compared to the 
low AGE diet, AGE-LDL was approximately 40% higher. The levels of the endothelial 
adhesion molecule VCAM-1and mononuclear tumor necrosis factor (TNF) alpha were 
considerably higher during the high AGE diet [236]. Although the study was too small Clinical relevance of AGEs 
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to draw definite conclusions, the results suggest that high AGE diets may result in 
higher levels of inflammatory mediators in diabetes patients and so contribute to the 
chronic complications. In apoE-deficient mice in whom a femoral artery injury had 
been induced, a low AGE diet compared to a diet with a tenfold higher AGE content 
resulted, 4 weeks after the injury in a decrease in neointima formation and a less 
stenotic luminal area [237]. Markedly lower number of macrophages and a reduced 
number of smooth muscle cells, associated with a 40% decrease in circulating AGE 
levels and AGE deposition in endothelial cells, smooth muscle cells and macrophages 
of the neointima in the low AGE diet mice were observed. The same group tested the 
effects of a low AGE diet also in two diabetic mouse models for type 1 and type 2 
diabetes, respectively. The mice on a low AGE diet had a marked reduction in the 
diabetic nephropathy glomerular lesions and an extended survival [238]. In the renal 
cortex expression of transforming growth factor-beta1, laminin B1 mRNA and alpha-
IV collagen mRNA was lower in the low AGE diet group, along with reduced serum 
and kidney AGE levels. The relation between diet and exogenous AGE load and 
resulting (serum) AGE levels is not always straightforward: Sebekova expected to find 
higher AGE levels in omnivores eating more heat-treated food would be higher than in 
vegetarians cooking their food. However, plasma AGE levels (measured with ELISA 
for CML, also plasma fluorescence) were higher in the vegetarians [239]. More 
specific food substances, for example green tea extracts, have been tested for their 
effect on protein glycation and oxidation in vitro [240]. Gugliucci found that in vitro 
extracts of the flavonoid-rich herbal species Achyrocline saturoides and Ilex 
paraguariensis inhibited the effects of the reactive carbonyl compound methylglyoxal 
on heparin activation of antithrombin III and plasminogen activity [241]. 
 
 
CONCLUSIONS 
AGE have evolved from noxious bystanders of long-time glycation to endproducts of 
both oxidative and carbonyl stress. In association with the expansion in the biological 
effects of AGE, this makes AGE the primary targets for pharmaceutical interventions. Chapter 3 
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Pharmaceutical strategies can be aimed both at prevention of AGE formation and at 
AGE breaking. A weak point remains the dearth of feasible AGE assay methods 
available for clinical practice to monitor the effects of such pharmaceutical 
interventions. Introduction of reproducible, easily available assays of tissue AGE 
accumulation are warranted for a more focused application of treatment strategies.  
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ABSTRACT 
Introduction Advanced glycation end products (AGEs) are thought to have a role in the 
pathogenesis of diabetes complications. We recently reported the association between 
skin autofluorescence, as a measure of tissue AGE accumulation, and diabetic 
neuropathy in a selected diabetic population. In this study, we investigated the relation 
between skin autofluorescence and clinical variables including micro- and 
macrovascular complications in a type 2 diabetes primary care population. 
Methods Clinical data and skin autofluorescence were obtained in the type 2 diabetes 
group (n=973) and in a control group (n=231). Skin autofluorescence was assessed by 
illumination of the lower arm with a fluorescent tube (peak intensity ~370 nm). 
Results Skin autofluorescence was significantly higher in type 2 diabetic patients 
compared with control subjects in each age category. Multiple regression analysis 
showed significant correlation of skin autofluorescence with age, sex, diabetes 
duration, BMI, smoking, HbA1c, plasma creatinine, HDL cholesterol, and albumin-to-
creatinine ratio in the type 2 diabetes group (R
2=25%) and with age and smoking in the 
control group (R
2=46%). Skin autofluorescence was significantly higher in the type 2 
diabetes group, with both micro- and macrovascular disease, compared with the group 
without complications and the group with only microvascular complications. 
Conclusion This study confirms in a large group of type 2 diabetic patients that skin 
autofluorescence is higher compared with age-matched control subjects and is 
associated with the severity of diabetes-related complications. Skin autofluorescence 
reflecting vascular damage might be a rapid and helpful tool in the diabetes outpatient 
clinic for identifying diabetic patients who are at risk for developing complications. 
 
 
INTRODUCTION  
The formation of advanced glycation end products (AGEs) is increased in diabetes [1–
3]. Accumulated AGEs have deleterious effects on the vascular wall, contributing to 
the development of micro- and macrovascular disease, as shown especially in type 1 
diabetes [4–8]. The Diabetes Control and Complications Trial substudy on skin Skin autofluorescence as a noninvasive marker 
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collagen glycation found strong associations between skin AGE levels and long-term 
diabetes complications in type 1 diabetes, which persisted after adjustment for HbA1c 
[7]. The relation between AGE accumulation and outcome has been studied very little 
in type 2 diabetes. Besides, several laboratory assessments of AGEs are used 
worldwide. In the earlier studies of the 1990s, AGEs were mostly assessed in tissue by 
collagen linked fluorescence (CLF) or specific AGE measurements (pentosidine, 
carboxymethyllysine) [4,9,10]. During the last few years, AGEs are increasingly 
measured in serum or plasma using high-performance liquid chromatography, enzyme-
linked immunosorbent assay, or fluorescence. The blood compartment is more 
practical for repeated measurements than tissue requiring biopsies, but plasma AGE 
assays are unfortunately less reproducible and less well related to tissue contents of 
AGEs [11,12]. We recently described a tool to noninvasively assess tissue AGEs in 
vivo using skin autofluorescence [13]. This method utilizes the fluorescent properties 
of AGEs, like the extensively used CLF method, and has been validated with specific 
AGE measurements and CLF in skin biopsies [13]. By linking skin autofluorescence to 
AGE accumulation and, therefore, to cumulative glycemic and oxidative damage in 
diabetes, we aim to create a tool that is able to give rapid impression of the risk for 
diabetes complications. Using this tool in a prospective cohort of type 2 diabetic 
patients, we aim to address the predictive value of skin autofluorescence on diabetes-
related complications. This study involves a cross-sectional analysis of the baseline 
data of this cohort to study the association between skin autofluorescence and clinical 
variables, including the presence of complications at baseline.  
 
 
METHODS 
Patients We recruited subjects participating in the ZODIAC (Zwolle Outpatient 
Diabetes project Integrating Available Care) study, which has previously been 
described [14]. In short, this study investigates the effects of a shared care project in a 
primary care population– based cohort of type 2 diabetic patients in the eastern part of 
the Netherlands. All patients of 32 general practitioners receiving their diabetes support Chapter 4 
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in the primary care setting and who additionally visited the diabetes outpatient clinic 
annually were approached. Patients were included from May 2001 to May 2002. 
Patients with cognitive disability or terminal diseases were excluded from the ZODIAC 
study and, consequently, also ineligible to the present study. After obtaining informed 
consent, autofluorescence was measured in 1121 of the 1450 patients (77%) that visited 
the outpatient clinic during the inclusion period. Additionally, skin autofluorescence 
was measured in a nondiabetic control group of 231 consecutive preoperative 
evaluation visitors of the outpatient clinic who did not have a history of diabetes, 
cardiovascular events, or renal disease [15]. The study was approved by the local 
ethical committee.  
Autofluorescence Skin autofluorescence was assessed by the autofluorescence reader 
(AFR: patent PCT/NL99/00607, prototype of current AGE Reader; DiagnOptics BV, 
Groningen, the Netherlands) as described previously [13]. In short, the 
autofluorescence reader illuminates a skin surface of ~4 cm
2, guarded against 
surrounding light, with an excitation light source (8-W blacklight; Philips) between 
300 and 420 nm (peak excitation ~370 nm). Emission light and reflected excitation 
light from the skin are measured with a spectrometer (AVS-USB2000; Avantes, 
Eerbeek, the Netherlands), in the 300 to 600 nm range, using a 50-µm glass fiber 
(Farnell, Leeds, U.K.). Measurements were performed at room temperature, while 
patients were in a seated position, at the volar side of the arm 10 cm below the elbow 
fold. Since skin pigmentation may influence autofluorescence by light absorption [16], 
autofluorescence was calculated by dividing the average emitted light intensity per 
nanometer in the range 420–600 nm by the average excitated light intensity per 
nanometer in the range 300–420 nm. Autofluorescence was expressed in arbitrary units 
(a.u.) and multiplied by 100. Skin reflection was calculated in the range 300–420 nm 
by dividing the mean intensity reflected from the skin by the mean intensity reflected 
from a white Teflon block (assuming 100% reflectance). Autofluorescence 
measurements were performed in 1121 type 2 diabetic patients at two different 
locations, with two identical autofluorescence reader systems, by six diabetes nurses. 
Measurements in 148 patients (13%) had to be discarded: 74 for improper previous Skin autofluorescence as a noninvasive marker 
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calibration, 36 showed light leakage from surrounding light, 7 because the tube was 
switched off inadvertently, and 31 because of too dark skin type, resulting in almost 
complete absorption of all the excitation light (skin reflection <7.5%), leaving too little 
light to measure autofluorescence with the current set up. Autofluorescence 
measurements in the control group were performed by one examiner. None of the 
measurements in the control group were discarded. Thus, autofluorescence 
measurements in 973 type 2 diabetic patients and 231 control subjects were available 
for analysis. Overall, the autofluorescence measurements and mean age-corrected 
autofluorescence per measuring month (p=0.3), per examiner (p=0.6), and per 
autofluorescence reader system (p= 0.1) did not differ significantly. 
 
Clinical data Clinical data are derived from the Diabetic Electronic Monitoring System 
containing all data of the diabetic patients since the start of the shared-care project 
(1998) [17]. Clinical data and laboratory results obtained on the date of the 
autofluorescence measurement were used in the analysis. The blood pressure was a 
seated single measurement, obtained after 5 min rest, using an aneroid device. HbA1c 
was measured with a Primus CLC-385 using boronate affinity chromatography and 
high-performance liquid chromatography (reference value 4.0–6.0%). A Roche/Hitachi 
MODULAR analyzer was used for serum creatinine (kinetic colorimetric assay), 
nonfasting total cholesterol (cholesterol sterase/peroxidase enzymatic method), 
nonfasting HDL cholesterol (HDL-Cholesterol, homogeneous enzymatic colorimetric 
test), nonfasting triglycerides (lipase glycerol kinase enzymatic method), and urinary 
microalbumin (Tina-quant Albumin, immunoturbidimetric assay). Retinal photography 
was scored by an independent ophthalmologist as absent, background, or proliferative 
retinopathy. Microalbuminuria was defined as an albumin-to-creatinine ratio >3.5 in 
women or >2.5 in men, in two subsequent samples (at baseline and in the year before 
baseline) or once in the year before baseline while using an ACE inhibitor at baseline. 
Diminished sensibility at least at one foot was considered as neuropathy (tested with a 
5.07 Semmes Weinstein monofilament, applied on three areas of each foot) [18]. The 
presence of microvascular complications was defined as meeting the criteria of Chapter 4 
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microalbuminuria, neuropathy, and/or at least background retinopathy. Cardiovascular 
disease was defined as ischemic heart disease (ICD-9 codes 410 – 414 and/or a history 
of coronary artery bypass surgery or percutaneous coronary intervention), 
cerebrovascular accidents, or peripheral vascular disease (surgical intervention, 
claudication, and/or diminished or absent pulsations of ankle or foot arteries). The 
presence of macrovascular complications is defined when meeting at least one aspect 
of cardiovascular disease. The following clinical data of the control group were 
collected: age, sex, current tobacco use, BMI, and blood pressure. An 
independent anaesthesiologist classified the subjects according to the American Society 
of Anaesthesiologists (ASA) classification, ASA class 1–5 (ASA 1 means a healthy 
patient without medical problems, and ASA 5 means moribund, not expected to live for 
another 24 h) [19]. The large majority of the control group were classified as ASA 1 
and 2 (>90%). 
 
Statistical analyses Multiple linear regression analysis was used to determine 
independent relations between skin autofluorescence and clinical variables. ANOVA 
was applied to compare differences between groups. Calculation of sample size of the 
diabetic population was based on a Cox regression power analysis. As the present 
cross-sectional study is part of a follow-up study in which cardiovascular end points 
will be the most critical end point, 741 patients are needed to detect a 6% difference in 
event-free surviving proportion (0.93 vs. 0.87) with 80% power and α=0.05 in a two-
sided test, with 17% lost to follow-up (200 of 1200). Sample size of the nondiabetic 
control population was calculated according to formula of Altman [20]. In our previous 
study, skin autofluorescence was 20–30% higher in diabetic patients [13]. This was a 
heterogeneous group, including type 1 and type 2 diabetic patients. Furthermore, the 
mean HbA1c was higher (7.8%) than the mean HbA1c (7.1%) of the type 2 diabetic 
patients in this study (calculated in an interim analysis after inclusion of 475 patients). 
This taken into account, we considered a difference of 10–15% as clinically relevant. 
According to the nomogram of Altman [20], with 80% power and α=0.05, a sample 
size of 200 nondiabetic control subjects was needed. Skin autofluorescence as a noninvasive marker 
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Table 1. Clinical Characteristics of the type 2 diabetic population and the control group. Mean 
skin autofluorescence of the total groups and per age-category are shown. Values are expressed 
as mean (SD) and % when indicated. 
  T2DM (n=973) Controls  (n=231) 
Characteristic 
Age (years)  66 (11) 52 (17)
Male gender  47%  38%
Caucasian 97% 100%
Smoking 19% 30%
Body mass index (kg/m2)  29 (5)   27 (5)
Systolic blood pressure (mmHg)  146 (20) 144 (22)
Diastolic blood pressure (mmHg)  81 (10) 82 (11)
Diabetes duration, (years)  *4.2 (1.6-8.3) -
HbA1c (%)  7.0 (1.3)
#
Creatinine (µmol/l)  96 (20)
#
Creatinine clearance (Cockroft-formula) (ml/min)  76 (27)
#
Urinary albumin/creatinine ratio  *1.47 (0.8-4.1)
#
Total cholesterol (mmol/l)  5.2 (1.0)
#
HDL (mmol/l)  1.3 (0.3)
#
LDL (mmol/l)  2.9 (0.9)
#
Triglycerides (mmol/l)  2.3 (1.3)
#
Microvascular disease  49% -
Macrovascular disease  39% -
Autofluorescence: 
Skin autofluorescence (a.u), total group  2.79 (0.8) 2.14 (0.6)
   40-49 years (n=64; n=44) 
¶2.17 (0.5) 1.84 (0.4)
   50-59 years (n=199; n=47) 
¶2.57 (0.7) 2.12 (0.3)
   60-69 years (n=278; n=32) 2.69  (0.7) 2.50  (0.6)
   70-79 years (n=307; n=37) 
¶3.04 (0.8) 2.76 (0.6)
   >80 years    (n=108; n=7) 3.17  (0.7) 2.89  (0.5)
 
*Median and Interquartile range. 
¶p<0.01 (t-tests in horizontal direction, per age-category). 
#Reference values of the laboratory. HbA1c 4.0-6.0%, Creatinine 70-110 µmol/l, Creatinine clearance 
(Cockroft-formula) 80-120 ml/min, Urinary albumin/creatinine ratio 0-2.5, Total cholesterol 3.5-5.0 
mmol/l, HDL 0.9-1.7 mmol/l, LDL  3.6-4.4 mmol/l, Triglycerides 0.6-2.2 mmol/l Chapter 4 
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RESULTS 
In the analysis of this study, 973 type 2 diabetic patients and 231 control subjects were 
included. The medical characteristics are depicted in Table 1. All data were distributed 
normally, except for diabetes duration and albumin-to-creatinine ratio. Mean age in the 
control group was 14 years lower compared with the type 2 diabetes group, and 
there were more male subjects in the type 2 diabetes group (47% vs. 38% in the control 
group). In the type 2 diabetes group, median diabetes duration was 4.2 years (mean 6.3 
years). Mean HbA1c was 7.0%, while 16% of the diabetic population was treated with 
insulin and 84% on noninsulin strategies (diet and/or oral agents). Microvascular 
complications were present in 49% of the patients (prevalence of retinopathy, 20%; 
microalbuminuria, 21%; and neuropathy, 28%). The prevalence of macrovascular 
disease was 39% (ischemic heart disease, 21%; cerebrovascular disease, 8%; and 
peripheral vascular disease, 22%). There were no patients with (near) end-stage renal 
disease. Skin autofluorescence. Overall, mean skin autofluorescence was 33% higher 
(2.79 a.u.) in the type 2 diabetes group compared with the control group (2.14 a.u.). In 
both type 2 diabetic and control subjects, autofluorescence was higher at each 
increment in age category (p<0.01), Table 1. Autofluorescence was also higher in the 
type 2 diabetes group compared with the control group at each specific age category, 
which was significant (p<0.01) in the age categories 40–49, 50–59, and 70–79 years, 
and nonsignificant (p=0.1, p=0.3) in the age categories 60 – 69 and >80 years.  Sample 
sizes of the latter categories were very small in the control group. Multiple regression 
analysis showed that 25% (R
2) of the variance of skin autofluorescence could be 
predicted by age (β=0.35, p<0.0001), female sex (β=0.17, p<0.0001), current tobacco 
use (β=0.14, p<0.0001), diabetes duration (β=0.10, p<0.01), plasma creatinine (β=0.15, 
P  0.0001), HbA1c (β=0.10, p<0.001), albumin-to-creatinine ratio (β=0.10, p<0.001), 
BMI (β=0.08, p<0.01), and HDL cholesterol (β=0.07, p<0.05). Blood pressure and 
other nonfasting lipids were not significant in this model. In the nondiabetic control 
group, multiple regression analysis showed that 46% (R
2) of the variance of skin 
autofluorescence could be predicted by age (β=0.71, p<0.001) and current tobacco use 
(β=0.17, p<0.001).  Skin autofluorescence as a noninvasive marker 
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Figure 1. These boxplots show the distribution of skin autofluorescence (AF, y-axis) per 
quintile of age. Only the first, third and fifth age-quintile are shown (x-axis). Panel A shows the 
effect of smoking in control subjects compared to type 2 diabetes groups. The boxplot of  the 
smoking controls in the age category above 77 years has not been depicted because of the too 
small group size. Panel B shows the differences in AF due to sex at different age-categories in 
the type 2 diabetes population. Skin AF is significantly higher in female patients under 56 years 
of age (p<0.01). The horizontal line within a box represents the median,  the lower and upper 
end of a box are the first and third quartile respectively. The lower line and the upper line 
outside the box represent the 5th and 95th percentile, respectively. Chapter 4 
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In this multivariate analysis, the univariate correlation of autofluorescence with BMI 
(r=0.2, p<0.05) and systolic blood pressure (r=0.3, p<0.001) disappeared. Smoking was 
independently and positively related to autofluorescence in both groups. Smoking was 
more prevalent at younger age in both groups; in the type 2 diabetes group, the 
prevalence of smoking was 27% before age 65 years and 14% after age 65 years and in 
the control group, 37% and 13%, respectively. Figure 1A illustrates the effect of 
smoking on skin autofluorescence in control and type 2 diabetic subjects. Female sex 
was independently and positively associated with skin autofluorescence in type 2 
diabetes. No sex relation with autofluorescence was found in the control group. Further 
analysis in the type 2 diabetes group showed that autofluorescence was significantly 
higher in women under age 56 years compared with men (2.56 vs. 2.30 a.u., 
respectively; p<0.01), Figure 1B. There was no significant sex-related difference of 
autofluorescence in the higher age categories. Figure 2 shows the mean skin 
autofluorescence in the type 2 diabetic population per complication category with the 
95% CI. Mean skin autofluorescence was significantly higher in the group with both 
micro- and macrovascular disease compared with the group without complications and 
the group with only microvascular complications (mean 3.12 [95% CI 3.01–3.23] vs. 
2.57 [95%CI 2.50–2.65] and 2.71a.u. [95%CI 2.62–2.80]; p<0.001). Autofluorescence 
in the group with only macrovascular complications (2.91 a.u [95%CI 2.78 –3.03]) was 
higher than in the group without complications. These differences remained significant 
when autofluorescence was corrected for age. The same result was found by 
categorizing the type 2 diabetes group with both micro- and macrovascular disease and 
the type 2 diabetes group without complications in age decades. In each age decade 
>60 years, skin autofluorescence was significantly higher in type 2 diabetic patients 
with complications versus type 2 diabetic patients without complications (40-49 years: 
2.27 vs. 2.08 a.u. [p=NS]; 50-59 years: 2.77 vs. 2.55 a.u. [p= NS]; 60-69 years: 2.83 vs. 
2.53 a.u.; 70-79 years: 3.24 vs. 2.86 a.u; and >80 years: 3.47 vs. 3.01 a.u. [p<0.05]). 
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Figure 2. Mean Skin AF with 95% Confidence interval in different categories of complications 
in the type 2 diabetes population. Skin AF is represented at the X-axis and the complication 
categories are depicted at the Y-axis. Matching symbols means significant difference between 
the groups (p<0.001). These differences remained significant after age-correction of skin AF. 
The lined column represents the mean skin AF with 95% confidence interval of the control 
group. 
 
 
DISCUSSION 
This study confirms that in a large group of type 2 diabetes patients, skin 
autofluorescence higher compared with age-matched control subjects. Moreover, skin 
autofluorescence was associated with a graded increase in the presence and severity of 
diabetes-related complications.  
Known diabetes duration was relatively short, and, moreover, metabolic control was 
good (mean HbA1c 7.0%) compared with the previously reported smaller group with 
increased skin autofluorescence [13]. Thus, our type 2 diabetes group might be 
expected to represent a more or less “healthy” diabetes population relatively unaffected Chapter 4 
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by chronic complications. However, about half of this group was already diagnosed 
with micro- or macrovascular complications.  
HbA1c had a small independent contribution to autofluorescence in our study. Sharp et 
al. [21] found no correlation with HbA1c and serum low–molecular weight AGEs 
(LMW-AGEs). They suggest that glycaemia itself may not be responsible for increased 
AGE accumulation in diabetes, but other factors are involved. However, it can also be 
hypothesized that the restricted relation between glycaemia (HbA1c) and AGEs is 
caused by the short turnover time of HbA1c. HbA1c represents metabolic control of 
the last ~8 weeks, which implies a rather “short-term memory” of glycemic stress. 
AGEs can also link to haemoglobin (Hb-AGE). Hb-AGE was slightly superior to 
HbA1c as a measure for metabolic control, which was attributed to the irreversible 
nature of AGEs [22]. However, the relatively short turnover time of haemoglobin 
remains the limiting factor for the use of Hb-AGE or HbA1c as a real long-term 
glycemic index. An earlier study that confirmed the  importance of protein turnover in 
AGE accumulation estimated the half-life of skin collagen on 15 years [23]. Thus, skin 
AGE levels might provide a more “long-term memory” of glycemic stress and, 
therefore, be better in predicting complications. The Diabetes Control and 
Complications Trial substudy already demonstrated in type 1 diabetes that skin 
collagen glycation was a better predictor for diabetes complications compared with 
HbA1c [7,24].  
Sex was an independent variable of skin autofluorescence in the type 2 diabetes group, 
with a higher autofluorescence in women (aged <56 years). This suggests an estrogen-
related effect. The loss of sex difference in autofluorescence at an older age may be due 
to a decrease in skin collagen content in postmenopausal women [25]. Sex hormones 
influence the collagen turnover rate and is important in the rate of AGE accumulation. 
Another large study in type 2 diabetes found a similar independent positive relation 
between female sex and levels of LMW-AGEs [26].  
BMI and HDL cholesterol also contributed significantly to autofluorescence in the 
regression model. Although the coefficients were low, these relations can be valid. It is 
possible that skin autofluorescence is affected by the skin content of lipoxidation Skin autofluorescence as a noninvasive marker 
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products, as some of these products are fluorescent [27]. These advanced lipoxidation 
end products are formed analogous to AGEs from reactive carbonyl intermediates 
through oxidation of polyunsaturated fatty acids instead of sugars. If an increase in 
subcutaneous fat mass and a decrease in HDL cholesterol are associated with increased 
formation of advanced lipoxidation end products, this might explain the contribution to 
skin autofluorescence.  
This study further supports the earlier finding that smoking results in increased AGE 
accumulation, as we showed that smoking independently increases autofluorescence in 
both type 2 diabetic and control subjects in the multivariate analysis [28].  
Skin autofluorescence had an explained variance, with the tested clinical variables in 
the regression analysis of 46% in the control group and 25% in the type 2 diabetes 
group. It should be noted that the total variance (SD
2) was approximately two times 
higher in type 2 diabetes, which implies that the explained variances in the control 
group and the type 2 diabetes group are about the same [SD
2(1-R
2 )]. Sharp et al. [21], 
who measured fluorescent LMW-AGEs in plasma, also found an R
2 value of 25% and 
increased total variance in type 2 diabetic compared with control subjects. 
 One of the reasons for a higher total variance in the diabetic population might be that 
other “disturbing” disease-related factors exist. For example, interindividual 
differences in actual hyperglycaemic induced oxidative stress during the 
autofluorescence measurement [2]. It is also possible that genetic factors are involved 
in the individual susceptibility to glycation, as has been described previously [29].  
There are some restrictions of the skin autofluorescence technique. First, non-
fluorescent AGEs are not measured with our tool. In our previous study, however, skin 
autofluorescence was well correlated with levels of both fluorescent (pentosidine) and 
nonfluorescent AGEs (e.g., carboxymethyllysine) assessed in skin biopsies, which 
suggests a parallel trend formation of AGEs. It is unclear, so far, whether skin 
autofluorescence represents some intracellular-produced AGEs, which may be 
nonfluorescent. Secondly, other fluorophores might be measured (e.g., NADH, which 
has an overlapping excitation spectrum: 350–370 nm) [16]. Finally, the large majority 
of our study population was Caucasian. Some non-Caucasian type 2 diabetes patients Chapter 4 
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had to be excluded because of their skin type. The tool is in further development to 
measure autofluorescence in dark skin. Skin autofluorescence has recently shown 
clinical relevance as a strong and independent predictor of total and cardiovascular 
mortality in a study in patients with end-stage renal disease undergoing hemodialysis 
[30].  
In this study, we showed that increased levels of skin autofluorescence was related to 
the extent of diabetes related complications. In a 4-year follow-up study, the 
progression of microvascular and macrovascular complications, as well as mortality, is 
now evaluated in the current study group of type 2 diabetes patients to analyze whether 
skin autofluorescence contributes to the prediction of the development or progression 
of diabetes complications. If this hypothesis is confirmed, skin autofluorescence, 
reflecting vascular damage, will become an easy tool for clinical practice to identify 
diabetic patients who are at increased risk for developing vascular complications.  
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ABSTRACT 
Introduction The United Kingdom Prospective Diabetes Study (UKPDS) risk-engine  
has become a standard for cardiovascular (CV) risk-assessment in type 2 diabetes 
mellitus. Skin autofluorescence (AF) was recently introduced as an alternative tool for 
cardiovascular risk-assessment in diabetes. We investigated the prognostic value of 
skin autofluorescence for cardiovascular events, in combination with the UKPDS risk 
score in a type 2 diabetes primary care cohort. 
Methods Clinical data, UKPDS risk score and skin autofluorescence were obtained at 
baseline in 2001-2002 in the type 2 diabetes group (n=973). Follow-up data concerning 
fatal and non-fatal CV-events (=primary endpoint) were obtained until 2005. Patients 
were classified as ‘low risk’ when their 10-yr UKPDS risk score for fatal CV-events 
were <10%, and ‘high risk’ if >10%. Skin autofluorescence was measured 
noninvasively with an autofluorescence reader. Skin AF was classified by the median 
(<median as low risk, >median as high risk). 
Results Incidence of CV-events was 119 (44 fatal, 75 non-fatal). In multivariate 
analysis skin autofluorescence, age, sex and diabetes duration were predictors for the 
primary endpoint. Addition of skin autofluorescence to the UKPDS risk engine 
resulted in reclassification of 55 of 203 patients from the low risk to the high risk 
group. The 10-yr CV-event rate was higher in patients with a UKPDS score >10% 
when skin AF was above the median (55.8% vs. 38.9%) 
Conclusion Skin autofluorescence provides additional information to the UKPDS risk 
engine which can result in risk-reclassification of a substantial number of patients. It 
furthermore identifies patients who have a particularly high risk for developing 
cardiovascular events. 
 
 
INTRODUCTION 
Increased formation and accumulation of advanced glycation endproducts (AGEs) is 
one of the pathogenetic mechanisms of accelerated atherosclerosis in type 2 diabetes 
[1]. Both cross-linking of proteins by AGEs, and receptor-mediated cellular activation Skin autofluorescence and cardiovascular prognosis 
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contribute to loss of vascular elasticity and to propagation and maintaining of 
inflammation, contributing to the development of microvascular and macrovascular 
disease. The DCCT-EDIC substudy on skin collagen glycation, found that skin tissue 
AGE levels predict long-term diabetic complications in type 1 diabetes, also after 
adjustment for HbA1c [2,3]. 
Recently, skin autofluorescence (AF) has emerged as a noninvasive and reproducible 
tool to estimate the skin tissue AGE level. Skin AF has been validated against skin 
levels of several specific AGEs, and against a classical assay method for AGEs, 
collagen-linked fluorescence, in different populations (diabetes, renal failure and 
controls) [4-6]. Skin AF was consistently shown to be related to both micro- and 
macrovascular complications in type 2 diabetes, and to be a strong and independent 
predictor of cardiovascular mortality in patients with diabetes mellitus, and in 
haemodialysis patients [5,7,8]. 
For a cardiovascular risk biomarker like skin AF to be useful in clinical practice, it is 
mandatory that it adds information to conventional risk factors or risk models in 
unselected cohorts. Several simulation models have been developed over the last few 
years to estimate the risk for future occurrence of diabetes-related complications. The 
UKPDS risk-engine has emerged as the most used tool to predict complications in type 
2 diabetes [9]. Although it was developed in newly diagnosed type 2 diabetes, it is now 
also used in patients with known diabetes. Still the incorporation of established 
cardiovascular risk factors, and the derived algorithms like the UKPDS risk-engine do 
not fully explain cardiovascular risk [10]. Combining the UKPDS risk score and AF 
might improve the prediction of cardiovascular complications, especially since AGE 
accumulation may reflect a distinct biological pathway in atherogenesis, not or only 
partly covered by other risk factors. Therefore, our aim was to assess the additional 
value of skin AF on top of that obtained from the UKPDS risk-engine for the 
prediction of cardiovascular morbidity and mortality, in primary-care well-controlled 
patients with relatively recently diagnosed type 2 diabetes. 
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METHODS 
Patients The previously described cohort of 973 patients was used for this follow-up 
study [7]. In short, the cohort was recruited from subjects participating in the Zwolle 
Outpatient Diabetes project Integrating Available Care (ZODIAC)-study, which 
investigated the effects of a shared-care project in a primary care population based 
cohort of type 2 diabetes patients in the eastern part of the Netherlands, since 1998 
[11]. All known type 2 diabetes patients of 32 general practitioners who received their 
diabetes support in the primary care setting and additionally visited the diabetes 
outpatient clinic annually, were approached for participation. Patients were included 
from May 2001 until May 2002. The large majority was of Caucasian ethnicity (97%). 
Patients with cognitive disability or terminal diseases were not included in the 
ZODIAC-study and, consequently, also ineligible for the present study. This study was 
approved by the local ethical committee. Written informed consent was obtained from 
the participants. 
Material and technique. Skin autofluorescence was assessed at baseline using the 
Autofluorescence Reader (a prototype of the current AGE Reader, DiagnOptics BV, 
Groningen, The Netherlands) as described previously [7]. In short, the 
Autofluorescence Reader illuminates a skin surface of ~4 cm2, guarded against 
surrounding light, with an excitation light source with peak intensity at ~370 nm. 
Emission light and reflected excitation light from the skin are measured with a 
spectrometer in the 300-600 nm range, using a glass fibre. Measurements were 
performed at the volar side of the arm. AF was calculated by dividing the average 
emitted light intensity per nm in the range between 420-600 nm by the average 
excitated light intensity per nm in the range between 300-420 nm. AF was expressed as 
arbitrary units (a.u.), and multiplied by hundred. Over all AF measurements, the mean 
age-corrected AF per measuring month, per examiner, and per AFR-system did not 
differ significantly. Repeated AFR measurements taken over a single day in control 
subjects and diabetic patients showed an overall Altman error percentage of 5.03%. 
Intra-individual seasonal variance among control subjects and diabetic patients showed 
an Altman error percentage of 5.87%. Skin autofluorescence and cardiovascular prognosis 
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Clinical data The methods of baseline clinical data collection and laboratory 
assessments have been described in detail elsewhere, including the definition of a 
history of any microvascular disease (retinopathy, neuropathy and/or nephropathy) or 
any macrovascular disease (coronary heart, cerebrovascular and/or peripheral vascular 
disease) [7]. Follow-up data, obtained in the period between the date of the baseline 
autofluorescence measurement and January  2005, were used in the analysis. 
UKPDS. The UKPDS risk-score (10-year non-fatal CHD risk, 10-year fatal 
CHD/Stroke risk) was calculated with the UKPDS risk-engine (version 2.0, 
http://www.dtu.ox.ac.uk) using the values of the required variables collected at 
baseline (single observations).  
Events. Fatal or non-fatal events were registered from the date of inclusion until 
January 2005. Fatal events were categorized as: due to coronary heart disease (CHD), 
International Classification of diseases (ICD-9) codes 410-414, cerebrovascular disease 
430-438, other cardiovascular disease 390-409, 415-429, 439-459, sudden death 798-
798.9, and non-cardiovascular deaths (all other causes). The coded causes of death 
were combined to total mortality (all codes) and cardiovascular mortality (390-459 + 
sudden death). The following non-fatal cardiovascular events were registered: CHD 
(myocardial infarction, coronary artery bypass surgery and percutaneous coronary 
intervention), major cerebrovascular accidents or peripheral vascular disease 
(amputation, percutaneous transluminal angioplasty, bypass surgery). In case of 
multiple non-fatal cardiovascular events during the follow-up period, only the first 
event was considered in the study. All cases and timepoints of cardiovascular death or 
events were adjudicated by two independent physicians unaware of the skin AF results, 
using the hospital and general practitioner records. The primary endpoint was ‘any 
cardiovascular event’ (fatal + non-fatal CV-events), the secondary endpoints were all-
cause mortality + non-fatal CV-events, and all-cause mortality only. 
 
Statistical analysis. The size of the cohort was calculated before the start of the study 
in 2001, allowing sufficient CV-events during the follow-up period to detect a 6% 
difference in event-free surviving proportion (93% vs. 87%) [7,12]. Incidence rates of Chapter 5 
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endpoints were calculated per 1000 person-years. Univariate and multivariate Cox 
regression analysis were performed for the primary endpoint and the secondary 
endpoints. For the analysis of the possible additional information of skin AF to the 
UKPDS risk score, the participants were divided in those with a 10-years UKPDS risk 
for a fatal CV-event above and below 10%, and in those with a skin AF value above 
and below the median, resulting in four groups. The cut-off point of the UKPDS risk 
score was chosen because it is used in the Dutch cardiovascular risk management 
guidelines 2007 as a treatment decision cut-off value [13]. The classification of skin 
AF above and below the median was determined previously as a result of receiver-
operating curve (ROC) analyses (non published data): ROC curves of skin AF 
expressed as continuous variable, or using classification defined by median, tertile and 
quartile were constructed for the endpoint all cause mortality. Area under the receiver-
operating curve (AUC) using median-skin AF was highest: 0.63, 95% CI 0.58-0.69. 
AUC using AF on a continuous scale was 0.61, 95% CI 0.55-0.67, AUC using AF>2nd 
tertile 0.59 (95%CI 0.52-0.65), or AUC using AF in highest quartile 0.57 (95%CI 0.51-
0.64) . Therefore, when we set up the methods for this manuscript, we decided to use 
median skin AF in the analysis. For the analysis of the possible additional information 
of skin AF to the UKPDS risk score we performed reclassification analyses, 
calculations of AUCs of 2 models with and without skin AF [14,15], and construction 
of Kaplan-Meier curves with the cumulative incidence of events in the four subgroups. 
Differences between the Kaplan-Meier curves were tested using Log rank test.  
P<0.05 (two-tailed) was considered significant. Increment of AUC of 0.025 was 
considered clinically relevant. This study was not powered to reach statistical 
significance at an AUC increase of 0.025, which needs a sample size of  >10.000 
patients (80% power, α=0.05). 
Data are shown as mean ± SD, unless otherwise indicated. Skin autofluorescence and cardiovascular prognosis 
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Table 1. Baseline characteristics of the 967 T2DM-patients. Values are expressed as mean (SD) 
and % when indicated 
Characteristic Mean  (SD) 
Age (years)  66 (11) 
Male gender  47%  
Smoking 19% 
Body mass index (kg/m2)  29 (5)  
Systolic blood pressure (mmHg)  146 (20) 
Diastolic blood pressure (mmHg)  81 (10) 
Diabetes duration, (years) 
a4.2 (1.6-8.3) 
HbA1c (%)  7.0 (1.3) 
Creatinine (µmol/l)  96 (20) 
Creatinine clearance (Cockroft-formula)  76 (27) 
Urinary albumin/creatinine ratio 
a1.47 (0.8-4.1) 
Total cholesterol (mmol/l) 5.2  (1.0) 
Chol/HDL-ratio 4.3  (1.2) 
HDL (mmol/l)  1.3 (0.3) 
LDL (mmol/l)  2.9 (0.9) 
Triglycerides (mmol/l)  2.3 (1.3) 
Microvascular disease  53% 
   Microalbuminuria  25% 
   Retinopathy  20% 
   Neuropathy  29% 
Macrovascular disease      39% 
   Coronary heart disease (CHD)  21% 
   Cerebrovascular disease  8% 
   Peripheral vascular disease (PVD)  22% 
Skin autofluorescence (a.u.), mean  2.79 (0.8) 
Skin autofluorescence (a.u.), median 
a2.69 (2.26-3.19) 
UKPDS risk score (%) 
a27.4 (16.6-46.9) 
aMedian and Interquartile range 
 
 
RESULTS 
Group characteristics In 2001-2002, 973 type 2 diabetes patients were included. Six 
patients were lost to follow-up. Baseline characteristics of the 967 patients are depicted 
in Table 1. Mean age was 66 yrs, mean HbA1c 7.0% and mean diabetes duration was Chapter 5 
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6.3 yrs. Median follow-up was 1131 days (IQR 1019-1212 days). Forty-two patients 
died of non-cardiovascular causes. There were 119 cardiovascular events: 44 
cardiovascular deaths, and 75 non-fatal cardiovascular events, corresponding with an 
incidence rate of this primary endpoint of 40.1 per 1000 person-years. A history of 
CHD was present in 204 patients. In these patients, the incidence of the primary 
endpoint was 75 per 1000 person-years at follow-up compared to 32 per 1000 person-
years in patients without a history of CHD. 
 
Validation of UKPDS risk engine in this cohort For all participants (including those 
with a history of CHD), the calculated median UKPDS risk score in 10 years for the 
primary endpoint was 35%. The calculated median UKPDS risk score in 3.2 years was 
12.3%. This expected CV-event rate was not significantly different from observed: 
13%, in this study.  
 
Predictors in univariate and multivariate models of the primary and secondary 
endpoints Table 2 shows the univariate HR’s for the different endpoints. The first 
multivariate model including all items of the UKPDS risk engine (except atrial 
fibrillation and ethnicity) plus AF, showed significant HR’s for age, diabetes duration, 
female gender, and skin AF for the primary endpoint, see Table 2. Smoking, HbA1c, 
systolic blood pressure and lipid profile were not significant. The second multivariate 
model consisted of  a history of microvascular disease, a history of a macrovascular 
disease, the 10-years UKPDS risk score for total fatal cardiovascular disease above 
10%, and AF, and showed significant HR’s for UKPDS risk score and for a history of 
macrovascular disease on all endpoints. Significant HR’s were only observed for AF at 
both secondary endpoints. All HR’s are presented in the lower part of Table 2. History 
of microvascular complications was not significant for any endpoint. 
 
 Skin autofluorescence and cardiovascular prognosis 
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Table 2. Cox-regression analysis, univariate and multivariate 
Primary endpoint: fatal + non-fatal CV-events, 1st secondary endpoint: non-fatal CV-events + all 
cause mortality, 2nd secondary endpoint: all cause mortality. 
aHR for continuous variables are 
expressed per SD increase. 
bcalculated with the UKPDS Risk Engine. 
csignificant HR. 
  Primary endpoint  1st Sec. endpoint  2nd Sec. endpoint 
Univariate  HR  95% CI  HR  95% CI  HR  95% CI 
Age
a  1.38
c  1.18-1.58 1.46
c  1.29-1.64 1.78
c  1.51-2.05 
Female gender  0.64
c  0.45-0.92 0.69
c  0.51-0.95 0.68  0.44-1.03 
Diabetes duration
a 1.22
c  1.07-1.37 1.21
c  1.08-1.34 1.22
c  1.05-1.40 
Current smoking  1.16  0.75-1.79  1.20  0.83-1.73  1.52  0.94-2.45 
BMI
a 0.94  0.76-1.12  0.94  0.78-1.09  1.01  0.80-1.22 
Hypertension 0.96  0.64-1.43  1.06  0.74-1.52  1.24  0.75-2.07 
Systolic blood pressure
a 1.08  0.90-1.26  1.10  0.95-1.25  1.17  0.97-1.38 
Diastolic blood pressure
a 0.83  0.65-1.01  0.80  0.64-0.95  0.84  0.64-1.06 
HbA1c
a 1.04  0.87-1.23  1.03  0.89-1.20  1.03  0.83-1.26 
Creatinine
a 1.26
c  1.12-1.40 1.26
c  1.14-1.38 1.30
c  1.15-1.45 
Total Cholesterol
a 0.96  0.80-1.15  0.87  0.74-1.02  0.80  0.64-1.00 
Chol/HDL-ratio
a 1.17  0.99-1.37  1.13  0.97-1.30  1.04  0.84-1.28 
HDL-cholesterol
a 0.86  0.78-1.02  0.85
c  0.78-0.97 0.89  0.78-1.10 
LDL-cholesterol
a 0.97  0.81-1.16  0.94  0.80-1.10  0.95  0.77-1.82 
Skin AF above median  1.80
c  1.24-2.62 2.05
c  1.48-2.84 3.13
c  1.93-5.08 
History of PVD  3.19
c  2.22-4.58 3.01
c  2.21-4.12 3.96
c  2.59-6.06 
History of CHD  2.48
c  1.71-3.60 2.18
c  1.57-3.01 1.98
c  1.26-3.10 
Albuminuria 1.76
c  1.21-2.56 1.85
c  1.35-2.55 2.50
c  1.63-3.82 
Neuropathy 1.49
c  1.03-2.16 1.51
c  1.09-2.07 1.85
c  1.20-2.84 
Retinopathy 1.23  0.81-1.88  1.04 0.71-1.53 1.17  0.70-1.95 
Microvascular complications  1.25  0.87-1.81  1.33  0.97-1.83  2.04
c  1.29-3.24 
Macrovascular complications  4.33
c  2.91-6.45 3.26
c  2.36-4.52 2.99
c  1.93-4.63 
10-yrs CHD-risk
a,b  2.19
c  1.48-3.59 2.32
c  1.63-3.56 3.55
c  2.04-6.84 
10-yrs risk for fatal CV-event
a,b  1.80
c  1.34-2.60 1.90
c  1.46-2.61 2.62
c  1.75-4.25 
10-yrs risk for fatal CV-event  <10%
a,b  3.97
c  1.94-8.13 3.57
c  1.98-6.42 4.71
c  1.91-11.63 
Multivariate         
model 1  HR  95% CI  HR  95% CI  HR  95% CI 
Age
a  1.33
c  1.11-1.56 1.41
c  1.21-1.61 1.71
c  1.40-2.02 
Diabetes duration
a  1.18
c  1.01-1.35 1.15
c  1.01-1.29 1.07  0.87-1.27 
Female gender  0.59
c  0.40-0.86 0.65
c  0.46-0.90 0.59
c  0.37-0.94 
Smoking 1.18  0.75-1.86  1.24  0.84-1.82  1.71
c  1.03-2.82 
HbA1c
a  0.97 0.79-1.18 0.98 0.82-1.16 1.00  0.78-1.26 
Systolic blood pressure
a  1.01 0.83-1.20 1.02 0.87-1.18 1.10  0.85-1.36 
Total Cholesterol
a  1.06 0.88-1.28 0.96 0.82-1.14 0.88  0.70-1.10 
HDL Cholesterol
a  0.86 0.77-1.04 0.86 0.78-1.00 0.94  0.80-1.24 
Skin AF  1.28
c  1.01-1.62 1.57
c  1.10-2.25 2.05
c  1.22-3.45 
model 2         
Microvascular complications  0.86 0.59-1.26 0.94 0.68-1.30 1.40  0.88-2.25 
Macrovascular complications  3.79
c  2.51-5.72 2.74
c  1.96-3.83 2.16
c  1.38-3.40 
10-yrs risk for fatal CV-event >10%
a  2.79
c  1.34-5.84 2.50
c  1.36-4.58 2.78
c 1.10-7.03 
Skin AF  1.21  0.82-1.79  1.46
c  1.04-2.05 2.18
c  1.32-3.59 Chapter 5 
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Additional value of skin AF to UKPDS risk score for the primary and secondary 
endpoints. Reclassification of risk groups  Table 3 shows multivariate Cox-regression 
analyses and comparison of AUCs  for models with the UKPDS risk score (cut-off 
point 10%), with or without addition of skin AF (cut-off point median), for all three 
endpoints. In model 1, for the primary endpoint, the AUC of the model including skin 
AF increased from 0.581 to 0.618, which is relevant (>0.025), but not significant. For 
the 2nd secondary endpoint, the AUC increased significantly to 0.667 (p=0.03). AUC 
was highest in model 2 (AUC 0.718), including also microvascular, macrovascular 
complications and skin AF. The AUC of this model without skin AF was 0.712, so in 
model 2 AF had no relevant contribution in the prediction of the primary endpoint. 
Table 4 presents the proportion of patients initially classified as having a 10-year risk 
of less than 10% or higher than 10%, who would be reclassified to a higher or lower 
risk category by having a skin AF lower or higher than the median. It appeared that 55 
of 203 persons (27%) with a calculated 10-year fatal CV risk of <10% with the 
UKPDS risk-engine had an AF above the median, resulting in reclassification from low 
to high risk. The calculated 10-year CV-event rate (based on the observed CV-events in 
the first 3.2 years) in this group with low risk concerning the UKPDS risk score and 
high risk concerning skin AF, is 17.8%, which is 59% higher than the patients with low 
UKPDS risk score and skin AF below the median (11.2%). This difference was not 
significant (p=0.5). Within the high risk group (UKPDS risk score >10%), the 
calculated 10-year CV-event rate was significantly higher (55.8%) in patients with skin 
AF > median, compared to patients with skin AF <median (38.9%), p=0.049. 
Figure 1 depicts this result, showing Kaplan-Meier survival curves for the primary end 
point of the four groups. For this endpoint, survival was significantly different between 
group 4 and all other groups (1: p<0.001, 2:p<0.05, 3: p<0.05), and between group 3 
and group 1 (p<0.01). Similar differences between groups were found in the analysis 
concerning the secondary endpoints (survival curves not shown). When subjects with a 
known history of CHD at baseline were excluded from the analysis, similar differences 
between the same groups were also found for the primary end point, except that the 
difference between groups 3 and 4 lost significance (p = 0.053). Skin autofluorescence and cardiovascular prognosis 
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Table 4. Risk reclassification for the primary endpoint (fatal + non-fatal cardiovascular events) 
in 967 type 2 diabetes patients by addition of skin autofluorescence to the UKPDS Risk Engine.  
 aobserved events during follow-up (~3-years). 
bcalculation based on the observed incidence in 
the first ~3 years. 
cAF = skin autofluorescence  
 
 
 
Figure 1. Kaplan-Meier survival curves for the primary endpoint for the four groups: Group1. 
AF < median and UKPDS risk score <10% (n=144). Group 2. AF > median and UKPDS risk 
score <10% (n=59). Group 3. UKPDS risk score >10% and AF < median (n=328). Group 4. AF 
> median and UKPDS risk score >10% (n=436). Survival was significantly different between 
group 4 and al other groups, and between group 3 and group 1. 
10-Year risk categories using 
the UKPDS Risk Engine 
Total 
cAF<median AF>median  p  No (%) 
reclassified 
<10%            
  n  203 148  55    55/203=  27% 
 events
a  8 (3.9%)  5 (3.4%)  3 (5.4%)     
  10-years event rate
 b  12.8% 11.2%  17.8%  0.500   
>10%            
  n  764 334  430     
 events  111(14.5%)  39(11.7%)  72(16.7%)     
  10-years event rate  47.90% 38.90%  55.80%  0.049   
All   967         
 events  119 
(12.3%) 
      
  10-years event rate  40.5%         
Group 1 
Group 2 
 
Group 3 
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DISCUSSION 
This study shows that skin autofluorescence is of additional clinical value in the 
evaluation of risk for fatal and non-fatal cardiovascular events and total mortality in 
type 2 diabetes mellitus. Firstly, it is concluded that skin autofluorescence was able to 
identify a patient group with a more increased event rate within the group of patients 
with a high risk for a fatal cardiovascular event of more than 10% within the next 10 
years, calculated with the UKPDS risk-engine. The patientgroup with a UKPDS risk 
score >10% and a skin AF value above the median, had a significantly higher 10-year 
event rate of 55.8%, compared to group with a UKPDS risk score >10% and a skin AF 
below the median (38.9%). Since the large majority (79%) of this well-controlled 
primary-care cohort with relatively recent onset of type 2 diabetes study population has 
a UKPDS risk score of >10%, it is clinically helpful to have an extra clinical tool to 
further differentiate the risk in the high risk group. Secondly, when adding skin AF 
categories (below and above the median) for risk reclassification of patients with 
UKPDS risk scores of <10%, substantial numbers of patients (27%) would be 
reclassified to a higher risk group. The incidence of cardiovascular events in patients 
with a low risk calculated with the UKPDS risk score was 59% higher if they had an 
AF above the median compared an AF below the median. Reclassification of patients 
from low to high risk by AF seems, therefore, justified and should result in 
reconsideration of treatment strategies by extending or intensifying treatment in such 
individuals. Skin autofluorescence should not result in reclassification of patients from 
high risk (UKPDS-risk score >10%) to low risk when skin AF is below the median, 
because the incidence rate of cardiovascular events is high in this group and 
‘undertreatment’ is unwanted. 
A history of macrovascular disease and an UKPDS risk score above 10% were 
significant predictors in the multivariate Cox-regression for all endpoints, and had the 
highest hazard ratios. The AUC of the Cox-regression analysis in the first model with 
the UKPDS risk score increased relevantly (>0.025) by addition of skin 
autofluorescence, which was not statistically significant for the primary endpoint due 
to the sample size. For the endpoint ‘all-cause mortality’ the increment of AUC of the Chapter 5 
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model with AF was higher and significant. In model 2 where a history of 
macrovascular disease was also included, the addition of AF was not relevant for the 
primary endpoint and just relevant for the secondary endpoint. The small contribution 
of AF in this model might be due to the relation of AF with macrovascular disease. In 
our previous study with cross-sectional data we already showed the relation between 
AF and clinical apparent vascular damage like a history of macrovascular disease [7]. 
The present follow-up study confirms skin AF to be a marker of preclinical apparent 
vascular damage because the incidence of CV-events has increased in the patient group 
with a baseline skin AF value above the median.  
The contributions of skin AF to all models were higher for the secondary endpoints, 
where ‘all cause mortality’ was included. This suggests that skin AF or AGEs might 
also be involved in non-cardiovascular causes of death such as cancer. 
A long term follow-up study in a Finnish type 2 DM population, showed that serum 
levels of AGEs were predictive for all cause and cardiovascular mortality [16]. Besides 
the papers of this Finnish diabetes cohort, original papers about the predictive value of 
AGEs for cardiovascular morbidity or mortality are scarce. However, the mechanisms 
how AGEs can result in vascular injury have been described in the past in extension [1, 
17, 20]. A recent study showed a pathophysiological example of the role of AGEs in 
cardiovascular disease by finding increased myocardial AGE depositions in patients 
with diabetes and heart failure with reduced left ventricular ejection fraction [18]. 
Despite our inclusion of patients with a history of CHD (which is different from the 
UKPDS study), the expected 3.2-year UKPDS-score event-rates in our group were in 
line with the observed rates, confirming that the UKPDS scores were well applicable 
and calibrated for our group. The incidence of new CV-events in our group was twice 
as high in the 20% patients with a history of CHD, compared to patients without a 
history of CHD. Including patients with a history of CHD seems to be justified by daily 
practice where a history of CHD is common in even newly diagnosed type 2 diabetes. 
The UKPDS risk-engine was developed in a young (25-65 years, mean age at diagnosis 
52 years) newly-diagnosed type 2 diabetes group without previous cardiovascular 
disease, detected between 1977 and 1991, selected for participating in a clinical trial, Skin autofluorescence and cardiovascular prognosis 
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and using the mean of HbA1c, BP and lipid levels in the first 2 years after diagnosis 
[9]. Despite the increased incidence at younger ages, the presentation of type 2 diabetes 
involves mainly subjects over 60 years of age in the Netherlands, often with previous 
CHD and already treated with statins or antihypertensives. When in such treated 
patients blood pressure or cholesterol values are put in the UKPDS risk-engine, the 
calculated risk score might be an underestimated risk. In those patients the clinician is 
expected to identify those at the highest CV-risk to adapt treatment targets. Our older 
patient group with HbA1c-levels comparable to that of the UKPDS cohort but with 
prevalent (39%) macrovascular disease, reflects the differences between our ‘daily 
practice’ type 2 diabetes cohort and the UKPDS cohort.  
In the present study, no additional contribution of HbA1c was found as predictor for 
any of the endpoints. The contribution of HbA1c to increased CV-risk in type 2 
diabetes was illustrated in the UKPDS by an almost twofold increase in 10-year CHD 
risk, and by a higher odds ratio for fatal to non-fatal events, both myocardial infarction 
and stroke [9,19]. This seeming discrepancy with our models including skin AF may be 
influenced by the relatively low mean HbA1c in our population, but another 
explanation is the following concept. First, skin AF and skin biopsy AGEs may reflect 
the impact of the history of hyperglycaemic episodes in diabetes and preceding 
impaired glucose tolerance, rather than the short-term measure of hyperglycaemia by 
HbA1c (weeks). Second, AGEs are also formed during oxidative stress via the pathway 
of reactive carbonyl compound formation [20]. An earlier study found skin AF to be 
related to CRP and inversely related to antioxidant levels, addressing that skin AF also 
represent inflammatory along with hyperglycaemic episodes [21]. The DCCT-EDIC 
group that skin collagen AGE and collagen-linked fluorescence from skin biopsies 
were better predictors than HbA1c of diabetic complications in type 1 diabetes mellitus 
[2,3]. They introduced ‘metabolic memory’, the long-term (years) memory, of stable 
AGEs bound to long-lived proteins like skin collagen, for episodes of hyperglycaemia 
and oxidative stress as an explanation for the superiority of skin AGE as a risk 
predictor. The recent long-term follow-up of glucose control  in the UKPDS cohort, 
showed in the intensive therapy group a continued reduction in risk for microvascular Chapter 5 
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complications, myocardial infarction and all-cause mortality during 10 years of post-
trial follow-up. This is despite the early loss of glycemic and HbA1c differences, and 
further support to the above concept [22]. 
Some limitations of our study should be kept in mind: the follow-up period is relatively 
short. Our calculations were all based on single measurements. Effects of regression 
dilution bias cannot be excluded. As for the comparison with the UKPDS risk score, in 
the design of the UKPDS the years 0-4 were excluded from the analysis, since in the 
first years of the clinical trial mortality rates were lower. We used a cohort which had 
been recruited and followed for at least 3 years before the baseline AF measurements. 
Furthermore, our population size was small compared to larger studies who are 
specifically designed to develop risk-prediction models. Like described in the method 
section, this study was not powered to reach significance of the clinically relevant 
increase of AUC of 0.025 by skin AF. However, relevant increase in AUC became 
visible in this small cohort in this stage of the follow-up. Finally, our results were 
obtained in a predominantly Caucasian group. AF measurements in dark skinned 
persons were not considered reliable using the prototype device in our study. Thus, the 
predictive results of skin AF may not directly be extrapolated to groups with darker 
skin, but probably need additional validation with newer versions of the AGE Reader.  
In conclusion, non-invasive skin AF is a clinical tool which could be used in addition 
to the UKPDS risk score to identify diabetic subjects with preclinical vascular damage 
who have a particularly high risk for developing cardiovascular events. A high skin AF 
value can also result in reclassification to a high risk group in patients who are 
classified as ‘low-risk’ according to the UKPDS risk-engine. Although many type 2 
diabetes patients are nowadays controlled tightly according to guidelines for their 
classical risk factors, they still develop micro- and macrovascular complications. 
Therefore, there is a need for additional markers to identify patients at high risk for 
complications. Furthermore, risk calculators might underestimate cardiovascular risk in 
patients who are already treated with blood pressure or lipid lowering drugs. 
Improvement of risk prediction strategies is important to further reduce the incidence 
or progression of complications in patients with diabetes. Skin autofluorescence and cardiovascular prognosis 
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ABSTRACT 
Introduction Earlier studies showed increased mortality in individuals with type 2 
diabetes mellitus. As a result of major changes in treatment regimes over the past 
years, with more stringent goals for metabolic control and cardiovascular risk 
management, improvement of life expectancy should be expected. In our study, we 
aimed to assess present-day life expectancy of type 2 diabetes patients in an ongoing 
cohort study. 
Methods We included 973 primary care type 2 diabetes patients in a prospective cohort 
study who were all participating in a shared care project in the Netherlands. Vital status 
was assessed from May 2001 until May 2007. Main outcome measurement was life 
expectancy assessed by transforming survival time to standardised survival time 
allowing adjustment for the baseline mortality rate of the general population. 
Results At baseline, mean age was 66 years, mean HbA1c 7.0%. During a median 
follow-up of 5.4 years, 165 patients died (78 from cardiovascular disease) and 17 
patients were lost to follow-up. There was no difference in life expectancy of type 2 
diabetes patients compared to the life expectancy of the general population. In 
multivariate Cox regression analyses, concentrating on the endpoints ‘all-cause’ and 
cardiovascular mortality, a history of cardiovascular disease: HR 1.71 (95% CI 1.23-
2.37), and HR 2.59  (95% CI 1.56-4.28), and albuminuria: HR 1.72 (95 %CI 1.26-2.35) 
and HR 1.83 (95%CI 1.17-2.89), respectively, were significant predictors, whereas 
smoking, HbA1c, systolic blood pressure and diabetes duration were not.  
Conclusion This study shows a normal life expectancy in type 2 diabetes patients in 
primary care. A history of cardiovascular disease and albuminuria, however, increase 
the risk of a reduction of life expectancy. These results show that, in a shared care 
environment, a normal life expectancy is achievable in type 2 diabetes patients. 
 
INTRODUCTION 
The incidence and prevalence of diabetes mellitus has risen worldwide during the past 
few decades. Recently published data from the Framingham Heart Study showed an 
absolute increase in the incidence of diabetes of ~ 2.5% during the 1990s compared to Normal life expectancy in type 2 diabetes 
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the 1970s [1]. The proportion of cardiovascular disease attributable to diabetes mellitus 
has increased as well [2]. Other studies over the last decades of the previous century 
also showed increased mortality rates in diabetes mellitus compared to the general 
population, mostly due to cardiovascular events [3-7]. However, since the introduction 
of new pharmaceutical therapies and more stringent regimens for the treatment of 
hyperglycaemia, hypertension, dyslipidaemia, and other cardiovascular risk factors, 
trends in reduction of (cardiovascular) mortality rates amongst diabetic patients have 
been seen [8-12]. This improvement of survival could be expected to be comparable to 
the decrease in cardiovascular mortality rates in the general population due to 
aggressive management of cardiovascular risk factors as well.  
Most published data were extracted from representative national cohorts in North-
America or the United Kingdom. Some reports showed a decline in mortality rates 
amongst diabetic men only, whereas women showed an increase or no change in 
mortality rates at all [4,8,11,12]. A recently published Scandinavian study showed a 
substantial decrease in mortality rates from coronary heart disease in all age groups 
irrespective of sex and diabetes status over two consecutive time periods. However, the 
more than twofold higher mortality from coronary heart disease in diabetes patients 
compared to the non-diabetic population remained over time. This finding also suggest 
a longer survival in diabetes patients resulting from intensified treatment of 
cardiovascular risk factors [13].  
Our aim was to investigate present-day life expectancy in a type 2 diabetes population 
treated in a primary care, who also received additional support in a shared care setting 
in a West-European country. 
 
 
METHODS 
Subjects In 2001, 973 type 2 diabetes patients participated in a cross-sectional study 
with measurements of skin advanced glycation endproduct (AGE) accumulation as 
described previously [14]. This study was embedded in a long-term shared care project 
(ZODIAC: Zwolle Outpatient Diabetes project Integrating Available Care) concerning Chapter 6 
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a primary care treated population-based sample of type 2 diabetes patients in an eastern 
district of The Netherlands. Figure 2 of Chapter 1 (page 15) shows an overview of the 
enrolment of the current study cohort started from the beginning of the ZODIAC. 
During this project, 32 general practitioners (GPs) were supported by hospital diabetes 
specialist nurses and consultant-physicians [15]. In short, all type 2 diabetes patients 
were exclusively treated by their GPs and visited the diabetes specialist nurses for 
evaluation of metabolic control and diabetes related complications annually. After 
these evaluations, treatment advice for individual patients as well as for benchmarking 
was given to the GPs by internists in the Isala Clinics in Zwolle, the Netherlands. 
Advice and referrals were based on guidelines of the Dutch College of General 
Practitioners [16]. Patients with a cognitive disability or terminal disease were not 
included in the ZODIAC study because of their inability to undergo educational 
programs. Furthermore, patients who were physically unable to visit the diabetes 
specialist nurse at the outpatient clinic were not enclosed in the present cohort. This 
study was approved by the local ethical committee of the Isala Clinics, Zwolle, The 
Netherlands and all patients gave written informed consent. 
 
Procedures Methods of clinical data collection and laboratory assessments have been 
described in detail elsewhere [14]. Before participation in our study, diagnosis of 
diabetes mellitus was already made in individuals with fasting plasma glucose levels ≥ 
7.0 mmol/liter. The following definitions representing the diabetic complications at 
baseline are: retinopathy, which was defined as the presence of at least background 
retinopathy or a history of laser coagulation for diabetic retinopathy. Albuminuria was 
defined as an albumin-to-creatinine ratio >3.5 mg/mmol for women or >2.5 mg/mmol 
for men. Diminished sensibility at least at one foot was considered as neuropathy, 
tested with a 5.07 Semmes-Weinstein monofilament, applied on three areas of each 
foot [16]. The presence of microvascular disease was defined as meeting the criteria of 
retinopathy, albuminuria, and/or neuropathy. The presence of cardiovascular disease at 
baseline was defined when meeting at least one aspect of cardiovascular disease: 
ischemic heart disease (IHD), International Classification of Diseases ninth revision Normal life expectancy in type 2 diabetes 
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(ICD-9), codes 410-414 and/or a history of coronary artery bypass surgery or 
percutaneous coronary intervention, cerebrovascular accidents including transient 
ischemic attacks (CVAs) and/or peripheral vascular disease (PVD). PVD is defined as 
surgical intervention, claudication and/or absent pulsations of ankle or foot arteries 
(absence of pulsations of the dorsalis pedes arteries bilaterally was not scored as PVD 
when tibial artery pulsations were present).  
Mortality was registered from the date of inclusion until May 2007. Death was certified 
according to the following procedure. In addition to the list of deceased patients 
reported in the files of the scheduled annual follow-up visits, survival status of the 
patients was obtained from the local hospital information system and verified with the 
GPs. Date of death was collected likewise. None of the GPs had involvement or 
interest in study outcome. Causes of death were coded according to ICD-9 and 
categorised as: neoplasms (140 – 239), diseases of the cardiovascular system (390 – 
459), diseases of the respiratory system (460 – 519), diseases of the digestive system 
(520 – 579), diseases of the genitourinary system (580 – 629), injury and poisoning 
(800 – 999). Sudden death, with symptoms present less than one hour, was encoded in 
the category of coronary heart disease. For the in-hospital deaths, the medical records 
were retrieved. For the out-of-hospital deceased patients, the assigned causes of death 
by the GPs were obtained from the medical records of the GPs. The coded causes of 
death were combined to all-cause mortality (all codes) and cardiovascular mortality 
(390 – 459 or sudden death). 
 
Statistical analyses Analysis of life expectancy was performed primarily by the use of  
‘standardised survival time’ (SST), which is a novel approach to survival analysis [17]. 
SST is another expression of follow-up time than survival time in years. This method 
provides survival time which is adjusted for the median residual life span of individuals 
in the general population with the same age and sex. Due to this standardisation of 
survival time there is no influence of the interactions between age and the presence and 
effects of other risk factors. Furthermore, it allows assessment of the effectiveness of 
treatment on regaining a normal residual life span. SST was calculated as the ratio Chapter 6 
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between the observed survival time of an individual and the median residual life span 
of individuals with the same age and sex in the general population at the starting date 
of the study. The median residual life span was derived from gender specific reports 
provided by the Dutch Central Office of Statistics, which is the national institution of 
statistics and demographics [18]. Direct comparisons between study samples and the 
general population were done by comparing the 95% confidence interval (CI) of each 
median SST with an expected value of 1. The 95% CI of mortality at a SST of 0.25 and 
0.5 were calculated and compared with the expected mortality as calculated for the age 
and gender matched general population, assuming Poisson distribution of the events. 
Kaplan-Meier curves were constructed for survival and for standardised survival. A 
Cox proportional hazard model to estimate hazard ratios (HR) and 95% CI was used in 
the standard way using survival time in years, and additionally by using SST. 
Methodologically, it is allowed to use SST instead of survival time in years in a Cox-
regression model, as it is consistent with the preconditions of a Cox regression 
analysis: an increase in mortality and an increase in follow-up time have to be present. 
P values <0.05 were considered to be statistically significant. Clinical and laboratory 
variables with an expected risk for mortality were first analysed in a univariate 
analysis, and secondly, in a multivariate model. Detailed analyses were done for two 
end-points: all-cause mortality and cardiovascular mortality.  
 
 
RESULTS 
Characteristics of the 973 type 2 diabetes patients at baseline (2001) are shown in 
Table 1. The population had a relatively short median diabetes duration of 4.2 
(interquartile range 1.6 – 8.3) years and on average a good glycemic control (mean 
HbA1c 7.0%). Table 1 also shows the baseline characteristics of patients when 
subdivided in survivors (791 patients) and non-survivors (165 patients). At the end of a 
median follow-up duration of 5.4 years (interquartile range 5.1 – 5.6), 165 patients had 
died (17%) and 17 patients were lost to follow-up.  Normal life expectancy in type 2 diabetes 
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Table 1. Baseline characteristics of type 2 diabetes patients: total and subdivided in survivors 
and non-survivors, expressed as mean ± SD or  n (%) 
Seven patients were lost to follow-up and did not define the baseline characteristics of the 
survivors/non-survivors. 
aMedian and interquartile range, 
bAngiotensin-converting enzyme inhibitors 
and Angiotensin II receptor blockers, 
cLarge majority represented by statins (99%). Reference values 
of the laboratory: HbA1c 4.0-6.0 %, creatinine 70-110 µmol/l, creatinine clearance (Cockcroft-
formula) 80-120 ml/min, urinary albumin-to-creatinine ratio 0-2.5 for men and 0-3.5 for women, total 
cholesterol 3.5-5.0 mmol/l. Abbreviations: IHD, ischemic heart disease; PVD, peripheral vascular 
disease. 
Characteristic  Total (N = 973)  Survivors (N=791)  Non-survivors (N=165)  p-value 
Age in years  66.4 (11.3)  64.8 (11.1)  73.6 (9.4)  <0.001 
Male gender (%)  47  46.3  50.9  0.278 
Smoking (%)  19.3  19.3  20.6  0.71 
Body mass index in kg/m
2  29.38 (4.87)  29.5 (4.8)  28.7 (5.1)  0.077 
Systolic blood pressure in mmHg  146.01 (20.15)  145 (20)  149 (20)  0.015 
Diastolic blood pressure  in mmHg  81.18 (10.34)  81 (10)  80 (11)  0.046 
Diabetes duration in years 
a4.16 (1.62-8.31) 
a3.92 (1.50-8.04) 
a5.03 (2.40-10.8)  0.002 
HbA1c (%)  6.96 (1.3)  6.95 (1.32)  6.998 (1.23)  0.69 
Creatinine in µmol/l  96.0 (19.88)  94.56 (17.6)  103.16 (27.69)  <0.001 
Creatinine clearance in ml/min   76.13 (26.91)  78.8 (26.6)  63.22 (24.75)  <0.001 
Urinary albumin-to-creatinine ratio  
a1.49 (0.80-4.17) 
a1.35 (0.75-3.44) 
a3.09 (1.23-11.01)  0.001 
Total cholesterol  in mmol/l  5.16 (1.01) 5.17  (1.02)  5.08  (1.00) 0.302 
Cholesterol-to-HDL ratio  4.34 (1.23)  4.37 (1.21)  4.22 (1.36)  0.171 
HDL cholesterol in mmol/l   1.25 (0.33)  1.24 (0.32)  1.29 (0.35)  0.141 
LDL cholesterol in mmol/l  2.87 (0.93)  2.85 (0.92)  2.92 (0.98)  0.388 
Triglycerides  in mmol/l  2.32 (1.36)  2.39 (1.40)  2.03 (1.14)  0.002 
Microvascular disease (%)  54.1  50.2  70.9  <0.001 
  Retinopathy (%)  19.6  18.5  24.8  0.050 
  Microalbuminuria (%)  25.5  21.4  45.5  <0.001 
  Neuropathy (%)  29.1  26  40.6  <0.001 
Cardiovascular disease (%)    39.5  34.6  63.6  <0.001 
  Ischemic heart disease (%)  21.5  19.6  30.3  0.002 
  Cerebrovascular disease (%)  7.8  6.4  14.5  <0.001 
  Peripheral vascular disease (%)  23.0  18.1  47.3  <0.001 
RAS-inhibitors
b (%)  37.2  36.5  39.4  0.489 
  in patients with IHD (%)  42.1 38.7  50  0.159 
  in patients with PVD (%)  46.9 44.1  50  0.397 
Lipid-lowering drugs
c (%)  29.8  30.7  26.1  0.234 
  in patients with IHD (%)  57.4 61.9  44  0.026 
  in patients with PVD (%)  32.6 33.6  29.5  0.535 
Antiplatelet drugs (%)  24.9  22.1  38.2  <0.001 
  in patients with IHD (%)  67.5 68.4  64  0.565 
  in patients with PVD (%)  40.2 35.7  46.2  0.127 
Diabetes treatment – Diet only (%)  20.2  21.4  16.4   
                                  Oral medication  64.1  64.3  63   
                                  Insulin (%)  9.8  8.3  15.8   
                                  Both (%)  5.9  5.9  4.8   Chapter 6 
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Minimum follow-up duration of all survivors was 5.0 years. Ten persons of the losts to 
follow-up have had a last visit to the outpatient clinic between baseline and the end of 
follow-up; this last registered visit date was determined as the end of follow-up of 
these patients. The remaining 7 persons lost to follow-up had a mean age of 68 years, 
were non-smokers, and 2 patients had cardiovascular disease at baseline. Their median 
diabetes duration was 9.7 years with a mean HbA1c of 7.5 %.  
The proportion of prescribed lipid-lowering drugs, renin-angiotensin system (RAS) 
inhibitors and antiplatelet therapy at baseline, is shown at the end of Table 1. The 
percentages prescribed lipid-lowering drugs and antiplatelet drugs were significantly 
higher in patients with a history of IHD compared to the patients with PVD (p<0.001). 
At baseline, antiplatelet drugs were significantly more prescribed in the non-survivors 
compared to the survivors. By contrast, in patients with ischemic heart disease lipid 
lowering drugs were significantly less prescribed in the non-survivors compared to the 
survivors. 
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Figure 2. Kaplan-Meier survival curve for survival in years in the entire type 2 diabetes group 
(A) and Kaplan-Meier survival curve for survival expressed as Standardised Survival Time 
(SST) in the entire type 2 diabetes group (B). The median SST in type 2 diabetes mellitus 
(T2DM) 1.00 is not different from the general Dutch population 1.00 (Expected); the observed 
mortality (all-cause) at SST 0.25 and 0.50 of 0.09, respectively 0.20 does not significantly differ 
from the general Dutch population (0.08 respectively 0.18 , p>0.1). 
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The proportion of cardiovascular deaths,  47%, was increased when compared to the 
general Dutch population. In 2007, 31% of all deaths in the general Dutch population 
were due to cardiovascular disease, with a highest relative incidence of 38% 
cardiovascular deaths in the population above 85 years [18]. 
Figure 2A shows the Kaplan-Meier curve of the cumulative proportion of survivors in 
our type 2 diabetes population against survival time in years. A Kaplan-Meier plot of 
the cumulative proportion of deaths in our study population against standardised 
survival time is shown in Figure 2B; the expected mortality for the age- and gender-
matched general population is also shown. The median standardised survival time in 
our study population was 1.00 [95 % confidence interval (CI) 0.88 – 1.12] and did not 
differ from the general population. The cumulative proportion of deaths at half 
standardised survival time (SST = 0.50) was 0.20 (95 % CI 0.16 – 0.23), which did not 
differ from the expected value of 0.18 in the general population.  
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Figure 3. Cumulative proportions of deaths  against Standardised Survival Time (SST) in 
patients with (A) albuminuria (Alb) yes/no (+/-) and (B) previous cardiovascular disease (CVD) 
yes/no (+/-), compared to the expected deaths of the general population. Differences in mortality 
between the diabetes-subgroups and the general population are tested at SST= 0.25 and 
SST=0.5. For patients with albuminuria, mortality rate at SST 0.25 is 0.15 (95 % CI 0.10-0.19) 
and the expected value is 0.076 (p=0.002). At SST 0.50 mortality rate is 0.26 (95 % CI 0.19-
0.33), which was also higher than the expected value of 0.18 (p=0.014). For patients with a 
history of cardiovascular disease (CVD) mortality rate at SST 0.25 is 0.13 (95% CI 0.096-0.17) 
and an expected value is 0.076, p<0.001. At SST 0.50 mortality rate is 0.25 (95% CI 0.19-0.30) 
and the expected value is 0.18, p<0.0001. 
B AChapter 6 
140 
Figure 3A shows a mortality rate in the type 2 diabetes patients with albuminuria at 
SST 0.25 of 0.15 (95 % CI 0.10 – 0.19), which was higher than the expected value of 
0.076 (p=0.002). At SST 0.50 mortality rate was 0.26 (95 % CI 0.19 – 0.33), which 
was also higher than the expected value of 0.18 (p=0.014). This also holds for the type 
2 diabetes patients with a history of cardiovascular disease, who had a higher mortality 
at SST 0.25 [0.13 (95% CI 0.096 – 0.17), p<0.001] and SST 0.50 [0.25 (95% CI 0.19 – 
0.30), p<0.0001], Figure 3B. 
 
 
Table 2.  Predictors of overall mortality in type 2 diabetes mellitus by univariate and 
multivariate Cox  regression analysis using “survival in years” (= standard method) and using 
“standardised survival time”  
 
HR=hazard ratio; CI=confidence interval; NS=not significant. 
a The standardised survival time 
was calculated as the ratio between the observed survival time of an individual and the median 
residual life span of individuals with the same age in the general population. 
Survival in years  Standardised survival time
 a 
Univariate 
Predictors of all-cause mortality 
HR 95%  CI  p-value  HR 95%  CI  p-value 
Gender (man = reference) 
Age  
Smoking  
Systolic blood pressure 
Diabetes duration 
HbA1c 
Albuminuria (yes/no) 
History of cardiovascular disease (yes/no) 
Use of lipid-lowering drugs (yes/no) 
Use of antiplatelet drugs (yes/no) 
0.84 
1.08 
1.10 
1.01 
1.03 
1.02 
2.33 
2.95 
0.83 
2.00 
0.62 – 1.14 
1.06 – 1.10 
0.75 – 1.60 
1.00 – 1.02 
1.02 – 1.05 
0.91 – 1.15 
1.71 – 3.17 
2.15 – 4.06 
0.59 – 1.18 
1.46 – 2.74 
0.25 
<0.001 
0.63 
0.016 
0.001 
0.71 
<0.001 
<0.001 
0.30 
<0.001 
0.91 
1.00 
1.49 
1.00 
1.02 
1.08 
1.81 
1.87 
1.34 
1.47 
0.67 – 1.24 
0.98 – 1.02 
1.02 – 2.18 
0.99 – 1.01 
1.00 – 1.04 
0.95 – 1.22 
1.32 – 2.46 
1.35 – 2.58 
0.80 – 1.62 
1.07 – 2.01 
0.56 
0.90 
0.039 
0.66 
0.073 
0.23 
<0.001 
<0.001 
0.48 
0.018 
                                       Multivariate 
Gender (man = reference) 
Age 
Smoking (yes/no) 
Systolic bloodpressure 
Diabetes duration 
HbA1c 
Albuminuria (yes/no) 
History of cardiovascular disease (yes/no) 
Use of lipid-lowering drugs (yes/no) 
Use of antiplatelet drugs (yes/no) 
 
1.07 
 
 
 
 
1.79 
1.79 
 
 
1.05 – 1.09 
 
 
 
 
1.30 – 2.46 
1.29 – 2.50 
NS 
<0.001 
NS 
NS 
NS 
NS 
<0.001 
0.001 
NS 
NS 
x 
x 
 
 
 
 
1.72 
1.71 
x 
x 
 
 
 
 
1.26 – 2.35 
1.23 – 2.37 
x 
x 
NS 
NS 
NS 
NS 
0.001 
0.001 
NS 
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Table 2 shows the hazard ratios (HRs) and 95% CI of univariate and multivariate Cox-
regression analyses for all-cause mortality. The HRs in the univariate analyses are 
higher for all cardiovascular disease items compared to the method of using SST in the 
model. In the multivariate analysis, predictive factors for all-cause mortality were 
comparable for both methods when age and gender were included in the model of the 
standard method: a history of cardiovascular disease (HR 1.79 and 1.71) and, 
albuminuria (HR 1.79 and 1.72). Univariate analysis of the endpoint: cardiovascular 
mortality (not shown in Table 2) resulted in the same significant predictive factors, but 
with higher HRs. Multivariate analysis of cardiovascular mortality resulted in the same 
significant predictive factors with higher HRs (SST) as well: albuminuria 1.83 (95% CI 
1.17 – 2.89); history of cardiovascular disease 2.59 (95% CI 1.56 – 4.28). Smoking, 
systolic bloodpressure, diabetes duration and HbA1c were not significant in both 
multivariate models. 
 
 
DISCUSSION 
This study shows a normal median overall life expectancy in a cohort of type 2 
diabetes patients treated in a primary care setting, during a follow-up period from 2001 
until 2007. This finding implies that the current available treatment strategies are 
effective in supporting the opportunities for a life expectancy equal to the general 
population in this subset of type 2 diabetes patients. Secondly, in this type 2 diabetes 
study population, patients with a history of cardiovascular disease and/or the presence 
of albuminuria had an increased risk to die before their median life expectancy was 
reached. The differences in effects of all items of cardiovascular disease on ‘survival in 
years’ and SST, could be explained by the age correction enclosed in the SST – 
method. As the prevalence of cardiovascular diseases is increasing during aging, SST 
seems to be preferable to the ‘classical survival time’ in identifying premature 
mortality.  
Finally, we still found an increased proportion of deaths due to cardiovascular disease 
compared to the general population (47% versus 31%). This is in agreement with Chapter 6 
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established observations of increased cardiovascular disease in diabetes, and also with 
the presence of cardiovascular risk factors we found to be most intimately related to 
reduce life expectancy [13,19].  
The United Kingdom Prospective Diabetes Study reported a 5 years reduction of life 
expectancy for males aged 45 to 50 years at diagnosis of diabetes when compared to 
the general United Kingdom population [6]. Estimations of reduction of life 
expectancy for patients with diabetes diagnosed at an older age are not presented 
explicitly in this paper, but might be smaller than 5 years, as other studies showed that 
reduction of life expectancy decreases with diagnosis at older age [5,12,20].  
A large study of the noninstitutionalised United States population, which was 
conducted between 1971 and 1993, showed a median reduced life expectancy of 8 
years for the diabetic population aged 55-64 years, and a 4 years reduction for the 
diabetic population aged 65-74 years [4]. However, these studies were all executed in a 
period during which treatment with statins, angiotensin-converting enzyme inhibitors 
and antiplatelet medication was much less common practice. A more recent study, 
showing slightly increased mortality in women but no excess mortality in men, 
included exclusively patients diagnosed with type 2 diabetes mellitus over the age of 
65 [12]. Our study is of additional value, as we included primary care type 2 diabetes 
patients of all ages, representing a large amount of the type 2 diabetes patients in the 
Netherlands who are mostly treated in primary care according national guidelines. 
Sixty-four percent of our study population was diagnosed with type 2 diabetes mellitus 
before the age of 65 years.  
A previous study in the first ZODIAC-cohort (1998) reported an annual mortality rate 
of 4.8% between 1998 and 2000, which was higher than the mortality rate in the 
current study (~3%), whilst continuing the follow-up in this shared care environment 
[21]. This difference could be explained by the fact that the earlier analysis was 
performed in a more extended type 2 diabetes cohort, which also included patients who 
were referred to secondary care. It is also possible that the cohort as presented in this 
earlier study had to benefit yet from participation in a long-term shared-care 
environment with supportive care and monitoring of implementation of the guidelines.  Normal life expectancy in type 2 diabetes 
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More than half of our population received either a statin, RAS-inhibitor or aspirin at 
baseline. At follow-up, this proportion was increased to at least 80%. Widespread 
treatment of the traditional cardiovascular risk factors resulted in vastly improved 
blood pressure readings and lipid levels. This could also be the explanation for 
disappearance of systolic blood pressure from the model to predict mortality. Recent 
studies addressed the importance of statins and blood pressure lowering drugs in 
patients with type 2 diabetes mellitus, showing a reduction in cardiovascular events 
with these lipid-lowering drugs compared to placebo [22-24]. 
Remarkably, we observed a lower proportion of prescribed lipid-lowering drugs and 
antiplatelet drugs in the PVD patients of our total cohort, compared to those with IHD. 
This prescription behaviour was reported before [25]. In general, IHD has a more clear 
and urgent manifestation and is therefore diagnosed in an earlier phase. Patients with 
PVD are often asymptomatic and clinicians are less focused on screening and the 
treatment of PVD and its associated risk factors [26,27]. Furthermore, we observed a 
lower proportion of prescribed lipid-lowering drugs in patients with IHD who did not 
survive. This suggests the beneficial role of these drugs on mortality. The higher 
proportion of antiplatelet drug use at baseline in the non-surviving group and its risk on 
mortality in univariate analyses remained unexplained.  
HbA1c had also no effect on life expectancy in uni- and multivariate analysis. One 
might assume that this may be explained by the low number of patients with poor 
glycemic control (only 7% had a HbA1c >9%). Alternatively, other mechanisms could 
be involved in the development of diabetes related complications. Recently, we 
reported increased levels of advanced glycation endproducts (AGEs) in the same study 
group, which were related to chronic complications [14].  
Patients who were referred to the secondary care in the past, mainly for reasons of poor 
metabolic control or comorbidity, were not included in this study and could have a 
reduced life expectancy. Also, there will be a selection bias by excluding patients with 
a very short life expectancy (terminally ill patients, cognitive disabled people and 
patients who are unable to undergo educational programs), as described in the methods 
section. Still, 40% of the included study population suffered from cardiovascular Chapter 6 
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disease at baseline. Despite the apparent selection bias, we did have a large subset of 
patients with a life expectancy comparable to that of the general population of the same 
age and sex. Furthermore, in The Netherlands, the large majority (70 – 80%) of type 2 
diabetes patients is treated in primary care or a shared-care setting. Therefore, this 
study population could be representative for the majority of type 2 diabetes patients in 
The Netherlands, and probably also for a larger part of type 2 diabetes patients in other 
countries with structured diabetes care.  
Our choice to compare life expectancy of this type 2 diabetes cohort to the general 
population could be criticised, because the general population also includes people 
with diabetes, cardiovascular disease, cancer, and other life shortening diseases. We 
nevertheless preferred to choose the general population instead of a non-diabetic 
control group, because one of the aims of caregivers within the medical community is 
to regain a life expectancy for their patients equal to the general population when life 
expectancy is reduced due to a specific disease.  
To visualise whether a life expectancy equal to the general population had been 
achieved, we used SST. Traditional survival analysis focuses more on ‘mortality’ 
within a certain follow-up time, but with this method it is not clear whether it is 
‘normal mortality’ or ‘excess mortality’. Using SST, the mortality rate is adjusted for 
the median survival of subjects in the general population of the same age and sex. 
Excess mortality or a reduced life expectancy will be identified more easily in that 
way. 
The results of this study are relevant for clinical practice, because they offer a hopeful 
perspective of a definitely improved life expectancy in type 2 diabetes patients. We 
suggest that those results are also (partly) due to the fact that these patients were and 
are participating in a care system promoting adherence to evidence-based guidelines 
and strong lines of cooperation between health care providers focusing on this patient 
group. Our study once more confirms the implications of the presence of 
cardiovascular disease and the diagnosis of albuminuria on mortality risk in type 2 
diabetes mellitus.  Normal life expectancy in type 2 diabetes 
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In summary, this study shows a normal life expectancy in a large subset of type 2 
diabetes patients treated in a primary care setting. The presence of previous 
cardiovascular disease and albuminuria, however, can markedly reduce life expectancy. 
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ABSTRACT 
Introduction Skin autofluorescence (AF) is a noninvasive measure of the level of tissue 
accumulation of advanced glycation endproducts, representing cumulative glycemic 
and oxidative stress. Recent studies have already shown a relationship between skin AF 
and diabetic complications, and its predictive value for total and cardiovascular 
mortality in type 2 diabetes mellitus. Our aim was to investigate the predictive value of 
skin AF for the development of microvascular complications in type 2 diabetes 
mellitus.  
Methods At baseline, skin AF of 973 well-controlled type 2 diabetes patients was 
noninvasively measured with an AF reader. The aggregate clinical outcome was 
defined as the development of any diabetes associated microvascular complication of 
881 surviving patients which was assessed at baseline and at the end of follow-up. 
Single endpoints were the development of diabetes associated retinopathy, neuropathy 
and (micro)albuminuria. 
Results After a mean  follow-up period of 3.1 years, baseline skin AF was significantly 
higher in patients who developed any microvascular complication, neuropathy and 
(micro)albuminuria, but not in those who developed retinopathy. Multivariate analyses 
showed skin AF as a predictor for the development of any microvascular complication 
along with HbA1c; for the development of neuropathy along with smoking, and for the 
development of (micro)albuminuria together with gender, HbA1c and diabetes 
duration. Skin AF did not have predictive value for the development of retinopathy, 
albeit diabetes duration did.  
Conclusion Our study is the first observation of skin AF measurement as an 
independent predictor for the development of microvascular complications in type 2 
diabetes mellitus. 
 
 
INTRODUCTION 
Hyperglycaemia, individual susceptibility and life-style are three key factors, which 
play an important role in the development of microvascular disease in diabetes Skin autofluorescence in microvascular complications 
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mellitus. One of the consequences of hyperglycaemia and attendantly increased 
generation of free radicals is the increased formation of advanced glycation 
endproducts (AGEs), besides the increased polyol and hexosamine fluxes, and 
activation of protein kinase C, which all contribute to tissue damage in diabetes [1,2]. 
Those AGEs can be described as the final products of slowly occurring non-enzymatic 
glycation of proteins that form cross-links with long-lived proteins such as collagen 
(the so called Maillard reaction). They may also accumulate as a result of oxidative 
stress related glycoxidation and lipoxidation pathways.  
In the DCCT, intensive treatment as compared with conventional treatment showed 
that long term intensive treatment of hyperglycaemia in type 1 diabetic patients 
improved glycemic control, and delayed the progression of microvascular 
complications [3]. The UKPDS and other prospective studies have also shown an 
association between hyperglycaemia and increased risk of microvascular complications 
in type 2 diabetes [4-6]. The DCCT skin collagen ancillary study group showed the 
association of long-term intensive treatment of hyperglycaemia, as compared with 
conventional treatment, with lower levels of AGEs in skin collagen and they showed 
that these AGE levels in skin biopsies predicted the risk of development or progression 
of microvascular disease in type 1 diabetes mellitus, even after adjustment for HbA1c 
[7,8].  
A newly described noninvasive method to assess tissue AGEs concerns skin 
autofluorescence (AF). This method is based on the specific fluorescence 
characteristics of AGEs and has been validated against specific AGE levels in skin 
biopsies in patients with diabetes or on hemodialysis, and in healthy controls [9,10]. 
Recently, the relationship between skin AF, reflecting AGE accumulation, and 
outcome has been studied in type 2 diabetes. Besides its relation with chronic 
complications of diabetes (in cross-sectional analyses), skin AF has also shown its 
independent predictive value for cardiovascular mortality and morbidity in patients 
with type 2 diabetes, and in patients with end-stage renal disease undergoing 
hemodialysis [10-12]. Chapter 7 
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In this study, we analyzed whether skin AF, as a marker of AGE accumulation, can 
predict the development of microvascular complications in a type 2 diabetes 
population. 
 
 
METHODS 
Patients. Between May 2001 and May 2002, 973 primary care type 2 diabetes patients 
were included in the study cohort and had a skin AF measurement. The included 
patients were all participating in a shared-care project of the Zwolle Outpatient 
Diabetes project Integrating Available Care (ZODIAC)-study and have also been 
described elsewhere [11]. During follow-up, data of 967 patients were analyzed for this 
study (6 patients were lost to follow-up). Eighty-six patients died before the end of 
follow-up and this subgroup will be addressed separately from the surviving 881 
patients. Patients with a Fitzpatrick class V-VI skin type were excluded, because of the 
limitation of the autofluorescence reader (AFR) to measure accurately in dark skin 
types [13-15]. All participating patients visited the outpatient clinic at least once a year. 
Follow-up ended at January 2005. All of the included patients had given their informed 
consent, and approval by the local ethical committee had been obtained.  
Skin autofluorescence. The AFR (prototype of the current AGE Reader; DiagnOptics 
BV, Groningen, the Netherlands), which measures skin AF, illuminates a skin surface 
of ~4 cm
2, guarded against surrounding light, with an excitation light source with peak 
intensity at ~370 nm. Emission light and reflected excitation light from the skin are 
measured with a spectrometer in the 300-600 nm range, using a glass fiber. AF was 
computed by dividing the average light intensity of the emission spectrum 420-600 nm 
by the average light intensity of the excitation spectrum 300-420 nm, multiplied by 
hundred and expressed in arbitrary units (a.u.). Skin AF of all patients was assessed at 
the volar side of the arm, 10 cm below the elbow fold. Six diabetes specialist nurses 
did the AF measurements with 2 identical AFR devices. The AFR has been validated 
and more extensively been described in previous studies [9,11]. Skin autofluorescence in microvascular complications 
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Data collection. Clinical data and laboratory results were obtained at the time of the 
baseline skin AF measurement. Serum creatinine, nonfasting lipids (total cholesterol, 
LDL cholesterol, HDL cholesterol, triglycerides), and urinary albumin and creatinine 
were measured according to the standard laboratory procedures. HbA1c was measured 
with a Primus CLC-385 using boronate affinity chromatography and high-performance 
liquid chromatography (reference value 4.0 – 6.0%). Blood pressure measurement was 
a single measurement obtained after 5 minutes rest, with the patient in seated position, 
and using an aneroid device. At each visit to the outpatient clinic, and at the end of 
follow-up, the absence or presence of retinopathy, neuropathy and (micro)albuminuria 
were assessed. 
Clinical endpoints. The aggregate clinical endpoint was the development of any 
diabetes associated microvascular complication, which was defined as the presence of 
at least one of the following diabetic complications: retinopathy, neuropathy and/or 
(micro)albuminuria, according the ADA Diabetes definitions [16]. The single clinical 
endpoints were described as the development of retinopathy, neuropathy or 
(micro)albuminuria. Retinopathy was determined by an ophthalmologist based on 
retinal photography. Presence of at least background retinopathy was assumed to imply 
retinopathy. Neuropathy was examined using a 5.07/10-g Semmes-Weinstein 
monofilament, applied on the dorsum of both feet at three different, non-callused areas 
(first toe, and first and fifth distal metatarsal bone). Neuropathy was considered in case 
of diminished sensibility, which was defined in case of at least two incorrect responses 
after 3 applications at each area (2 real and 1 false application) [17,18]. 
(Micro)albuminuria at baseline was defined as an albumin-to-creatinine ratio >2.5 
mg/mmol for men and >3.5 mg/mmol for women in 2 subsequent urine samples or 
once in the year before baseline while using an ACE-inhibitor at baseline [19]. Newly 
developed (micro)albuminuria at follow-up was defined as an albumin-to-creatinine 
ratio >2.5 mg/mmol for men and >3.5 mg/mmol for women in 2 urine samples (one in 
the year before and one at the moment during follow-up) or an abnormal level of the 
albumin-to-creatinine ratio in the year before the end of follow-up whilst using an 
ACE-inhibitor at follow-up.  Chapter 7 
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Statistical analysis 
Oneway ANOVA using posthoc multiple comparisons (with Bonferroni correction) 
was used to compare mean skin AF between subgroups of microvascular complications 
in the 881 surviving patients. Subgroups are: A. no microvascular complication at 
baseline nor at follow-up. B. no microvascular complication at baseline, but a 
microvascular complication at follow-up. C. a microvascular complication at baseline 
and at follow-up. 
Univariate and multivariate multinominal regression analyses were performed to 
determine the relationship of skin AF to the presence or development of microvascular 
disease. Patients without signs of microvascular complications at baseline nor at follow 
up were the reference categories in these calculations. In the multivariate analyses we 
controlled for potential confounding risk factors for the development of microvascular 
complications which were derived from the UKPDS findings, thereby including: 
gender, diabetes duration, HbA1c, current smoking, systolic blood pressure, HDL 
cholesterol, LDL cholesterol and triglycerides with the addition of BMI [4].  
Odds-ratios (OR) and confidence intervals (95%) for skin AF were calculated in the 
univariate and in the multivariate analyses; p-values <0.05 were considered to be 
statistically significant. 
 
 
RESULTS 
The baseline characteristics of the surviving study population including mean skin AF 
of the total group are shown in Table 1. Mean age of our study population was 66 
years, 46% male, with a relatively short median diabetes duration of 4.0 years and an 
interquartile range between 1.5 and 8.1 years. Eighty-five percent of this well-
controlled diabetic study population was on a diet and/or oral agents; the other 15% of 
patients received insulin or combined insulin/oral agent treatment. In the 881 survivors, 
the prevalence of retinopathy, neuropathy and (micro)albuminuria at baseline was 19%, 
24% and 24% respectively, resulting in an overall percentage of patients with a 
diabetes associated microvascular complication of 50%.  Skin autofluorescence in microvascular complications 
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Table 1. Characteristics of the type 2 diabetic patients 
Characteristic n=881 
Age in years  66 (11) 
Gender (M/F)  406/475 
Smoking (%)  19 
BMI (kg/m²)  29.4 (4.8) 
Systolic blood pressure (mmHg)  146 (20) 
Diabetes duration (years)  4.0 (1.5-8.1)* 
HbA1c (%)  6.6 (6.0-7.6)* 
Creatinine (µmol/l)  95 (19) 
Creatinine clearance (Cockcroft-formula) (ml/min)  77 (27) 
Urinary albumin-to-creatinine ratio  1.41 (0.76-3.79)* 
Total cholesterol (mmol/l)  5.2 (1.0) 
HDL cholesterol (mmol/l)  1.3 (0.3) 
LDL cholesterol (mmol/l)  2.9 (0.9) 
Triglycerides (mmol/l)  2.1 (1.4-2.9)* 
Microvascular disease (%) 
Retinopathy (%) 
Neuropathy (%) 
             (Micro)albuminuria (%) 
50 
19 
24 
24 
Macrovascular disease (%)  37 
Skin autofluorescence (total group) (a.u.)  2.74 (0.7) 
Values are expressed as mean (SD). *Median and Interquartile range. 
 
 
Table 2 shows the mean baseline skin AF of the 881 survivors subdivided in groups 
with continued absence or presence or the development of microvascular complications 
at follow-up. During a median follow-up period of 3.1 years, 61 patients (7.0%) 
developed retinopathy; their baseline skin AF did not differ from skin AF levels of 
patients who did not show or already had retinopathy at baseline. However, skin AF 
was higher in the patient groups who developed neuropathy or (micro)albuminuria 
compared to those without these complications. At follow-up newly developed 
neuropathy was diagnosed in 7.5% and newly developed (micro)albuminuria was 
found in 10.1%; 12.5% of the population developed at least one microvascular 
complication. Skin AF at baseline was also significantly higher in the patient groups 
who developed any microvascular complication or who already had a microvascular 
complication at baseline, compared to those patients who did not develop any 
microvascular disease at all.  Chapter 7 
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Table 2. Mean skin AF (SD) at baseline and mean differences between groups  
Data are means (SD) of skin AF in arbitrary units within the group, and mean differences (∆AF) 
between groups calculated with ANOVA (95% Confidence interval) with Bonferroni correction;  t0, 
baseline; tfu, follow-up 
 
Multinominal logistic regression analysis showed that skin AF was a strong predictor 
of the development of the aggregate of microvascular complications (OR 2.05 [1.51-
2.80], p<0.001. Skin AF was significantly associated with the development of 
retinopathy (OR 1.42 [1.01-1.99], p=0.042), neuropathy (OR 1.59 [1.15-2.19], 
p=0.005), and (micro)albuminuria (OR 1.73 [1.28-2.34], p<0.001). After correction for 
the confounding risk factors, baseline skin AF still appeared to be significantly 
associated with the development of these endpoints, except for retinopathy  (OR 1.21 
[0.83-1.74], p=0.32), Table 3. Diabetes duration at baseline was the only significant 
independent variable for the development of retinopathy in this multivariate analysis 
(OR 1.10 [1.06-1.15], p<0.001). Surviving smokers developed less often neuropathy 
compared to non-smokers. In the non-surviving group (86 patients) 70% had a 
microvascular complication at baseline; there were 23 non-surviving smokers. Seventy 
percent of the non-surviving smokers already had a microvascular complication at 
         
                        
Microvascular               
complication 
 
A= 
 
t0  : absent  
tfu: absent 
B= 
 
t0  : absent   
tfu: present 
C= 
 
t0  : present  
tfu : present 
  B vs. A  C vs. A  C vs. B 
Retinopathy 
AF 
n 
 
2.69 (0.73)
647
2.88 (0.74)
61
2.91 (0.72)
169
∆AF
95% CI
p
 
0.20 
-0.04-0.43 
0.14 
 
0.22 
0.07-0.37 
0.002 
 
0.02 
-0.24-0.29 
1.00 
Neuropathy 
AF 
n 
 
2.67 (0.72)
596
2.93 (0.75)
66
2.88 (0.75)
215
∆AF
95% CI
p
 
0.26 
0.03-0.49 
0.019 
 
0.21 
0.07-0.35 
0.001 
 
-0.05 
-0.29-0.20 
1.00 
(Micro)albuminuria 
AF 
n 
 
2.62 (0.68)
570
2.91 (0.67)
87
2.97 (0.83)
207
∆AF
95% CI
p
 
0.28 
0.09-0.48 
0.002 
 
0.34 
0.20-0.48 
<0.001 
 
0.06 
-0.16-0.28 
1.00 
Any 
AF 
n 
 
2.52 (0.69)
322
2.86 (0.66)
109
2.88 (0.75)
441
∆AF
95% CI
p
 
0.34 
0.15-0.53 
<0.001 
 
0.36 
0.23-0.48 
<0.001 
 
0.01 
-0.17-0.20 
1.00 Skin autofluorescence in microvascular complications 
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baseline and 13% of the non-surviving smokers developed a microvascular 
complication before they died. 
When baseline skin AF levels are categorized in subgroups of practically feasible 
levels of skin AF (3 categories in rounded tertiles: skin AF < 2.35 a.u.;  2.35 ≤ skin AF 
< 3.00 a.u.; skin AF ≥ 3.00 a.u.), patients in the category skin AF ≥3.00 a.u do have a 
higher chance to develop a microvascular complication compared to patients with a 
lower skin AF level (Table 4). 
 
Table 3. Variables related to the development of microvascular complications in type 2 diabetes 
mellitus by multinominal logistic regression analysis 
Any microvascular 
complication 
Retinopathy Neuropathy  (Micro)albuminuria  
 
 
Variables 
p 
value 
OR 
(95%CI) 
p 
value 
OR 
(95% CI) 
p  
value 
OR 
95% CI 
p 
value 
OR 
95% CI 
Skin AF  <0.001  2.02 
(1.45-2.81) 
0.32 1.21 
(0.83-1.74) 
0.026 1.50 
(1.05-2.14) 
<0.001 1.88 
(1.36-2.61) 
Gender 0.02  0.55 
(0.33-0.90) 
0.91 0.97 
(0.53-1.75) 
0.78 1.09 
(0.61-1.93) 
0.001 0.42 
(0.25-0.71) 
HbA1c 0.004  1.30 
(1.09-1.55) 
0.13 1.18 
(0.95-1.45) 
0.87 1.02 
(0.82-1.26) 
0.034 1.21 
(1.01-1.44) 
Diabetes 
duration 
0.66 1.01 
(0.96-1.06) 
<0.001 1.10 
(1.06-1.15) 
0.032 1.04 
(1.00-1.08) 
0.04 0.95 
(0.90-0.997) 
Smoking 0.07  0.56 
(0.29-1.05) 
0.09 0.48 
(0.21-1.11) 
0.011 0.29 
(0.11-0.75) 
0.96 1.02 
(0.56-1.85) 
Systolic BP  0.43  1.01 
(0.99-1.02) 
0.39 1.01 
(0.99-1.02) 
0.49 1.01 
(0.99-1.02) 
0.18 1.01 
(0.996-1.02) 
LDL cholesterol  0.48  1.09 
(0.85-1.40) 
0.66 0.93 
(0.69-1.27) 
0.35 0.87 
(0.64-1.17) 
0.30 1.15 
(0.89-1.49) 
HDL cholesterol  0.26  0.62 
(0.27-1.43) 
0.36 0.63 
(0.23-1.70) 
0.081 0.41 
(0.15-1.12) 
0.40 0.38 
(0.15-0.96) 
Triglycerides 0.54 0.94 
(0.78-1.14) 
0.41 0.91 
(0.72-1.15) 
0.85 0.98 
(0.79-1.22) 
0.19 0.87 
(0.71-1.07) 
BMI 0.27  1.03 
(0.98-1.08) 
0.33 1.03 
(0.97-1.09) 
0.56 0.98 
(0.93-1.04) 
0.39 1.02 
(0.97-1.08) 
 
Table 4. Newly developed microvascular complications subdivided in 3 skin AF-groups 
n 
Microvascular 
complication  Skin AF <2.35 a.u.  2.35 ≤ Skin AF < 3.00 a.u.  Skin AF ≥ 3.00 a.u 
708  Retinopathy  15/241 (6.2)  18/251 (7.2)  28/216 (13.0) 
662  Neuropathy  11/219 (5.0)  27/247 (10.9)  28/196 (14.3) 
65  (Micro)albuminuria  18/225 (8.0)  31/253 (12.3)  38/179 (21.2) 
431  Any  23/161 (14.3)  41/167 (24.6)  45/103 (43.7) 
Number (%) of newly developed microvascular complications of subgroups; n is number of patients 
who did not have the complication at baseline  Chapter 7 
158 
DISCUSSION 
Our study provides the first evidence that skin AF is an independent predictor of the 
development of microvascular complications in a well-controlled type 2 diabetes 
population. Separately, this also holds for the development of neuropathy and 
(micro)albuminuria (and in univariate analysis for retinopathy). This noninvasive 
marker of tissue AGE accumulation may reflect the deleterious effects of long-term 
glycemic and oxidative stress. It was recently shown that skin AF is a predictor of 5-
year coronary heart disease and mortality in diabetes [12]. The present study showed 
that skin AF also has a predictive value for the development of microvascular 
complications, which in the analysis of this study is superior to that of many other 
commonly used risk predictors like diabetes duration and HbA1c in type 2 diabetes. 
This conclusion is applicable for primary care type 2 diabetes patients, treated 
according to current standards, which is the large majority of type 2 diabetes patients in 
the Netherlands. 
The DCCT/EDIC substudy already showed the predictive value for skin AGE levels 
obtained from skin biopsies for the progression of microvascular complications in 
patients with type 1 diabetes [8]. Our study population consisted of type 2 diabetes 
patients, with skin AGE level assessment by means of a noninvasive, rapid method. 
Another difference is that the DCCT-substudy investigated the development as well as 
the progression of microvascular complications. The limited follow-up period, the low 
rate of clearly classifiable progression of the microvascular complications, especially 
retinopathy, and the confounding role of introduced medication made us decide to 
restrict our study to the evaluation of the development of microvascular complications 
and not to address progression of these diabetic complications. 
In retinopathy, skin AF turned out to have no prognostic value in the multivariate 
analysis. Possible explanations are the short follow-up period and the smaller amount 
of patients who developed retinopathy compared to the development of the other 
complications. Moreover the different pathophysiologic mechanisms of microvascular 
damage in the different organs (retina, kidneys and neurons) could play a role in the 
differences in incidence rates of outcomes. In particular, the pathobiology of Skin autofluorescence in microvascular complications 
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retinopathy might be different from those in the kidney and neurologic system due to a 
different role of vascular endothelial growth factor (VEGF) as a possible mediator for 
proliferation [20]. 
(Micro)albuminuria is an early clinical sign of diabetic nephropathy; when left 
untreated it predicts a high risk for the development of progressive renal damage which 
will eventually may lead to end stage renal disease. Progressive renal disease is also 
associated with a vastly increased cardiovascular risk. This study defined 
(micro)albuminuria as a sign of microvascular complication with the intention to 
reflect early stages of diabetic nephropathy.  
In the predictive analyses the non-surviving patients were excluded from the analyses. 
These non-survivors had markedly increased skin AF values, but they also had a very 
high prevalence of microvascular complications at baseline (70%), so this does not 
reduce the strength of the relation between skin AF and microvascular complications at 
all.  
Ethnicity is one of the mentioned UKPDS confounding risk factors for the 
development of microvascular disease. Because of the limitation of measuring skin AF 
in dark skin types, with the prototype of the AGE reader used in the present study, 
people with dark skin had to be excluded. Over 95% of the participants were 
Caucasian, therefore ethnicity was not taken into account in the analyses. Further 
developments of the AGE reader may hopefully enable measurements in dark skin type 
in future investigations. 
Lutgers et al. previously described the other limitations of the AFR as a marker of 
tissue AGE accumulation: non-fluorescent AGEs will not be measured with the AFR, 
and other tissue components which fluoresce in the same range of wavelength might be 
confounders [11]. 
In conclusion, our study confirms skin autofluorescence as a helpful clinical method to 
identify type 2 diabetes patients who are at risk for (developing) any microvascular 
complication, neuropathy and (micro)albuminuria. Further investigation with longer 
follow-up needs to be done to assess whether or not skin autofluorescence is a factor in 
the development of diabetic retinopathy, and to assess the relationship of skin AF and Chapter 7 
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the progression of microvascular complications. Its non-invasive and time-saving 
application makes the AFR an easy clinical tool useful in the out-patient clinic in the 
risk assessment as well as for monitoring changes in accumulation of tissue AGEs 
reflecting long term glycemic stress. 
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Summary 
Advanced glycation endproducts (AGEs) are a heterogeneous group of 
compounds formed by glycation and oxidation of proteins. AGEs accumulate on long-
lived proteins like collagen. This results in increased cross-linking and causes changes 
of structure and function of the proteins with consequently damaging effects on tissue. 
Besides, AGEs bind to receptors, especially the receptor for advanced glycation 
endproducts (RAGE) [1]. This AGE-RAGE complex induces intracellular transduction 
mechanisms and cellular activation which can also result in tissue damage. Because of 
the stability of AGEs, they accumulate slowly over a person's lifespan. AGE 
accumulation is accelerated in conditions with increased supply of substrates (carbonyl 
stress), increased oxidative stress, decreased clearance of AGE moieties, or a 
combination. Diabetes mellitus, rheumatic diseases and renal failure are examples of 
diseases with accelerated AGE accumulation. The altered structure and function of 
proteins by crosslinked AGEs play a pathogenetic role in the complications of these 
diseases. 
In diabetes mellitus, AGE accumulation in skin collagen is related both with 
cumulative glycemic and oxidative stress, and with the presence of long-term 
complications [2,3]. Tissue AGE assessments previously required invasive sampling. 
AGEs linked to collagen have a characteristic fluorescence spectrum at 440 nm upon 
excitation at 370 nm. Classically, this ‘Collagen Linked Fluorescence’ (CLF) has been 
used to quantify tissue AGE accumulation in extracts from homogenates of skin 
biopsies [2]. More recently developed biochemical and immunochemical assays 
measuring fluorescent en non-fluorescent AGEs can be applied to skin or blood 
samples [4]. These techniques are unfortunately time-consuming and expensive. A 
further concern of serum or plasma AGE assays is that they have poor relation with 
tissue contents of AGEs and initially low reproducibility. 
Skin autofluorescence (AF) represents the fluorescence of skin tissue 
fluorophores which was earlier serendipitously discovered to be increased in patients 
with diabetes [5]. Combining that observation with the existing literature about 
fluorescence of specific AGEs and CLF, it was recognized as a potential non-invasive Summary and discussion 
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measure for tissue AGE-accumulation. Considering this, since 1996 the 
Autofluorescence Reader (AFR) was developed to provide a marker representative for 
tissue AGE-accumulation to be easily applicable in a clinical setting for predicting 
diabetes related complications. 
The validation study of the AFR showed good relations between skin 
autofluorescence and fluorescent and non-fluorescent AGEs in skin-biopsies, and also 
good reproducibility [6]. In a later study, it was shown that skin AF appeared to be a 
predictor for cardiovascular complications in diabetes patients [7]. The study 
population was, however, a small, mixed group of type 1 and type 2 diabetes patients. 
In the present thesis, we studied prospectively in a large type 2 diabetes 
population (~1000), whether skin AF is a risk indicator for chronic diabetes 
complications and cardiovascular morbidity and mortality. We furthermore evaluated 
in different groups of diabetes patients (type 1, type 2, both with and without 
complications), whether the excitation spectrum of the AFR needed to be further 
optimized to detect possible differences in fluorescence characteristics in these 
different populations. 
Chapter 1 shortly outlines background information about the skin and its 
biochemical composition, the development of the Autofluorescence Reader (AFR), and 
the calculation of skin AF. Since skin pigmentation may influence autofluorescence by 
light absorption, skin AF was calculated by dividing the average emitted light intensity 
per nanometer in the range 420–600 nm by the average excitated light intensity per 
nanometer in the range 300–420 nm.  
Chapter 2 demonstrates the validity of a broad excitation wavelength range, 
such as applied in the AFR. In this chapter, an adapted version of the AFR was used: a 
monochromator, allowing to study the effects of small wavelength ranges of the 
excitation light, was connected to a measuring component that was similar to the AFR. 
With this instrument, excitation-emission maps were obtained in vivo from the skin of 
selected groups of type 1 and type 2 diabetes patients with and without complications, 
and in healthy controls. Consistent with our expectations, AF was increased in both 
type 1 and type 2 diabetes patients with complications compared to the diabetes Chapter 8 
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patients without complications. We found however no specific excitation wavelengths 
in the range 355 - 405 nm that would yield an increased distinction between diabetes 
patients with or without chronic complications. 
We furthermore evaluated whether specific excitation wavelengths could induce 
different fluorescence peaks corresponding with different fluorophores/AGEs. We 
hypothesized a possible difference of excitation-emission maps in type 1 and type 2 
diabetes, as these diseases with a different metabolic condition might generate different 
AGEs. We did not find however differences between these groups that depend on 
excitation wavelength and concluded that the involved fluorophores do not necessitate 
the use of a specific excitation wavelength between 355 and 405 nm.  
Different mechanisms of AGE formation that have been described over the last 
decades were summarised in Chapter 3. Besides the classical view involving the 
Maillard reaction, the role of oxidative and carbonyl stress, as well as overproduction 
of superoxide by the electron transport chain in mitochondria in endogenous AGE 
formation are demonstrated. These different pathways of AGE formation imply 
multiple substrates for AGE formation. This emphasises that accelerated AGE 
formation is not unique for diabetes/hyperglycaemia, but that AGE accumulation can 
occur in many more conditions characterised by increased supply of substrates and 
oxidative stress, for example in rheumatic diseases, ischemic heart disease, and renal 
dysfunction. This also suggests that in a metabolic disease like type 2 diabetes with 
concurrent problems like dyslipidemia and nephropathy, AGE accumulation could be 
an accurate measure of cumulative metabolic stress and is, therefore, supposed to be 
related to chronic complications of diabetes. Previous studies in fact showed this 
relation [8-11]. 
The developments of the different strategies in reducing AGE accumulation 
were also reviewed in this chapter, e.g. AGE formation inhibitors (aminoguanidine, 
pyridoxamine, benfotiamine and ACE-inhibitors) and AGE breakers (ALT-711). ALT-
711 and benfotiamine are currently being investigated in phase II studies. A novel 
AGE-breaker, C36, also a thiazolium-based AGE-breaker like ALT-711, claims less 
mutagenesis. In diabetic rats, C36 was demonstrated an effective AGE-breaker by Summary and discussion 
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showing beneficial effects on the cardiovascular system [12]. Unfortunately, since the 
first studies on aminoguanidine in the late 1980s, the development of specific AGE-
inhibitors or AGE-breakers did not result in clinically available drugs yet.  
 
The role of AF in diabetes and its relation to clinically used variables including 
the presence of diabetes complications in a cross-sectional study was described in 
Chapter 4. This study involves an analysis of the baseline data of the Zwolle type 2 
diabetes study cohort, as well as a non-diabetic control group. Skin autofluorescence 
was significantly higher in type 2 diabetic patients compared with control subjects in 
each age category, which was in agreement with the results of Meerwaldt et al [6]. 
Multiple regression analysis showed significant correlation of skin autofluorescence 
with age, sex, diabetes duration, BMI, smoking, HbA1c, plasma creatinine, HDL 
cholesterol, and albumin-to-creatinine ratio. HbA1c had a small independent 
contribution to autofluorescence. Skin autofluorescence was associated with a graded 
increase in the presence and severity of diabetes-related complications. 
In Chapter 5 we studied in a follow-up study whether skin autofluorescence has 
an additional value to the UKPDS risk engine. The UKPDS is a landmark randomized 
controlled trial conducted in the ~1990s in individuals newly diagnosed with type 2 
diabetes. It showed that both intensive treatment of blood glucose and blood pressure 
in diabetes can lower the incidence of diabetes-related complications [13,14]. A 
prediction model for fatal and non-fatal cardiovascular disease was extracted from 
these data, resulting in the UKPDS risk engine [15]. They showed that the addition of 
HbA1c to traditional risk factors improved risk prediction in T2DM-patients. Although 
this risk engine is the first calculator including HbA1c and consists of 10 different 
items, it still has a limited positive and negative predicted value for CV-events in 
T2DM [16]. In this chapter we studied whether skin autofluorescence has an additional 
value to this UKPDS risk engine. In a multivariate Cox regression analysis with all 
items of the UKPDS risk engine, skin autofluorescence was a significant predictor of 
fatal and non-fatal CV-events, together with age, diabetes duration and gender. A 
second multivariate analysis including a history of microvascular complications, Chapter 8 
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macrovascular complications, a UKPDS risk score >10% and skin autofluorescence, all 
were significant predictors for non-fatal CV-events and mortality except a history of 
microvascular complications. Furthermore, when a skin AF cut-off value at the median 
is used for risk reclassification of patients with a UKPDS risk score of <10%, 
cardiovascular risk of 55 of the 203 of the patients (~25%) would be reclassified from 
low risk to high risk. Finally, skin AF was able to identify a patient group with a more 
increased event rate within the group of patients with a high risk for fatal 
cardiovascular event of more than 10%  within the next 10 years. These findings could 
have treatment consequences with intensifying all aspects of individual diabetes 
management aiming for reduction of the development or progression of complications. 
The effects of improvements in diabetes care, since the results of the UKPDS 
were published at the end of the 1990s, has become obvious in a major improvement of 
life expectancy, as shown in Chapter 6. Until recently, most diabetes papers started in 
their introduction with the statement cardiovascular morbidity and mortality is 
increased in people with diabetes. Since 2006, the first papers reported the reduction of 
mortality-rate in diabetes. In a five-year follow-up study of our type 2 diabetes cohort, 
we found an equal life expectancy of the T2DM subjects compared to the general 
Dutch population. In this analysis, a history of cardiovascular disease and albuminuria 
were significant risk factors for early mortality (death before end of life expectancy 
was accomplished). 
Previous chapters have shown the relationship between skin AF and 
macrovascular complications, as well as its predictive value for total and 
cardiovascular mortality in type 2 diabetes mellitus. In Chapter 7 we investigated the 
predictive value of skin AF for the development of microvascular complications in the 
Zwolle type 2 diabetes study cohort. The Diabetes Control and Complications Trial 
(DCCT), the landmark study in type 1 diabetes published in 1993, showed that 
intensive treatment delays the onset and slows the progression of microvascular 
complications compared to conventional diabetes therapy [17]. A substudy of the 
DCCT, conducted by the DCCT skin collagen ancillary study group, evaluated the 
effects of long term intensive glycemic control on indicators of skin collagen glycation Summary and discussion 
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(furosine), glycoxidation and AGE-formation (pentosidine and carboxymethyllysine 
[CML]), and crosslinking (acid and pepsin solubility). They showed lower levels of 
AGEs in skin collagen in the intensive treatment group compared to the conventional 
treatment group [10]. It was also shown that skin AGE levels predicted the risk of 
development or progression of microvascular disease in type 1 diabetes mellitus, even 
after adjustment for HbA1c [10,11]. In our study in type 2 diabetes, skin AF at baseline 
was significantly higher in patients who developed any microvascular complication, or 
neuropathy or (micro)albuminuria alone, after a mean  follow-up period of  ~3 years. 
Multivariate analyses showed that skin AF remained as a predictor for the development 
of any microvascular complication along with HbA1c; for the development of 
neuropathy along with smoking, and for the development of (micro)albuminuria 
together with gender, HbA1c and diabetes duration. Skin AF did not have predictive 
value for the development of retinopathy separately. 
 
Discussion, future perspectives and conclusion 
It is concluded that skin autofluorescence represents cumulative metabolic stress 
and is therefore successful in predicting complications in type 2 diabetes mellitus. This 
was shown in this thesis for microvascular, macrovascular complications and for 
mortality. Moreover, skin AF was demonstrated to be superior to HbA1c and other 
conventional risk factors (like smoking, blood pressure and blood lipids). It 
furthermore provides clinically relevant additional information to the UKPDS risk 
engine in the prediction of cardiovascular events and mortality. Finally, we concluded 
that there was no difference in fluorescence spectra using the broad excitation spectrum 
of the Autofluorescence Reader/AGE-Reader or a variable specific excitation 
wavelength or set of wavelengths (between 355-405 nm). 
The limited role of HbA1c compared to skin autofluorescence or AGE-
accumulation in predicting complications in type 2 diabetes emphasises the importance 
of ‘metabolic memory’ rather than ‘glycemic memory’. Metabolic memory also 
includes AGEs formed during oxidative stress or other pathways of AGE formation 
using other substrates than glucose. Especially in a condition like type 2 diabetes where Chapter 8 
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besides hyperglycaemia multiple metabolic disturbances are present, measurement of 
AGEs could be more representative for cumulative metabolic stress compared to 
HbA1c. A second restriction of HbA1c is that post-prandial hyperglycaemia is not fully 
included, with consequently underestimation of cumulative metabolic stress. Post-
prandial hyperglycaemia might be important in developing AGE-accumulation and 
complications. The high glucose value induces oxidative stress, and at the same time, 
lots of substrate are available such as blood lipids and amino-acid levels that are also 
increased after a meal. The short turnover time of HbA1c is the third major explanation 
for the restricted relation between HbA1c, AGEs and complications. HbA1c represents 
glycemic control of the last 8 weeks. As the half-life of skin collagen is 15 years, it is 
likely that skin AGE levels provide a more “long-term memory” of glycemic stress and 
are, therefore, better in predicting complications. This should be further explored in 
future studies on the impact of integrated long-term follow-up of HbA1c measurement 
on skin AF, and also on the development of complications.  
Although it is not established whether skin autofluorscence, a technique based 
on fluorescent properties of certain AGEs, is a good measure for non-fluorescent 
AGEs, there are reasons to assume it is. Firstly, in the validation study, the correlation 
between skin AF and fluorescent AGEs/CLF was as good as with non-fluorescent 
AGEs, like CML. CML is also known as a product formed during oxidative stress or 
lipoxidation. Secondly, the thesis of Mulder (2007) showed multiple positive relations 
between skin AF and markers of oxidative stress [18]. Likewise, relations of skin AF 
with CRP and indirect oxidative stress markers (such as vitamin C) were also reported 
by Meerwaldt and Hartog [19,20]. Finally, the additional value of skin AF to the 
UKPDS risk engine in prediction of complications also suggests that this risk engine 
(which includes the traditional risk factors) does not fully incorporate ‘metabolic 
memory’ relevant for cardiovascular prognosis. The additional prognostic value of 
accumulated oxidative stress might be better covered by skin AF.  
Results of ongoing studies with follow-up measurements of skin AF are needed. 
Follow-up measurements of skin AF will provide information on the rate of AGE-
accumulation. The use of repeated skin AF measurements in intervention studies with Summary and discussion 
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e.g. benfotiamine and ALT-711 may also reveal which interventions are able to 
decelerate the AGE accumulation process to finally prevent complications in diabetes. 
Follow-up measurements may also answer the question whether a single AF 
measurement is sufficient for an individual patient to predict future complications, or 
that assessing the AF progression rate by multiple longitudinal measurements is better. 
Until now, one AF measurement has proven to be a good predictor for diabetes 
complications. 
The broad excitation wavelength range, such as applied in the AFR, is adequate 
for measuring the fluorescence of the fluorophores in different types and stages of 
diabetes. The current use of a relatively broad emission wavelength range for 
fluorescence does not have to be changed either. So no adjustments of the tool have to 
be made for applying it in all the studied groups. Technically, this implies that next 
generations of the currently used AGE-Reader may be developed with relatively simple 
light sources and less expensive spectrometers, which would make the tool less costly 
facilitating extended use in for instance primary care or even for screening application. 
A recent paper showed a higher sensitivity for detection of ‘impaired glucose 
tolerance’ or type 2 diabetes compared to the OGTT or a single HbA1c measurement 
[21]. Although more and larger population studies are necessary for implementing skin 
AF as a screening tool for (pre)diabetes, it would be an important improvement if 
increased cardiovascular risk could be detected earlier to decelerate the AGE 
accumulation rate in an earlier state preventing cardiovascular diseases. 
There was no significant seasonal variation of skin AF in the exclusively 
Caucasian study population. One important limitation of the used AFR has been its 
unreliability in people with dark skin. Recent improvements of the AGE-reader now 
allow to extend the application on non-Caucasian subjects. In these subjects, validation 
studies to assess the relation of skin AF with diabetes complications are now ongoing.  
There are no specific AGE-inhibitors or AGE-breakers clinically available yet, 
despite efforts to develop them since the 1980s. The cause of this disappointing 
development track could be toxicity problems, lack of efficacy or monitoring issues to 
detect decrease in AGE-levels. For aminoguanidine and pyridoxamine problems with Chapter 8 
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toxicity have indeed occurred, while in some studies efficacy has been found to 
limited. A general problem with AGE-breakers might be that breaking AGEs results in 
AGE degradation products which can be highly reactive and form new AGEs again 
contributing to low clinical efficacy. In vivo monitoring of effectiveness of 
interventions may also be difficult as mostly blood AGE levels are used which can 
even increase when tissue AGEs have degradated and entered into the circulation. Skin 
autofluorescence is expected to reflect tissue AGE accumulation and might therefore 
be better in monitoring a decrease in total body AGEs induced by AGE-breakers. 
Application of the AGE-Reader for monitoring therapeutic interventions has started in 
several ongoing studies and may so contribute to the development of a clinically 
available AGE-breaker. 
Since metabolic damage due to oxidative stress and inflammation can result in 
‘accelerated aging’ and its complications, the application of skin autofluorescence 
could be extended to other fields of medicine. Recently, increased skin 
autofluorescence has been reported in rheumatoid arthritis and in systemic autoimmune 
diseases, but other populations of interest include patients with amyotrophic lateral 
sclerosis, or identification of accelerated cardiovascular disease after chemotherapy 
[22,23]. Studies in such patient cohorts are in progress. Data of these studies are also 
important for general health care. Since treatment of diseases like acute myocardial 
infarction, cancer or post-transplantation immunosuppressive therapy had been 
improved, mortality in these patient groups are dramatically decreased over the past 
decades. Incidence of chronic diseases, like heart failure has, however, enormously 
increased with subsequently rise of medical costs. Follow-up skin autofluorescence 
measurements may provide insight in the future course of ‘chronic complications’ by 
therapy induced accelerated aging, and consequently insight to future expenditure 
and/or improvement of medical treatment strategies. 
 
In conclusion, skin autofluorescence may become a generally used clinical tool 
for estimating cardiovascular risk in conditions with increased oxidative stress and 
supply of substrates, especially in diabetes mellitus. Monitoring interventions might Summary and discussion 
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become a second application of the skin autofluorescence measurement aiming for 
further reduction of the incidence of diabetes complications by stimulating the 
development of AGE-inhibitors or AGE-breakers. 
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Advanced glycation endproducts (AGEs) ontstaan via chemische reacties waarbij er 
versuikering en oxidatie optreedt van o.a. eiwitten en vetten, waarbij vaak een 
onomkeerbare verbinding ontstaat met eiwitten, zoals collageen. Bij ieder mens 
stapelen AGEs gedurende het leven, maar bij iemand met diabetes mellitus gebeurt dit 
versneld. AGEs hebben een belangrijke rol bij het ontstaan van chronische 
complicaties van diabetes en atherosclerose.  
Tot recent werden weefsel-AGEs gemeten in huidbiopten. Dat is een 
belastende methode, ongeschikt voor toepassing op grote schaal, of voor herhaalde 
metingen. Het is vanuit de literatuur bekend dat sommige AGEs fluoresceren. Enkele 
jaren geleden is door de Biomedical Engineering van de Rijksuniversiteit Groningen en 
de afdeling Interne Geneeskunde van het UMCG de Autofluorescence reader (AFR) 
ontwikkeld, dat gebruikmakend van fluorescentieprincipes, niet-invasief 
autofluorescentie van de huid meet. De AFR is een draagbaar apparaat, waarin een 
UV-lamp (excitatie, golflengte 355-405 nm), waarop de onderarm kan worden gelegd. 
Een spectrometer analyseert de fluorescentie die de huid uitzendt (emissie, golflengte 
420-600 nm), waarna de computer de meetgegevens binnenkrijgt en verwerkt tot een 
getal (=ratio van de gemiddelde emissie en de gemiddelde excitatie). Uit de 
validatiestudie bleek dat autofluorescentie een goede maat was voor weefsel-AGEs.    
Inmiddels zijn er meerdere studies met de AFR verricht. Hierin werd o.a 
gezien dat autofluorescentie bij patiënten met diabetes, nierinsufficiëntie en tijdens een 
acuut hartinfarct hoger is ten opzichte van gezonde proefpersonen van dezelfde leeftijd. 
Verder bleek autofluorescentie in een kleine gemengde groep patiënten met type 1 en 
type 2 diabetes voorspellend te zijn voor cardiovasculaire complicaties. Inmiddels is 
het prototype AFR verder ontwikkeld tot de AGE-Reader. 
De doelen van de studies beschreven in dit proefschrift zijn als volgt. Ten 
eerste wilden we nagaan of verschillende aandoeningen (diabetes type 1 en type 2, met 
en zonder diabetische complicaties) ook tot verschillende fluorescentie spectra leiden. 
Met andere woorden, hebben mensen met type 1 diabetes andere fluorescerende 
stoffen/AGEs in hun huid t.o.v mensen met type 2 diabetes. En, is er verschil in AGEs 
bij diabetes patiënten met en zonder complicaties. Ten tweede hebben we in een Samenvatting 
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prospectief type 2 diabetes cohort (973 patiënten) uit de regio Zwolle uitgezocht wat de 
relatie is tussen autofluorescentie van de huid en bekende klinische variabelen bij 
diabetes als HbA1c (= geglycosyleerd hemoglobine) en reeds aanwezige micro- en 
macrovasculaire complicaties, en of autofluorescentie ook een voorspeller is voor 
nieuwe complicaties en overlijden. Alle studies beschreven in de hoofdstukken vanaf 
hoofdstuk 4 zijn uitgevoerd bij hetzelfde type 2 diabetes cohort uit de regio Zwolle. 
 
Hoofdstuk 2 beschrijft de studie waarin het eerste onderzoeksdoel is uitgezocht. Bij 5 
verschillende groepen van ieder ongeveer 20 personen met een leeftijd tussen 35 en 50 
jaar (controle groep, type 1 diabetes patiënten zonder complicaties, type 1 diabetes 
patiënten met complicaties, type 2 diabetes patiënten zonder complicaties, type 2 
diabetes patiënten met complicaties) werd autofluorescentie van de huid gemeten. Dit 
werd gedaan met een Excitatie-emissie scanner (EEMs), waarbij er niet zoals bij de 
normale meetopstelling (AFR) met licht van 1 breder golflengtebereik (355-405 nm) 
wordt gewerkt, maar smallere golflengtegebieden (à 5 nm) binnen het genoemde bereik 
op de huid werd geschenen. De hoeveelheid fluorescentie (emissie) en de vorm van het 
fluorescentiespectrum, geïnduceerd door de diverse smallere golflengtegebieden 
(excitatie), werd vergeleken tussen de verschillende groepen. De hoeveelheid 
autofluorescentie was verhoogd bij beide diabetesgroepen met complicaties t.o.v de 
diabetesgroepen zonder complicaties. Er was echter geen verschil in 
fluorescentiekarakteristieken tussen controle personen, type 1 en type 2 diabetes 
patiënten. Ook was er geen verschil in aanwezige fluorophoren in de huid bij aan- of 
afwezigheid van diabetes gerelateerde complicaties. Hieruit kan worden geconcludeerd 
dat het brede excitatie golflengtegebied, zoals gebruikt bij de AFR voldoet en niet 
verder hoeft worden aangepast om autofluorescentie van de huid te meten bij diabetes 
patiënten.  
  Hoofdstuk 3 is een bespreking van de literatuur die bekend is rondom de 
verschillende mechanismen die leiden tot vorming van AGEs, en de rol van AGEs bij 
het ontstaan van de complicaties van diabetes zoals retinopathie, neuropathie en 
nefropathie. Ook wordt beschreven dat AGEs een rol hebben bij normale Chapter 9 
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verouderingsprocessen (cataract, atherosclerose), nierziekten en de ziekte van 
Alzheimer. Tot slot komt in dit hoofdstuk aan de orde de verschillende geneesmiddelen 
die sinds enkele jaren in ontwikkeling zijn om stapeling van AGEs te kunnen remmen, 
en daarmee hopelijk ontwikkeling van complicaties vertragen of voorkomen. 
Voorbeelden van zogenaamde AGE-inhibitors zijn aminoguanidine en pyridoxamine, 
een voorbeeld van een AGE-breaker is ALT-711 (alagebrium).  
 In  hoofdstuk 4 wordt bij het Zwolse type 2 diabetes cohort (n=973) een cross-
sectionele analyse uitgevoerd van de basismeetgegevens die tussen 2001 en 2002 zijn 
verzameld. Autofluorescentie van de huid was gerelateerd aan leeftijd, geslacht, 
diabetesduur, BMI, roken, HbA1c, HDL-cholesterol en albuminurie. Verder bleek hoe 
meer complicaties er bij de patiënt reeds aanwezig waren (microvasculair, 
macrovasculair of beide), hoe hoger de autofluorescentie waarde.  
  Voor de risico-inschatting op het ontwikkelen van een fataal of niet-fataal 
cardiovasculair incident bij type 2 diabetes patiënten is sinds enkele jaren de UKPDS 
risicoscore beschikbaar. Deze risicoscore komt voort uit de United Kingdom 
Prospective Diabetes Study, waarbij >4000 nieuw ontdekte type 2 diabetes patiënten 
werden behandeld volgens een conservatief schema of volgens een intensief 
behandelschema. In hoofdstuk 5 werd geanalyseerd of autofluorescentie van de huid 
van toegevoegde waarde is aan de UKPDS risicoscore, bij het voorspellen van 
cardiovasculaire incidenten en dood. De resultaten van deze studie toonde dat binnen 
de groep patiënten die al een hoog risico (10-jaars risico op fataal CV-incident >10% 
met UKPDS risico score) heeft op cardiovasculaire complicaties, autofluorescentie een 
subgroep kan identificeren met een nog sterker verhoogd risico. Verder leidt 
toevoeging van autofluorescentie tot reclassificatie van 27% van de patiënten uit de 
laagrisico patiënten (UKPDS risicoscore <10%) naar een hoogrisico groep 
(=autofluorescentie groter dan de mediaan). Het reeds hebben van een macrovasculaire 
complicatie, een UKPDS risico score >10% en een autofluorescentie waarde boven de 
mediaan, zijn allen onafhankelijke voorspellers voor nieuwe cardiovasculaire 
incidenten en dood. Samenvatting 
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Hoofdstuk 6 laat zien dat de levensverwachting van dit type 2 diabetes cohort 
vergelijkbaar is met de levensverwachting van de Nederlandse bevolking. In het cohort 
bevinden zich type 2 diabetes patiënten uit de eerstelijns gezondheidszorg (=uit de 
huisartspraktijk), die in het kader van ‘transmurale  zorg’ jaarlijks door een 
diabetesverpleegkundige gescreend worden op complicaties, waarna de huisarts aan de 
hand van de bevindingen van de diabetesverpleegkundige en laboratoriumuitslagen een 
behandeladvies krijgt van een internist. Het halen van een normale levensverwachting 
bij mensen met type 2 diabetes is dus mogelijk, indien de patiënt zich in een dergelijk 
zorgprogramma bevindt. Binnen het normale levensverwachtingprofiel voor de hele 
groep heeft een individuele type 2 diabetes patiënt met een macrovasculaire 
complicatie in de voorgeschiedenis of albuminurie wel een toegenomen risico om 
vervroegd te overlijden. 
In  hoofdstuk 7 werd geanalyseerd of autofluorescentie een voorspeller is voor 
microvasculaire complicaties, zoals retinopathie, neuropathie en nefropathie. Baseline 
incidentie van microvasculaire complicaties werd vergeleken met nieuw opgetreden 
microvasculaire complicaties, na een follow-up van ~3 jaar. Autofluorescentie bleek de 
sterkste voorspeller te zijn voor alle nieuwe microvasculaire complicaties samen, ten 
opzichte van HbA1c en diabetesduur. Bloeddruk en lipiden waren niet significant. 
Voor de microvasculaire complicaties afzonderlijk, blijkt autofluorescentie alleen 
voorspellend voor neuropathie en microalbuminurie en niet voor retinopathie. Voor 
retinopathie was diabetes duur alleen voorspellend. 
 
Concluderend, autofluorescentie van de huid is in een grote groep type 2 diabetes 
patiënten een voorspeller voor de incidentie van microvasculaire, macrovasculaire 
complicaties en dood. Het is van aanvullende waarde aan de UKPDS risico-inschatting 
op het optreden van fatale en niet-fatale cardiovasculaire incidenten binnen 10 jaar. Bij 
het uitrekenen van een dergelijke 10-jaars risico score, zullen patiënten al gauw hoger 
dan 10% scoren. In de studie populatie uit dit proefschrift scoorde 79% boven de 10%. 
Toevoegen van autofluorescentie kan dan binnen deze hoogrisico groep, individuele 
patiënten identificeren met een extra hoog risico. Dit kan er toe leiden dat deze extra Chapter 9 
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hoogrisico patiënten nog strikter volgens de richtlijnen worden behandeld of bv. 
laagdrempeliger worden doorgestuurd voor cardiologische evaluatie. 
De UKPDS risico score kan ook foutief te laag uitvallen, als in het model 
behandelde waardes van HbA1c, bloeddruk en lipiden wordt ingevuld. Het 
cardiovasculair risico van de patiënt wordt dan onderschat. Als de UKPDS score laag 
uitvalt en de autofluorescentie waarde wel hoog is, dient patiënt gereclassificeerd te 
worden naar een hoogrisico groep. Aangezien uit dit proefschrift  blijkt dat 
autofluorescentie een maat is voor vastgestelde vasculaire schade maar ook voor 
preklinische vasculaire schade, kan autofluorescentie dus van toegevoegde waarde zijn. 
Ook voor risico-inschatting bij patiënten, waarbij type 2 diabetes recent is vastgesteld 
kan een autofluorescentie meting aanvullende informatie geven, omdat het vaak 
onduidelijk is hoelang de ziekte bestaat en wat de risico’s op korte of langere termijn 
zijn voor het ontwikkelen van diabetische complicaties.  
Follow-up studies met vervolgmetingen van autofluorescentie over de tijd 
(jaren) zijn gaande en moeten aantonen wat de progressie snelheid van 
autofluorescentie is, welke factoren deze progressie snelheid kunnen vertragen en of 
een eenmalige autofluorescentie meting genoeg is om de risico-inschatting te maken 
ten aanzien van het voorspellen van complicaties of dat meerdere autofluorescentie 
metingen danwel de ‘autofluorescentie progression-rate’ beter zijn. 
Een ander mogelijk toepassingsmogelijkheid van de AFR/AGE-Reader in de 
toekomst, is AGE-monitoring bij interventiestudies met de in ontwikkeling zijnde 
“AGE-inhibitors” en “AGE-breakers”. Als de AFR de uitvoering van klinische 
interventie trials kan vergemakkelijken, dan zou de klinische introductie van AGE-
inhibitors versneld kunnen worden, met als doel een daling van microvasculaire en 
macrovasculaire complicaties ten gevolge van diabetes mellitus. 
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Bij deze wil ik iedereen bedanken die betrokken is geweest bij de ontwikkeling en 
uitvoering van de studies uit dit proefschrift. Bovenal de patiënten en gezonde 
proefpersonen, zonder wie klinisch onderzoek doen niet mogelijk is. Mijn speciale 
dank gaat uit naar de volgende mensen: 
Prof. dr. R.O.B. Gans, beste Rijk. Tijdens mijn tijd in Zwolle hebben we niet heel 
frequent contact gehad over de studies in dit proefschrift. Toch gaf je bij het 
beoordelen van een manuscript altijd nuttig commentaar en gaf je me weer overzicht 
over de lijn in een artikel. In het UMCG aangekomen, spreek ik je gelukkig vaker en 
heb je ook nog een dubbelrol, als mijn opleider. Gedurende deze tijd ben ik je nog 
meer gaan waarderen. Bedankt voor je vertrouwen in mij destijds en nu. 
Prof. dr. H.J.G. Bilo, beste Henk. Jij bent altijd bereid iemand te helpen, als je er maar 
om vraagt (iets waar ik, zoals je weet, niet zo goed in ben). Ik bewonder je 
buitengewone oplossend vermogen. Als ik bij je kwam met een heel lijstje met 
problemen, had je voor alle punten binnen no-time een oplossing gevonden, zodat ik er 
weer mee verder kon. Bedankt ook voor je enorme gastvrijheid. 
Dr. A.J. Smit, beste Andries. Jij bent er gedurende m’n hele onderzoeksperiode altijd 
voor me geweest. Altijd als ik je benaderde met een probleem, vraag of als je op korte 
termijn iets door moest lezen, deed je dat zonder problemen. Tot op het laatst toe. Jouw 
enorm kennisdomein en up-to-dateheid van de literatuur bewonder ik enorm en was 
bovenal ook erg handig. 
Dr. Ir. R. Graaff, beste Reindert. Vele uren samen achter de computer programmeren in 
Pascal, een periode lang zelfs vrijwel iedere vrijdagochtend. Veel tijdsinvestering, 
maar met een heel fraai resultaat: van een brij aan getallen in multipele files per meting 
die het prototype van de AGE-reader uitspuwde, tot nu: een AF waarde binnen een 
minuut. Bovendien was het ook gezellig en bespraken we tijdens de koffiepauze ook 
andere belangrijke zaken uit het leven. 
Dr. T.P. Links, beste Thera, sinds ik je heb leren kennen nadat ik je tegenkwam als 
student met een paar kleine endo-onderzoekjes, ben je al een voorbeeld voor mij. Ik 
bewonder jouw organisatievermogen op het gebied van werk en thuis enorm. Jouw 
bijdrage aan mijn proefschrift en aan mij persoonlijk is groots. Tijdens de vele Dankwoord 
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besprekingen samen met Andries en Reindert, wist jij de heren goed te temperen en 
alles overzichtelijk te houden. De divergerende ideeën van de heren kon jij weer heel 
elegant convergeren. 
 
De leescommissie, bestaande uit Prof. dr. B.H.R. Wolffenbuttel, Prof. dr. J.B.L. 
Hoekstra en Prof. dr. F. Zijlstra, wil ik graag bedanken voor het beoordelen en de 
snelle goedkeuring van het manuscript. 
 
Nanno, Bas, Lielith, en later Gijs en Susan wil ik bedanken voor de zeer goede en 
inspirerende samenwerking. Jullie enorme enthousiasme heeft mij meermalen geholpen 
om de draad weer op te pakken, als ik het even weer moeilijk had met het combineren 
van het onderzoek en de kliniek. Gert Broekhaar dank ik voor de ICT-ondersteuning en 
het minder serieuze geklets tijdens lunchpauzes. Anke, Anneke en Gertie dank ik 
eveneens voor hun gedegen hulp bij het verzamelen van de data.  
Gerda, Anne-Marijke, Dineke, Hetty en alle andere diabetesverpleegkundigen van het 
MCC-klik die hebben meegewerkt (en geploeterd) aan de metingen van alle patiënten, 
dank ik hiervoor. Idem dito voor de secretaresses (Greetje, Clair, Herma) en alle andere 
medewerkers van de ‘oude diabetes poli’, in het transitorium. 
De Maatschap Interne geneeskunde (ZIF) te Zwolle, dank ik voor hun begrip en 
flexibiliteit t.a.v. het inpassen van een AGIKO met een wat complexer 
opleidingsschema. In het bijzonder wil ik dr. M.A. Alleman en dr. E. van Ballegooie 
bedanken. Maarten Alleman is mijn rolmodel voor een goede internist met een perfecte 
klinische blik. Mede dankzij hem zijn mijn klinische kennis en vaardigheden niet 
achtergebleven ten opzichte van mijn wetenschappelijke ontwikkeling. Evert van 
Ballegooie dank ik voor het vertellen van bijzondere levenslessen, in het Transitorium, 
de artsenkamer van B5 en op diabetescongressen.  
Robbert Meerwaldt dank ik voor de eerste studies die hij met het lampje heeft gedaan, 
alsmede Udo Mulder en Jasper Hartog, beide ook ‘lampje-onderzoekers’ van het eerste  
uur.   
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Rindert de Vries, Susanna Borggreve en Adrienne Persoon dank ik voor hun 
gastvrijheid voor mij op de Triade-kamer. Wim Sluiter dank ik voor zijn nuchtere kijk 
en analyses bij voor mij soms moeilijke statistische wensen van reviewers. Peter 
Oomen, Joop Lefrandt, waren mijn voorbeelden van jonge goede onderzoekers en 
dokters, toen ik begon. Ook Herman Kreeftenberg wil ik hier noemen, die ik in 2001 
moest teleurstellen toen ik uiteindelijk niet aan de slag ging als junior 
onderwijscoördinator, toen Andries mij destijds dit AGIKO-project aanbood.  
Mijn huidige collega AIOS, het AIOS-bestuur, internisten en stage-begeleiders van het 
UMCG, dank ik voor het stimuleren en de ruimte die me werd gegeven, om dit 
proefschrift af te ronden. 
Mijn verse collega’s van de afdeling Endocrinologie Erik Jan Verburg, Robin Dullaart, 
Bruce Wolffenbuttel en de overige stafleden dank ik voor het zeer welkome ontvangst 
en ik hoop nog lang en prettig met jullie te mogen samenwerken. 
 
Esther Gerrits, mijn paranimf, vriendin, getuige, collega en onderzoeksopvolger. Lieve 
Esther, ik ben zo blij dat ik al deze dingen met je kan delen. 
 
Donate Baas, mijn andere paranimf wil ik hier noemen mede ook als 
vertegenwoordiger van onze oorspronkelijk ‘Drentse’, maar inmiddels internationale 
vriendengroep. We zijn het er altijd over eens, Donate, dat onze vriendengroep uit 
alleen maar fantastische mensen bestaat met ieder hun eigen uniekheid en gekkigheid. 
Myra en Mei-Zei, onze regelmatige ‘four-women meetings’, waarbij ook Esther, zijn 
altijd heerlijk relativerend en inspirerend. Ik ga hier graag mee door. 
 
Mijn ouders wil ik bedanken voor hun onvoorwaardelijke steun en begrip. Het valt niet 
altijd mee om je dochter te moeten delen met al haar werkzaamheden en voorheen 
reistijden. Gelukkig is de telefoon gewillig. Ook mijn schoonouders en andere naasten 
wil ik bedanken voor hun oprechte steun en belangstelling. 
 
One. Jan Willem, met jou wil ik blijven dansen op dit liedje  
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